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Abstract 
 
Histone deacetylase (HDAC) inhibitors prevent neuronal death in in vivo models of 
cerebral ischaemia, brain injuries and neurodegenerative disease. However the 
molecular mechanisms underlying this are not fully understood and neither the cell 
type nor the specific HDAC isoform responsible is known. To address these 
questions, I investigated the effects of selectively inhibiting HDAC isoforms in 
different neural cell models of the pathophysiological mechanisms implicated in 
these brain conditions. Initially, the efficacy of HDAC inhibitors to protect cerebellar 
granule neurones from glutamate excitotoxicity and oxygen glucose deprivation 
(OGD) was examined. It was found that inhibiting HDACs did not protect isolated 
neurones from these insults. To determine if HDAC inhibitors are neuroprotective 
through effects in other neural cells, I investigated if inhibiting HDACs in BV2 
microglia could suppress the inflammatory response stimulated by 
lipopolysaccharide (LPS). Using this model, the data presented in this thesis shows 
for the first time that selective inhibition of class I HDAC isoforms, or knockdown of 
HDAC1 or HDAC2 in microglia, suppresses the expression of pro-inflammatory 
mediators interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-. 
Investigating the possible underlying mechanisms suggests an increase in protein 
expression is not important and HDAC inhibitors have an anti-inflammatory effect 
by increasing the acetylation state of pre-existing proteins. The data presented also 
suggests there is functional redundancy of HDAC1 & HDAC2 in regulating the 
inflammatory response. Therefore, selectively inhibiting either isoform may be a 
strategy to reduce neuroinflammation and by doing so protect neurones in cerebral 
ischaemia and other brain conditions, whilst minimising the side effects associated 
with pan-HDAC inhibition.  
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1.1. Preface 
 
This thesis is an investigation into the mechanisms underlying the neuroprotection 
observed when using histone deacetylase (HDAC) inhibitors in experimental models 
of brain insults, injuries and disease. There is an emphasis on their effects on the 
pathophysiological mechanisms involved in cerebral ischaemia. However, it is 
important to point out that some of these mechanisms are also involved in traumatic 
brain injury, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and motor 
neurone disease, and HDAC inhibitors are neuroprotective in in vivo models of these 
conditions as well. 
 
In the general introduction, I will introduce lysine acetylation a protein post-
translational modification regulated by HDACs. This will move on to a specific 
discussion of the function of protein acetylation and HDACs in the brain. Then, the 
pathophysiological components of cerebral ischaemia will be briefly examined, 
followed by an analysis of the current literature that demonstrates HDAC inhibitors, 
in appropriate experimental models of this and other brain conditions, are 
neuroprotective, neuro-restorative and improve neurological outcome. 
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1.2. Protein (lysine) acetylation 
 
Post-translational modification (PTM) of proteins is a major regulatory mechanism 
of protein function through changing functional activity, subcellular localisation, 
interactions with other molecules and protein stability. Lysine acetylation is a 
reversible PTM and from a historical perspective was originally discovered as a 
modification to histone proteins (Phillips, 1963; Allfrey et al., 1964). Since this 
discovery, many other proteins have been identified, which are modified in this way. 
Early studies revealed that proteins such as -tubulin (L'Hernault and Rosenbaum, 
1985), p53 (Gu and Roeder, 1997) and NF-nuclear factor kappa-light-chain-
enhancer of activated B-cells, Chen et al. (2001); Kiernan et al. (2003)) are regulated 
by acetylation (see reviews by Glozak et al. (2005); Spange et al. (2009); Yao and 
Yang (2011) for these and other examples). As technology has advanced, large-scale 
proteomic studies have expanded the library of known acetylated targets. Choudhary 
et al. (2009) have identified 1750 acetylated proteins in human cells and Zhao et al. 
(2010) have shown there are 1042 acetylated proteins in the human liver. The 
analysis of sixteen different rat tissues revealed a combined total of 4541 uniquely 
acetylated proteins (Lundby et al., 2012). On a similar scale, the Compendium of 
Protein Lysine Modifications (CPLM, Liu et al. (2014)) now reports a total of 4817 
and 4024 acetylated proteins in humans and mice respectively. Combined, these 
acetylated proteins make-up the “acetylome” (Smith and Workman, 2009; 
Choudhary et al., 2014) a collection of proteins that come from many; protein 
classes, subcellular compartments and are involved in many cellular processes. The 
size and diversity of the acetylome suggests acetylation is a PTM of great 
importance. Having now identified thousands of proteins that make-up the 
acetylome, much work needs to be done in order to understand the precise role 
acetylation and deacetylation of each protein, has on the processes and pathways 
they are involved in and how this affects normal cell physiology and how this is 
affected in injury and disease. 
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Fundamentally, the acetylation of a lysine residue within a protein involves the 
transfer of an acetyl moiety from acetyl coenzyme A to the amino group (NH3
+
) of a 
lysine residue. Conversely, deacetylation of a protein involves the removal of an 
acetyl moiety from an acetylated lysine. This process is controlled by the activity of 
two enzymes, histone acetyltransferases (HATs), which add acetyl groups and 
histone deacetylases (HDACs), which remove them (figure 1.1). These enzymes are 
named so because histone proteins were the first targets identified.  
 
Figure 1.1. Reversible lysine acetylation. A histone acetyltransferase (HAT) transfers an 
acetyl moiety (shaded box) from acetyl coenzyme A (CoA) to the amino group (NH3
+
) of a 
lysine (K) residue in a protein. A histone deacetylase (HDAC) removes an acetyl group from 
an acetylated lysine residue (AcK) in a protein. 
 
Acetylation can regulate the function of a protein in many ways (see sections 1.2.1 to 
1.2.3 for a discussion of some known examples). The addition of an acetyl group to a 
lysine neutralises the positive charge of the amino acid and the removal of an acetyl 
group (deacetylation) restores this positive charge. In brief, these alterations in the 
electrostatic properties of lysine are known to induce changes in the conformation of 
the protein and also affect how the protein interacts with other molecules. 
Furthermore, a lysine that is acetylated can act as a binding motif for other proteins 
and gaining or losing an interaction with another protein can have different 
functional outcomes. 
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1.2.1. Histone protein acetylation 
 
Deoxyribonucleic acid (DNA) in the nuclei of eukaryotic cells is packaged into a 
highly organised but dynamic structure called chromatin. At the fundamental level, 
chromatin is made up of repeating units called nucleosomes. These comprise of ~200 
base pairs (bp) of DNA of which ~146 bp is wrapped around an octamer structure of 
histone proteins; the remaining DNA serves as a linker between nucleosomes. In 
each nucleosome, there are two copies of the four histone proteins H2A, H2B, H3 
and H4. Each histone protein in the nucleosome has a C-terminal domain, a globular 
domain of -helices and protruding N-terminal tail which contains lysine residues. 
These are available for acetylation by HATs and deacetylation by HDACs (table 
1.1). An additional histone protein, histone H1 is found outside of octamer, 
interacting with the linker DNA between nucleosomes. This histone has a role in 
linking the nucleosomes together and regulating the packaging of chromatin into 
higher order structures. 
 
Table 1.1. Acetylated lysine residues found in N-terminal histone tails. 
Histone Tail length (aa’s) Acetylated lysine residuesa 
H2A 142 5, 9, 13, 15, 36, 95 & 118  
H2B 120 5, 11, 12, 15, 16, 20, 23, 24, 46, 85, 108, 116 & 120 
H3 129 4, 9, 14, 18, 23, 27, 36, 56, 64, 79, 115 & 122 
H4 91 5, 8, 12, 16, 20, 77, 79 & 91 
a
Found to be acetylated in humans and/or mice. aa’s: amino acids. Sources used: Wang et al. 
(2008); Tweedie-Cullen et al. (2012); Roadmap Epigenomics et al. (2015). 
 
Histone acetylation has been correlated with active and the activation of gene 
expression and histone deacetylation with inactive and the inactivation of gene 
expression (Wang et al., 2008). Non-acetylated/deacetylated lysine residues are 
positively charged and in histone proteins these residues have electrostatic 
interactions with negatively charged DNA and other histone proteins. This has a 
compacting effect on chromatin where the DNA is wrapped around the histones 
more tightly and the nucleosomes are pulled closer together (figure 1.2). As a 
consequence, access to the underlying DNA for factors that drive gene transcription 
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is reduced. On acetylation by HATs (figure 1.2), the positive charge of the lysine in 
the histone tails is neutralised, preventing the electrostatic interactions, resulting in 
an opening up of the chromatin for gene transcription to occur (Struhl, 1998; 
Kornberg and Lorch, 1999; Strahl and Allis, 2000; Kouzarides, 2007). In addition to 
structural changes in chromatin, acetylation of lysine residues in histone proteins 
further regulates gene expression by acting as binding motifs for “reader” proteins 
(figure 1.2). These proteins contain a bromodomain, which has been shown to 
specifically recognise and interact with an acetylated lysine (Dhalluin et al., 1999; 
Hassan et al., 2007; Filippakopoulos et al., 2012). This domain is found in many 
positive gene regulatory proteins including chromatin remodelling proteins, helicases 
and transcription co-activators (Strahl and Allis, 2000; Marmorstein and Zhou, 
2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Simplified representation of the effect of histone acetylation on chromatin 
remodelling and gene expression. A string of nucleosomes is shown, each grey cylinder 
represents an octamer of histone proteins. Protruding histone N-terminal tails are acetylated 
and deacetylated by histone acetyltransferases (HATs) and histone deacetylases (HDACs) 
respectively; only four tails and one acetyl group per nucleosome are shown for simplicity. 
Histone acetylation promotes gene expression through chromatin decondensation and 
generation of binding sites for transcriptional co-activators termed “readers”. Histone 
deacetylation results in the removal of binding sites for “reader” proteins, chromatin 
condensation and inhibition of gene expression. 
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Like many proteins, histones can undergo several other post-translational 
modifications in addition to acetylation including, methylation of lysine and arginine 
residues, phosphorylation of serine and threonine residues and ubiquitination and 
sumoylation of lysine residues (reviewed by Bannister and Kouzarides (2011); 
Kouzarides (2007)). Like acetylation, these modifications regulate chromatin 
structure and function, and therefore gene expression either through changing 
electrostatic interactions between histones and DNA (e.g. occurs following the 
addition of a negatively charged phosphate group), or by forming binding sites for 
“reader proteins” (e.g. occurs following methylation). In the case of ubiquitination, 
the large polyubiquitin molecule physically disrupts chromatin structure simply 
because of its size and bulkiness. 
 
The effects of these post-translational modifications on histone function and gene 
expression vary depending on which site is modified (reviewed by Kouzarides 
(2007)). For example, methylation at lysine 4 in histone H3 is associated with active 
gene expression whereas methylation at the adjacent lysine 9 is associated with a 
repression of gene expression. These two lysine residues are also targets for 
acetylation (see table 1.1) and so competition exists between methylation and 
acetylation at these and other sites. The functional effect following the modification 
of a site depends on which modification is present. For example, methylation at 
lysine 9 in histone H3 is associated with repressing gene expression, whereas 
acetylation at the same site is associated with promoting gene expression 
(Kouzarides, 2007). There is also interplay between the different modifications, 
where a modification at one site can promote or prevent a different modification at 
another site. For example, acetylation of histone H3 lysine 14 prevents the 
methylation of the adjacent lysine 9 (Kouzarides, 2007), methylation of arginine 3 in 
histone H4 promotes the acetylation of adjacent lysine residues 8 and 12 
(Kouzarides, 2007), and acetylation of lysine 18, 23 and 27 in histone H3 promotes 
the methylation of arginine 17 (Daujat et al., 2002; Kouzarides, 2007). For each of 
these three examples the patterns of histone modification are associated with active 
gene expression. In addition to methylation, histone phosphorylation can also 
regulate the acetylation of other sites. Phosphorylation of histone H3 serine 10 for 
example promotes the acetylation of the neighbouring lysine 14 (Walter et al., 2008). 
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The particular patterns generated by the interactions between histone modifications 
are thought to constitute a “histone code” and proteins, which regulate gene 
expression, are recruited to and bind to DNA by recognising specific sequences of 
this code (Strahl and Allis, 2000). Because of the crosstalk amongst protein post-
translational modifications, one should consider that when one particular 
modification is altered, this may in-turn effect others and these other changes may 
also be contributing to the generation of the phenotype observed. 
  
1.2.2. p53 acetylation 
 
One of the well-studied examples of non-histone protein acetylation is that of p53 
acetylation. This protein is both a transcription factor and a cell signalling molecule 
involved in stimulating cell-cycle arrest and apoptosis in response to cellular stresses, 
such as incorrect DNA replication and DNA damage (Prives and Hall, 1999). 
Normally, p53 exists in an inactive form and is present at low levels by the actions of 
its inhibitor protein, Mdm2 (mouse double minute 2 homolog) an ubiquitin ligase 
(Freedman et al., 1999). Upon an appropriate stimulus, p53 expression is increased 
and the protein undergoes post-translational modification. Then, p53 acts as a 
transcription factor to directly activate the expression of genes that control the cell 
cycle or apoptosis and a fraction of p53 also translocates to the mitochondria where it 
is involved in the release of the apoptosis inducing protein cytochrome c (Sykes et 
al., 2009). 
 
The protein p53 can be acetylated at lysine residues 120, 164 and 292 in the DNA 
binding domain and 320, 351, 357, 370, 372, 373, 381, 382 and 386 in the C-
terminal domain (Spange et al., 2009). Generally, acetylation of p53 is thought to 
promote its activity by inhibiting the interaction with the inhibitor protein Mdm2 
(Tang et al., 2008). Acetylation of p53 has also been reported to affect its binding to 
p53 dependent genes; however varying effects have been reported. Gu and Roeder 
(1997) have shown that acetylation of p53 in the C-terminal domain is essential for 
binding to the gene promoter and promoting the expression of the p53-dependent 
Gadd45 (growth arrest and DNA damage-inducible 45 alpha) cell-cycle arrest gene. 
Gu and Roeder (1997) go on to hypothesise how acetylation regulates binding of p53 
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to DNA. The C-terminal and the DNA binding domains of p53 are known to interact 
and when the C-terminal domain is not acetylated, the positively charged lysine 
residues can interact with the DNA binding domain, which locks the protein into a 
conformation that is unable to bind to DNA. Upon lysine acetylation in the C-
terminus and the neutralisation of the positively charged residues, the interaction 
between these and the DNA binding domain is disrupted and p53 undergoes a 
conformational change permissive for DNA binding (Gu and Roeder, 1997). In 
direct contradiction, Brochier et al. (2013) show specific acetylation of lysine 381 
and 382 in the C-terminus negatively regulates the binding of p53 to the promoters of 
and the expression of the cell-cycle arrest gene p21 and the pro-apoptotic gene 
PUMA (p53 upregulated modulator of apoptosis). 
 
In addition to the effects on DNA binding, acetylation also regulates the 
transcriptional activity of p53 by affecting interactions with transcriptional co-
activators. HATs and p53 are known to interact with one another and p53 requires 
HATs to remodel chromatin structure in order to promote gene transcription (Gu et 
al., 1997). This interaction is thought to be meditated via the acetylated lysine 382 in 
the C-terminal domain and the bromodomain found in HATs such as the cAMP 
response element binding protein (CREB)-binding protein (CBP, Mujtaba et al. 
(2004)). 
 
Acetylation at lysine 120 in the DNA binding domain, selects the activity of p53 
towards mediating apoptosis rather than cell-cycle arrest. This is mediated through 
the selective expression of apoptosis inducing genes (Sykes et al., 2006) and by non-
transcriptional effects on mitochondrial dependent apoptosis (Sykes et al., 2009). 
The mechanism underlying the selective expression of apoptosis genes and not cell-
cycle regulatory genes is not understood. Sykes et al. (2006) have hypothesised that 
the acetylation of lysine 120 may act as a binding motif for a specific transcriptional 
cofactor, which targets p53 to apoptosis-inducing genes over others. 
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1.2.3. NF- acetylation 
 
Another non-histone protein which is modified and whose function is regulated by 
acetylation is NF-, a transcription factor involved in regulating the inflammatory 
responses of innate immune cells. Prototypically, NF- is a heterodimer of the 
proteins p50 and RelA[p65]. In un-stimulated cells, NF- is sequestered in the 
cytoplasm by an association with an inhibitor protein  nuclear factor kappa-
light-chain-enhancer of activated B-cells inhibitor alpha. Upon an appropriate 
inflammatory stimulus, NF- is activated by a phosphorylation and ubiquitination 
dependent degradation of  Then, NF- rapidly translocates to the nucleus 
where it regulates inflammatory gene expression. NF- activity is stopped by its re-
association with  and export from the nucleus to the cytoplasm, where it 
remains sequestered until activated again (Baldwin, 1996; Ghosh et al., 1998). 
 
The RelA[p65] subunit of NF- can be reversibly modified by acetylation. Seven 
lysine residues; 122, 123, 218, 221, 310, 314 and 315 are acetylated and deacetylated 
by HATs and HDACs in the nucleus (Chen et al., 2001; Chen et al., 2002; Kiernan et 
al., 2003; Ziesche et al., 2013). Acetylation and deacetylation of these different sites 
has specific effects on NF- activity such as modulating binding to DNA. When 
RelA[p65] binds to a target DNA sequence, lysine residues 122 and 123 are found to 
be in close proximity to DNA (Chen et al., 1998). Neutralisation of these positively 
charged amino acids upon acetylation, is thought to destabilise the electrostatic 
interactions and therefore reduce the binding of RelA[p65] to the negatively charged 
DNA. This facilitates NF- removal, promoting its re-association with the inhibitor 
protein  and consequent export out of the nucleus (Kiernan et al., 2003). This 
ultimately reduces transcriptional activity (Kiernan et al., 2003; Ziesche et al., 2013). 
Acetylation of lysine 221 enhances DNA binding of RelA[p65] and together with the 
acetylation of  lysine 218 impairs its association with  (Chen et al., 2002). 
Furthermore, the acetylation of lysine residues 310, 314 and 315 in RelA[p65] can 
either inhibit or potentiate transcriptional activity of NF- at specific genes (Buerki 
et al., 2008; Rothgiesser et al., 2010b; Chen et al., 2002; Ziesche et al., 2013). 
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Acetylation of lysine 314 and 315 also has a role in terminating NF- dependent 
gene expression (Rothgiesser et al., 2010b). 
 
The p50 subunit of NF- can also be regulated by acetylation, with lysine residues 
431, 440 and 441 modified in this way (Furia et al., 2002). Acetylation of these 
residues increases the binding of p50 to DNA and enhances its transcriptional 
activity (Furia et al., 2002; Deng and Wu, 2003). 
 
 
1.3. Histone acetyltransferases (HATs) 
 
Histone acetyltransferases are enzymes that add acetyl groups to lysine residues in 
proteins. HATs are grouped on the basis of their catalytic domains (reviewed by 
Kimura et al. (2005); Lee and Workman (2007)). The GCn5 N-acetyltransferase 
(GNAT) family includes Gcn5 (general control nonrepressed 5, Brownell et al. 
(1996)) and p300/CBP-associated factor (PCAF, Yang et al. (1996)) amongst others. 
A second family of HATs the MYST family, is named after the founding members 
Morf (monocytic leukemia zinc finger protein-related factor, Champagne et al. 
(1999)), Ybf2 (Takechi and Nakayama, 1999), Sas2 (something about silencing 
protein 2, Kimura et al. (2002)) and Tip60 (60 kDa Tat-interactive protein, 
Yamamoto and Horikoshi (1997)). Other HATs include p300, CBP (Bannister and 
Kouzarides (1996); Ogryzko et al. (1996)) and TAF(II)250 (TATA box-binding 
protein associated factor 250) a subunit of transcription factor II D (TFIID), which is 
a major component of the transcription preinitiation complex (Mizzen et al., 1996). 
 
1.3.1. HAT expression and distribution in the brain 
 
To date, no comprehensive study looking at the expression of all the HATs 
throughout the brain has been performed, but an analysis of the literature supports 
the general opinion that HATs are ubiquitously expressed in the brain. Indeed the 
HATs, Gcn5, PCAF, Morf, Tip60, p300 and CBP are all expressed in the frontal lobe 
in humans (Pedre et al., 2011).  
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Additionally, some of these HATs have been observed in the brains and in various 
neural cell types of mice and rats. PCAF is expressed in the forebrain in mice 
(Maurice et al., 2008) and the hippocampus in both mice and rats (Maurice et al., 
2008; Bousiges et al., 2010). PCAF is also expressed in neurones isolated from 
mouse cerebellum (Rouaux et al., 2003) and in isolated murine microglia (Park et al., 
2013). The HAT p300 is expressed in mouse cortex and the amygdala (Oliveira et 
al., 2007), as well as the hippocampus of both mice (Ogawa et al., 2001; Oliveira et 
al., 2007) and rats (Bousiges et al., 2010). Consistent with this, neurones isolated 
from rat hippocampus (Hardingham et al., 1999), mouse cortex (Marinova et al., 
2009) and cerebellum (Rouaux et al., 2003) express p300 and this HAT is expressed 
in astrocytes (Ogawa et al., 2001; Fonte et al., 2007; Marinova et al., 2011) and 
microglia (Tang et al., 2007; Kim et al., 2013) isolated from rat and mouse brains 
respectively. Another HAT, CBP is found to be expressed in the cortex, thalamus, 
hypothalamus, hippocampus and amygdala of rats (Stromberg et al., 1999) and 
hippocampus (Korzus et al., 2004), midbrain, brainstem and cerebellum of mice 
(Chung et al., 2003). Neurones isolated from the mouse cortex and cerebellum 
(Rouaux et al., 2003) and rat hippocampus (Hardingham et al., 1999; Impey et al., 
2002) express CBP and so do astrocytes and microglia isolated from rat and mouse 
brains respectively (Delgado, 2002; Fonte et al., 2007). 
 
 
1.4. Histone deacetylases (HDACs) 
 
1.4.1. HDAC isoforms and classes 
 
There are eighteen different HDAC isoforms that deacetylate lysine residues and 
these are grouped into four classes according to their catalytic domains, sequence 
homology and similarity to Saccharomyces cerevisiae (yeast) deacetylases (de 
Ruijter et al., 2003; Gregoretti et al., 2004). The zinc-dependent HDACs (table 1.2) 
include class I HDACs (1, 2, 3 and 8), which are closely related to the yeast 
deacetylase RPD3 (reduced potassium dependency 3), and class IIa HDACs (4, 5, 7 
and 9) and class IIb HDACs (6 & 10), which are similar to the yeast histone 
deacetylase 1 (HDA1). The fourth class comprises of HDAC11, which shares limited 
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sequence homology to any of the other HDACs. Unlike class I, II and IV HDACs 
which require Zn
2+
 as a cofactor for catalytic activity, the class III HDACs known as 
sirtuins, of which there are seven members (SIRT1-7), are nicotinamide adenine 
dinucleotide (NAD)
+
-dependent enzymes. This thesis will focus on the role of and 
effects of inhibiting class I and II HDACs in the brain. 
 
Table 1.2. Zinc-dependent histone deacetylase (HDAC) isoforms. 
HDAC Protein domains Size  
Class I   
HDAC1 
 
482 
HDAC2 
 
488 
HDAC3 
 
428 
HDAC8 
 
377 
Class IIa   
HDAC4 
 
1084 
HDAC5 
 
1122 
HDAC7 
 
952 
HDAC9 
 
1011 
Class IIb   
HDAC6 
 
1215 
HDAC10 
 
669 
Class IV   
HDAC11 
 
347 
Grey box and striped box: number of amino acids comprising the zinc-dependent catalytic 
domain and the catalytically inactive domain respectively. Size: number of amino acids, N: 
N-terminus, C: C-terminus. Data sourced from Micelli and Rastelli (2015). 
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1.4.2. HDAC structure and catalytic mechanism 
 
The structures for all human class I HDACs isoforms, as well as HDAC4 and 
HDAC7 have been solved (reviewed by Micelli and Rastelli (2015)). Each zinc-
dependent class I and IIa HDAC is comprised of a single domain protein composed 
of a central eight stranded parallel -sheet flanked by numerous -helices on either 
side. Access to the catalytic site is through a tube structure lined mainly with 
hydrophobic residues leading to a cavity lined with polar residues and the catalytic 
cofactor Zn
2+
 (Micelli and Rastelli, 2015). Aligning the amino acid sequences of the 
catalytic domains of class I and IIa HDACs, reveals that the catalytic sites amongst 
these HDAC isoforms are largely conserved (Lahm et al., 2007). Three catalytic 
mechanisms of deacetylation by HDACs have been proposed (Finnin et al. (1999); 
Vanommeslaeghe et al. (2005); Corminboeuf et al. (2006) and reviewed by Micelli 
and Rastelli (2015)) and the residues involved, include those that bind the Zn
2+
 
cofactor (a histidine residue and two aspartic acid residues) and those that surround it 
and interact with the acetyl moiety of the substrate (a tyrosine and two histidine 
residues). In all three proposed catalytic mechanisms of deacetylation, the presence 
and reactivity of the tyrosine residue with its hydroxyl group (-OH) is important and 
class I HDAC isoforms lose deacetylase activity when this tyrosine is mutated to 
phenylalanine, or a histidine as found in class IIa HDACs (Lahm et al., 2007). 
Because class IIa HDACs lack the tyrosine residue, which is thought to be important 
for catalytic activity, it is not clear if these isoforms have intrinsic deacetylase 
activity. The pioneering studies that first identified HDACs 4, 5, 7 & 9 showed they 
were able to deacetylate histone proteins (Grozinger et al., 1999; Miska et al., 1999; 
Wang et al., 1999; Zhou et al., 2001). Furthermore, Bradner et al. (2010) as well as 
others who have studied the selectivity of HDAC inhibitors using commercially 
available recombinant full-length class IIa HDACs and acetylated substrates, 
measure deacetylase activity of these isoforms and this is subsequently inhibited with 
HDAC inhibitors (see section 1.8). However other groups have shown class IIa 
HDACs have no intrinsic deacetylase activity and any deacetylase activity associated 
with these isoforms is because they can interact with HDAC3 (Fischle et al., 2001; 
Fischle et al., 2002). However, Lahm et al. (2007) report that HDAC4 exhibits weak 
deacetylase activity against acetylated histones and commercially available 
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substrates in the absence of class I HDACs. This deacetylase activity is significantly 
increased when the histidine residue in the catalytic site of class IIa HDACs 4, 5 & 7 
is mutated to tyrosine as found in class I HDACs (Lahm et al., 2007). If class IIa 
HDACs do not have intrinsic deacetylase activity, or if it is relatively weak 
compared to other isoforms, this raises an interesting question; what is the 
contribution of class IIa HDAC activity towards regulating the acetylome? 
 
1.4.3. HDAC subcellular localisation 
 
The localisation of HDAC isoforms within a cell will dictate if the HDAC can 
deacetylate a specific protein substrate and which substrates are deacetylated. Class I 
HDACs 1, 2 and 8 each contain a nuclear localisation signal (NLS) and have often 
been thought to be exclusively located in the nucleus (de Ruijter et al., 2003). 
However, subcellular fractionation analysis and immunocytochemistry of human 
cells has shown HDAC1 and 2 can also be present in the cytoplasm and in other 
organelles in addition to the nucleus (Kahali et al., 2012). In support of this, Kim et 
al. (2010) have identified a putative nuclear export signal (NES) motif in the amino 
acid sequence of HDAC1 expressed in mice and observed translocation of HDAC1 
from the nucleus to the cytoplasm and axons of cultured murine neurones mediated 
by the nuclear pore Exportin 1 receptor (XPO1). Furthermore, Baltan et al. (2011a) 
have also observed HDAC1 in the cytoplasm and the nucleus of murine neurones 
and further show HDAC1 and 2 proteins are present in both the nucleus and 
cytoplasm of murine astrocytes as well.  
 
HDAC3 and class II HDACs 4, 5, 9 & 10 all contain a NLS and a NES and shuttle 
between the nucleus and cytoplasm (de Ruijter et al., 2003) via importins and 
exportins found in pores of the nuclear membrane. HDACs 4, 5 & 7, can be 
sequestered in the cytoplasm by 14-3-3 anchor proteins in a phosphorylation 
dependent manner (Grozinger and Schreiber, 2000; Bertos et al., 2001; Kao et al., 
2001). HDAC6 is predominantly a cytoplasmic protein but a fraction of this isoform 
can shuttle between the cytoplasm and nucleus (Verdel et al., 2000). Finally the class 
IV HDAC, HDAC11 is found to localise predominantly to the nucleus (Gao et al., 
2002). 
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1.4.4. HDAC containing multi-protein complexes 
 
In the nucleus, HDACs cannot bind to DNA directly and in order to deacetylate 
histones they must be recruited to genes as members of multi-protein complexes. 
These complexes bind to chromatin through DNA and histone-binding domains 
found within components of the complexes themselves and also through recruitment 
to genes by transcription factors. HDAC1 and 2 are components of three multi-
protein complexes called Sin3 (switch independent 3, Laherty et al. (1997)), NuRD 
(nucleosome remodelling and deacetylation, Zhang et al. (1999)) and CoREST (co-
repressor for element-1-silencing transcription factor, You et al. (2001)). The 
composition of these is reviewed by Kelly and Cowley (2013). These complexes 
contain a dimer of HDACs and are classically depicted with one molecule of both 
HDAC1 and 2 (Kelly and Cowley, 2013). In the case of human MCF-7 (Michigan 
cancer foundation-7) cells this is mostly true, where 80 to 90% of HDAC1 and 2 
proteins are associated with each other (He et al., 2005). However, HDAC1 has also 
been found in complexes as a homodimer as well as a heterodimer with HDAC2 
(Taplick et al., 2001). In mouse embryonic fibroblasts 40 and 60% of HDAC1 and 
HDAC2 respectively are found in the Sin3 and CoREST complexes independent of 
the other HDAC (Yamaguchi et al., 2010). In mouse embryonic stem cells and 
thymocytes, the Sin3 complex predominantly contains HDAC1 whereas the NuRD 
and CoREST complexes can contain HDAC1 and/or HDAC2 (Dovey et al., 2013; 
Dovey et al., 2010b). The dimerization of these two HDACs is indirect and is 
mediated via a HDAC binding domain found on a component of the multi-protein 
complex. For example, HDAC1 and HDAC2 can form homodimers or heterodimers 
through binding to the ELM2 (egg-laying defective protein 27 and metastasis-
associated protein 1 homology 2) domain of MTA1 (metastasis-associated protein 1) 
found in the NuRD complex (Millard et al., 2013). Together, these findings suggest 
that HDAC1 & HDAC1, HDAC2 & HDAC2 and HDAC1 & HDAC2 configurations 
for each multi-protein complex (CoREST, Sin3 and NuRD) exist, but how these 
configurations come about and the functional relevance of each of these different 
complexes is currently not known (Kelly and Cowley, 2013). 
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HDAC3 is a member of the nuclear receptor co-repressor (NCoR)/silencing mediator 
of retinoid and thyroid receptors (SMRT) complex (Wen et al., 2000) and class IIa 
HDACs 4, 5, 7, 9 and the class IIb HDAC10 can interact with this complex as well 
(Wen et al., 2000; Fischer et al., 2002; de Ruijter et al., 2003). In addition, HDAC4 
& 5 can also associate with the Sin3 complex (Nakagawa et al., 2006) and HDAC4, 
5 & 7 also interact directly with and inhibit MEF-2 (myocyte enhancer-binding 
factor-2) a transcription factor that controls neuronal function and survival (Miska et 
al., 1999; Wang et al., 1999; Lemercier et al., 2000; Bertos et al., 2001; Chawla et 
al., 2003; de Ruijter et al., 2003; Linseman et al., 2003). HDAC6 and 11 do not 
interact with any of the aforementioned complexes but are co-immunoprecipitated 
together (Gao et al., 2002).  
 
The acetylome is comprised of thousands of proteins from many classes and 
subcellular compartments. How HDACs are specifically recruited to, how they 
specifically interact with and deacetylate these diverse non-histone targets is not 
understood. It is likely that HDACs are recruited to and interact with these proteins 
as members of multi-protein complexes such as those already described or 
complexes that are yet to be identified. In support of this, Luo et al. (2000) show that 
deacetylation of p53 by HDAC1, does not occur through a direct interaction of the 
two proteins. Rather, HDAC1 is recruited to p53 as a member of the NuRD complex 
and it is MTA2 (metastasis-associated protein 2), another component of the NuRD 
complex, which is responsible for binding directly to p53 (Luo et al., 2000). These 
multi-protein complexes and the composition of them may also provide a mechanism 
to control the substrate specificity of the different HDAC isoforms. To identify novel 
HDAC containing multi-protein complexes, HDAC-protein “interactome” analysis 
can be performed. Joshi et al. (2013) have studied the protein interaction networks of 
HDAC isoforms in human T-cells and reveal a total of 180 HDAC-protein 
interactions across class I and II HDACs. For class I HDACs, the majority of these 
interactions are with components of the respective chromatin binding complexes 
mentioned earlier, but there are other interactions with proteins involved in cell 
signalling, protein folding, protein and ion transport and cellular metabolism. 
Whether these are substrates for HDACs or are co-members of multi-protein 
complexes and whether HDACs bind directly to these proteins or interact with them 
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via other proteins, is not clear. This study also confirmed that class IIa HDACs 4, 5 
& 7 predominantly interact with the NCoR multi-protein complex and 14-3-3 
proteins (Joshi et al., 2013). 
 
 
1.5. HDAC expression and distribution in the brain 
 
1.5.1. Human brain 
 
All eleven HDAC isoforms are expressed at the messenger RNA (mRNA) level in 
the human cerebrum; HDAC9 is the most prevalent followed by HDAC10, 11, 4, 6, 
5, 8, 3, 1, 2 and 7 (Lucio-Eterovic et al., 2008). An analysis of the expression of each 
HDAC in each brain region in the human brain is lacking. However, the distribution 
of each HDAC isoform has been mapped in the brains of mice and rats and the 
expression profile of each has also been determined for a variety of neural cell 
populations isolated from these brain regions. 
 
1.5.2. Rat brain 
 
Class I, II and IV HDACs are all expressed and widely distributed throughout the 
developed rat brain. Broide et al. (2007) have performed the most comprehensive 
study to date using in situ hybridisation techniques to compare the mRNA expression 
of each of the eleven HDAC isoforms for each brain region. Based on expression in 
the whole brain, HDAC11 is the most expressed followed by HDAC3, 5, 4, 2, 1, 6, 8, 
7, 9 and 10.  
 
Class I HDACs 3, 2 and 1 (in rank order of mRNA expression levels) are found in all 
brain regions studied including cerebral cortex, amygdala, striatum, hippocampus, 
hypothalamus, thalamus, midbrain, pons, the medulla oblongata and the granule cell 
layer of the cerebellum. HDAC3 is ubiquitously and equally expressed in all these 
regions whereas HDAC1 and HDAC2 are predominantly expressed in the cerebral 
cortex, amygdala and hippocampus. HDAC2 is expressed to a greater extent in the 
medulla oblongata compared to HDAC1. HDAC8 mRNA is found at very low levels 
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throughout the rat brain except in the hippocampus where it is expressed to a similar 
level as HDAC1 and in the granule cell layer of the cerebellum where it is expressed 
at a level half of that observed for HDAC1. 
 
Class IIa HDACs, HDAC4 and 5 are also expressed in all brain regions studied 
including the cerebral cortex, amygdala, striatum, hippocampus, hypothalamus, 
thalamus, midbrain, pons, the medulla oblongata and the granule cell layer of the 
cerebellum. HDAC5 mRNA is expressed at higher levels in the striatum and 
midbrain compared to HDAC4. HDAC7 and 9 are expressed at very low levels or 
are near absent in the cerebral cortex, hypothalamus, thalamus, midbrain and pons. 
HDAC7 is predominantly expressed in the amygdala, hippocampus, substantia nigra 
pars compacta and the granule cell layer of the cerebellum. HDAC9 is mostly 
expressed in the hippocampus and substantia nigra pars compacta. 
 
The class IIb HDAC6 is expressed in all brain regions studied with levels in the 
hippocampus being the greatest. HDAC10 is only found in the cortex and 
hippocampus, but even here HDAC10 mRNA expression is at relatively low levels 
compared to the other HDAC isoforms. The class IV HDAC11 is the most abundant 
HDAC in the rat brain and is universally present at high levels in all brain regions. 
 
1.5.3. Mouse brain 
 
HDAC1-11 mRNA is expressed in developed mouse cortex with HDAC2 and 5 
being the most expressed followed by HDAC11 then 4, whereas HDAC9 and 10 
have the lowest mRNA expression (Chen et al., 2012c). This trend in mRNA levels 
closely matches that in rat (Broide et al., 2007) but not in the human brain, where 
HDAC9 & 10 mRNA is found to be the most abundant and HDAC2 mRNA is 
expressed at relatively low levels compared to the other HDACs (Lucio-Eterovic et 
al. (2008) and see section 1.5.1). 
 
The expression of HDACs 1-3 at the protein level in the developed mouse brain is 
widespread and particularly prominent in the cerebral cortex and hippocampus 
(Baltan et al., 2011a). Another study, focusing on HDAC2, observed ubiquitous 
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protein expression throughout the whole of the developed mouse brain including the 
cerebral cortex, hippocampus, amygdala, basal ganglia, hypothalamus, thalamus, 
brain stem and the granule cell layer of the cerebellum (Yao et al., 2013). Class IIa 
HDAC4 protein is also widely expressed, in regions such as the cerebral cortex, 
amygdala, striatum, hippocampus, thalamus and the substantia nigra (Darcy et al., 
2010). Class IIb HDAC6 mRNA and protein is expressed in mouse cerebral cortex 
and hippocampus with lower levels observed in the cerebellum (Govindarajan et al., 
2013). 
 
1.5.4. Neural cells of mice and rat brains 
 
In summary, the majority of the HDAC isoforms are ubiquitously expressed across 
different brain regions and the specific neural cell populations of these. Table 1.3 
summarises the expression of mouse and rat HDACs 1-11 at the mRNA and/or 
protein level, in neurones from three important brain regions and also the three 
populations of glial cells in the brain; astrocytes, microglia and oligodendrocytes. 
 
Table 1.3. Expression of HDACs in mouse and/or rat neurones and glial cells. 
Neural cell type HDAC expressed 
Cortical neurones
3, 4, 5, 6, 12, 13, 15, 16, 19, 21 & 24
 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 & 11 
Hippocampal neurones
4, 5, 9, 10, 11, 15, 18 & 22
 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 & 11 
Cerebellar granule neurones
2, 3, 4, 5, 7, 16, 17 & 20
 1, 2, 3, 4, 5, 6, 7, 8 & 11 
Astrocytes
5, 8, 9, 12, 14, 15 & 23
 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 & 11 
Microglia
1, 8, 14 & 23
 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 & 11 
Oligodendrocytes
4, 12, 14, 15 & 22
 1, 2, 3, 4, 5 & 11 
References in superscript: 
1
Ajamian et al. (2004), 
2
Panteleeva et al. (2004), 
3
Bolger and Yao 
(2005), 
4
Broide et al. (2007), 
5
MacDonald and Roskams (2008), 
6
Kim et al. (2008), 
7
Leng et 
al. (2008), 
8
Faraco et al. (2009), 
9
Guan et al. (2009), 
10
Chen et al. (2010), 
11
Darcy et al. 
(2010), 
12
Kim et al. (2010), 
13
Sugo et al. (2010), 
14
Baltan et al. (2011b), 
15
Baltan et al. 
(2011a), 
16
Bardai and D'Mello (2011), 
17
Ma and D'Mello (2011), 
18
McQuown et al. (2011), 
19
Soriano and Hardingham (2011), 
20
Bardai et al. (2012), 
21
Chen et al. (2012c), 
22
Yao et al. 
(2013) 
23
Kannan et al. (2013) and 
24
Wei et al. (2015). Note: Reference 8 refers to HDAC 
expression in astrocyte and microglia co-cultures. 
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1.6. The acetylome of the brain 
 
HATs and HDACs are expressed throughout the brain where they control the 
acetylation state of proteins. To date histone proteins are one of the most studied 
members of the acetylome in the brain. Experimental evidence suggests that the 
acetylation of histone proteins regulates the expression of genes important for 
cognitive processes such as learning and memory (reviewed by Graff and Tsai 
(2013); Lopez-Atalaya and Barco (2014); Penney and Tsai (2014)). However, 
histones are only a small fraction of the collection of proteins that make-up the 
acetylome and in the rat brain this comprises of 1653 acetylated proteins in total 
(Lundby et al., 2012). These are located in many of the subcellular compartments 
including the nucleus, cytoplasm, mitochondria, endoplasmic reticulum, Golgi 
apparatus and the cell membrane (Lundby et al., 2012). Characterising these 
acetylated proteins and their known interacting partners on the basis of their known 
functions, shows acetylation regulates major processes in neurones including 
synaptic vesicle formation, trafficking and exocytosis, neurotransmitter release, axon 
guidance and migration, synaptogenesis, ion and solute transport across membranes, 
calcium signalling, phosphorylation and ubiquitination (Lundby et al., 2012). 
Therefore HATs and HDACs, which regulate the acetylation status of these proteins, 
are clearly important for normal brain function. 
 
 
1.7. Role of HDACs in the brain 
 
In order to study the function of HDACs in the brain; conditional brain specific 
deletions have been used. Knockout of HDAC1 (HDAC1KO, Montgomery et al. 
(2009)) or knockout of HDAC2 (HDAC2KO, Montgomery et al. (2009); Guan et al. 
(2009)) in the embryonic brain in mice has no effect on mouse brain development, 
histoarchitecture or mouse survival. In contrast, knockout of both HDAC1 and 2 is 
lethal by postnatal day seven. In these double knockout mice, neuronal precursors in 
the brain are unable to differentiate into mature neurones and subsequently undergo 
cell death resulting in major abnormalities in cerebral cortex, hippocampus and 
cerebellum structure (Montgomery et al., 2009). This suggests HDAC1 and 2 have 
Chapter 1    General Introduction 
21 
 
redundant functions during neural development. However, as will be subsequently 
discussed, in the developed brain, HDAC1 and 2 have some specific and independent 
roles; therefore at some point during postnatal development, the individual roles of 
these two HDACs must become established. 
 
Knockout of HDAC3 (HDAC3KO) in the mouse embryonic brain is lethal and pups 
die within 16 hours after birth. In the brains of these mice, there are fewer neural 
cells and major abnormalities in the development and cytoarchitecture of the cerebral 
cortex and cerebellum (Norwood et al., 2014). The loss of HDAC3 cannot be 
compensated for by other HDACs and this suggests that HDAC3 has a unique and 
important role in the development of the mouse brain. 
 
1.7.1. HDAC1 
 
Much of the research studying HDACs in the developed brain has focussed on their 
roles in cognition and behaviours associated with psychological disorders. 
Investigating these roles has often involved studying and manipulating the 
expression levels and activity of HDACs in in vivo and in vitro model systems. 
 
In order to understand the role of HDAC1 in cognition, brain specific overexpression 
mouse models have been employed. Mice overexpressing HDAC1 (HDAC1OE) in 
the brain have no obvious changes in brain anatomy, cellular architecture or overall 
neurone numbers (Guan et al., 2009). HDAC1 has been found overexpressed in 
frontal cortex of patients with schizophrenia (Sharma et al., 2008). Specifically 
overexpressing HDAC1 in the hippocampus of mice by directly injecting HDAC1 
expressing adeno-associated viral (AAV) vectors into the hippocampus, does not 
induce any quantifiable psychological effects such as anxiety or depression in these 
mice (Bahari-Javan et al., 2012). Furthermore, overexpression of HDAC1 in the 
brain and specifically in the hippocampus, does not affect learning and memory 
associated with object recognition (Bahari-Javan et al., 2012), fear conditioning or 
the Morris water maze (Guan et al., 2009; Bahari-Javan et al., 2012). Regarding the 
cellular correlates of learning and memory, HDAC1OE in hippocampal neurones has 
no effect on long-term potentiation (LTP) or synapse formation (Guan et al., 2009). 
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However, HDAC1 is important in the extinction of memories in particular those 
associated with fear. HDAC1 knockdown (HDAC1KD) in the hippocampus of mice 
prevents the extinction of fear memories whereas hippocampal HDAC1OE enhances 
extinction (Bahari-Javan et al., 2012). During fear extinction, HDAC1 is recruited to 
the promoters of memory genes c-Fos and early growth response protein 2 (Egr2). 
This is followed by the deacetylation of the histones of these genes, which correlates 
with a reduction in the expression of c-Fos and Egr2 and an extinction of the fear 
memory (Bahari-Javan et al., 2012). 
 
1.7.2. HDAC2 
 
HDAC2 also has a role in cognition. Mice overexpressing HDAC2 (HDAC2OE) but 
not HDAC1 in the brain, have impaired hippocampus-dependent learning and 
memory, as demonstrated by poor performances in the fear conditioning test and the 
Morris water maze compared to wild-type mice. HDAC2OE is accompanied with a 
global decrease in lysine acetylation as well as a decrease in histone acetylation at 
specific neuronal genes in the hippocampus. These mice also have a suppressed 
hippocampal LTP response and a reduction in the number of synapses on 
hippocampal neurones. In contrast, specific knockout of HDAC2 in the brains of 
mice improves learning and memory. Neurones of the hippocampus from 
HDAC2KO mice have an increased number of synapses and a more robust LTP 
response. HDAC2 but not HDAC1 is found enriched at the promoters of genes 
implicated in synaptic formation, synaptic plasticity, memory formation and genes 
regulated by neuronal activity such as synapsin, brain derived neurotrophic factor 
(BDNF), glutamate receptor subunits, cAMP response element binding-protein 
(CREB), CBP, c-Fos, Ca
2+
/calmodulin-dependent protein kinase II alpha (CaMKII 
and early growth response proteins 1 (Egr1). The cognitive enhancement in 
HDAC2KO mice is accompanied with an increase in the acetylation of histones 
found in the promoter of many of these genes and a subsequent increase in the 
expression of them. Collectively, these data suggest HDAC2 but not HDAC1, 
negatively regulates learning and memory formation in mice (Guan et al., 2009). 
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In support of this, the excitatory postsynaptic currents of isolated hippocampal 
neurones from HDAC2KO mice or HDAC2 knockdown (HDAC2KD) in neurones in 
rat hippocampal organotypic slice cultures are significantly increased compared to 
wild-type, HDAC1KO and HDAC1KD neurones (Nelson et al., 2011; Hanson et al., 
2013). HDAC2KD but not HDAC1KD also lowers the stimulation threshold to 
induce LTP in neurones in hippocampal slices (Hanson et al., 2013). Like Guan et al. 
(2009), Hanson et al. (2013) show that the increased excitatory synaptic function by 
reducing HDAC2 levels is accompanied by an increase in the expression of synaptic 
function genes including the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) glutamate receptor subunit GluR2. Furthermore, HDAC2KD reduces 
whereas HDAC2OE increases the amplitude of inhibitory postsynaptic currents in 
neurones in hippocampus slice culture. These changes are brought about by HDAC2 
dependent modulation of the abundance of synaptic inhibitory GABA (γ-
Aminobutyric acid)-ergic receptors. Together, these results suggest HDAC2 in the 
hippocampus suppresses neuronal excitation and enhances inhibitory synaptic 
transmission and both combined may contribute to the negative regulation of 
learning and memory by HDAC2 (Hanson et al., 2013). 
 
Since an increase in HDAC2 activity has a negative effect on learning and memory, 
it is not surprising to find that HDAC2 but not HDAC1 or 3 expression is increased 
in the hippocampus and the entorhinal cortex in the brains of individuals with early 
stage Alzheimer’s disease (Graff et al., 2012). It has been suggested that this increase 
in HDAC2 expression and activity, and consequent changes in gene expression, is an 
early pathological event (Graff et al., 2012). This specific increase in the expression 
of HDAC2 is recapitulated in isolated mouse hippocampal neurones exposed to 
amyloid beta (A) and in two mouse models of Alzheimer’s disease (the p25/Cyclin-
dependent kinase 5 (Cdk5) model and the five familial Alzheimer’s disease mutation 
model (5XFAD)), where HDAC2 levels are increased in the hippocampus and 
prefrontal cortex (Graff et al., 2012). Compared to wild-type mice, HDAC2 in the 
p25/Cdk5 mouse hippocampus is significantly enriched at the promoter regions of 
genes involved in synaptic function, synaptic plasticity and learning and memory, 
such as BDNF IV, Egr1, glutamate receptor subunits and synaptic proteins 
synaptophysin and synaptotagmin. This coincides with histone hypoacetylation in the 
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promoter region and a reduction in the expression of these genes. These findings 
suggest that in Alzheimer’s disease, HDAC2 represses genes important for learning 
and memory and this may contribute to the cognitive decline associated with this 
disease (Graff et al., 2012). Reducing HDAC2 expression in hippocampal neurones 
of p25/Cdk5 mice to wild-type levels, increases both histone acetylation and 
expression of those genes important in learning and memory already described. 
Furthermore, at the cellular level, HDAC2KD in p25/CdK5 mice improves LTP and 
significantly increases the synaptic density and abundance of dendrites of 
hippocampal neurones. As a consequence, HDAC2 knockdown significantly 
improves learning and memory in p25/Cdk5 mice as measured by fear conditioning 
and the Morris water maze tests (Graff et al., 2012).  
 
1.7.3. HDAC3 
 
Similar to other class I HDACs, HDAC3 is expressed in the cortex and hippocampus 
therefore it is not surprising to find it involved in regulating cognitive processes. 
Similarly to HDAC1, HDAC3 activity acts as a restraint on learning and memory. 
Focal deletion of HDAC3 in the hippocampus of adult mice enhances hippocampal 
dependent learning and memory for object locations. This is accompanied by histone 
hyperacetylation and increased expression of learning and memory genes such as c-
Fos (McQuown et al., 2011). In support of the role for HDAC3 containing 
complexes in the negative regulation of learning and memory, global knock-in mice 
that carry a mutation in the nuclear receptor co-repressor protein (NCoR is an 
essential component of the NCoR multi-protein complex) so it cannot interact with 
HDAC3, also have improved learning and memory associated with object 
recognition and locations (McQuown et al., 2011). 
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1.7.4. HDAC4 
 
Mice with a conditional cerebrum specific deletion of HDAC4 have reduced anxiety-
like behaviour but deficits in learning and memory examined using the Morris water 
maze test. This learning and memory deficit is associated with impairments in 
hippocampal LTP but not basal synaptic transmission, which suggests HDAC4 is a 
positive regulator of memory formation (Kim et al., 2012b). 
 
1.7.5. HDAC5 
 
Constitutive HDAC5 knockout mice are viable and display no abnormalities in 
behaviour, basal synaptic transmission or learning and memory associated with fear 
conditioning (Kim et al., 2012b). However, a second report showed there are deficits 
in learning and memory associated with fear conditioning and the Morris water maze 
test in old HDAC5 null mice (Agis-Balboa et al., 2013). 
 
1.7.6. HDAC6 
 
HDAC6 knockout (HDAC6KO) mice are viable, histological examination reveals 
there are no brain abnormalities and mice show no detectable motor deficits (Fukada 
et al., 2012; Taes et al., 2013). HDAC6 has been reported to be upregulated in the 
brains of Alzheimer’s disease patients (Ding et al., 2008) and also in the hippocampi 
of a mouse Alzheimer’s disease mouse model called APPPS1 (mutations in both 
amyloid precursor protein (APP) and presenilin 1 (PS1/PSEN1), Govindarajan et al. 
(2013)). Knocking out HDAC6 in this model reduces the deficit in learning and 
memory (Govindarajan et al., 2013). Changes in psychological behaviour following 
knockout of HDAC6 in healthy mice is currently disputed. Fukada et al. (2012) 
observe HDAC6KO mice to be emotionally aroused, hyperactive, have decreased 
anxiety and antidepressant-like behaviour, whereas Govindarajan et al. (2013) do not 
observe any of these changes when comparing HDAC6 knockout mice to wild-type 
animals. 
 
Chapter 1    General Introduction 
26 
 
HDAC6 has been implicated in regulating the microtubule transport system in 
neurones. Microtubules are a major component of the cytoskeleton and are important 
for anterograde and retrograde axonal transport of molecules and organelles. The 
efficient movement of materials along axons is critical for neuronal function. 
Inhibition of HDAC6 leads to the hyperacetylation of -tubulin (a constituent of 
microtubules); this enhances the recruitment of molecular motors to microtubules 
and consequently augments the transport of vesicles (Dompierre et al., 2007) and 
trafficking of mitochondria (Chen et al., 2010; Kim et al., 2012a) in axons of 
neurones. 
 
 
1.8. HDAC inhibitors 
 
Inhibitors of the zinc-dependent class I and II HDACs are classified into four groups 
on the basis of common pharmacophores; 1) short chain fatty acids, 2) 
hydroxamates, 3) cyclic tetrapeptides and 4) benzamides. By solving crystal 
structures of HDACs with bound HDAC inhibitors (reviewed by Micelli and Rastelli 
(2015)) we have an understanding of how these drugs interact with and inhibit 
HDACs. Each inhibitor comprises of 1) a zinc-binding domain, which chelates the 
Zn
2+
 cofactor in the active site and this chelation is responsible for inhibiting the 
catalytic activity of the HDAC, 2) a surface binding domain/cap which interacts with 
the entrance of the channel leading to the active site, thus blocking access for the 
natural substrate, and 3) a linker which connects the two domains and occupies the 
hydrophobic channel leading to the catalytic site (figure 1.3). Each of these 
pharmacophores is thought to contribute to the selectivity of HDAC inhibitors for 
particular HDAC classes and isoforms. 
 
The short-chain fatty acids sodium butyrate, sodium phenylbutyrate and valproate 
(VPA) are non-selective inhibitors of both class I and class II HDACs with effective 
concentrations in the millimolar range (Gurvich et al. (2004) and reviewed by 
Dokmanovic et al. (2007)). In addition to HDAC inhibition, these inhibitors have 
other targets. Valproate for example, is an approved drug to treat epilepsy and its 
mode of action is thought to be through inhibiting voltage-gated sodium channels 
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and potentiating GABAergic signalling. These combined produce a therapeutic effect 
by depressing the excitability of the brain (reviewed by Rosenberg (2007)).  
 
Hydroxamate HDAC inhibitors such as ITF2357 (Givinostat), suberoylanilide 
hydroxamic acid (SAHA, Vorinostat) and trichostatin A (TSA), inhibit HDACs 
through chelation of the zinc ion in the catalytic site of the HDAC via the 
hydroxamic acid group of the inhibitor (figure 1.3). Hydroxamate HDAC inhibitors 
are predominantly non-selective and inhibit HDACs in classes I and II with effective 
concentrations in the nanomolar concentration range (table 1.4).  
 
Cyclic tetrapeptide HDAC inhibitors are so named for their cyclic structure of four 
non-proteinogenic amino acids that forms the surface binding group/cap of the 
inhibitor (figure 1.3). One key member of this inhibitor class is apicidin, which is 
selective for class I HDACs (table 1.4). 
 
The final group of inhibitors, the benzamides, are some of the most selective HDAC 
inhibitors for class I HDACs that have been developed to date. These inhibitors are 
classified on the basis of their zinc-binding domain, the amino-benzamide group. 
MS-275 (Entinostat) is a well-studied example of this class, which is selective for the 
class I HDACs, HDAC1, 2 and 3 with nanomolar potency (table 1.4). Another 
benzamide HDAC inhibitor MI192, is selective for HDAC2 and 3 (half maximal 
inhibitory concentration (IC50) of 4.8 M, 30 nM, 16 nM, 5 M, >10 M, 4.1 M 
and >10 M for HDAC1, 2, 3, 4, 6, 7 and 8 respectively, Boissinot et al. (2012)). 
Benzamide HDAC inhibitors inhibit class I HDACs by co-ordinating the zinc ion in 
the catalytic site of the HDAC. The chemical moieties of the amino-benzamide 
group important for this are the nitrogen of the aniline amide and the oxygen of the 
amide carbonyl group (figure 1.3).  
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Figure 1.3. Structures of the representative histone deacetylase (HDAC) inhibitors and their 
pharmacophores. Adapted from Newkirk et al. (2009); Mottamal et al. (2015). 
 
 
Table 1.4. Selectivity of HDAC inhibitors, (Ki ± SD, nM). 
  H CT B 
Class HDAC TSA SAHA Apicidin MS-275 
I 
1 0.2 ± 0.045 1.3 ± 0.05 0.04 ± 4 × 10
-3
 22 ± 2 
2 0.65 ± 0.05 1.6 ± 0.05 0.12 ± 3 × 10
-3
 65 ± 5 
3 0.5 ± 0.1 5 ± 0.2 0.26 ± 5 × 10
-3
 360 ± 15 
8 45 ± 15 480 ± 20 49 ± 20 >10,000 
II
 
4 1400 ± 100 >10,000 >10,000 >10,000 
5 260 ± 35 3600 ± 380 >10,000 >10,000 
6 1 ± 0.1 1.6 ± 0.05 >10,000 >10,000 
7 195 ± 20 >10,000 >10,000 >10,000 
9 800 ± 100 >10,000 >10,000 >10,000 
Abbreviations, H: Hydroxamate, CT: Cyclic tetrapeptide, B: Benzamide, SD: Standard 
deviation. Data taken from Bradner et al. (2010). No data for HDAC10 or 11. 
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The inhibitor profiles of HDAC inhibitors for HDACs discussed and shown in table 
1.4 have been determined using individual recombinant HDACs and an acetylation 
reporter assay (Bradner et al., 2010). Bantscheff et al. (2011) have used a different 
approach looking at selectivity of HDAC inhibitors by performing chemoproteomic 
competition binding assays with human cell lysates. This technique first involved the 
development of a probe matrix based on hydroxamate HDAC inhibitors that would 
bind to and capture cellular HDACs and their associated complexes for subsequent 
identification and quantification by mass spectrometry. Using a competition binding 
approach with increasing concentrations of free-HDAC inhibitor, if the inhibitor is 
selective for the HDAC bound complex to the hydroxamate probe matrix, then the 
probe is outcompeted for binding and is displaced. This can be detected as a loss in 
signal for the HDAC and associated interacting proteins. This assay was performed 
for a range of HDAC inhibitors looking at the selectivity towards HDACs 1, 2, 3, 6, 
8 and 10. For the majority of the HDAC inhibitors tested, the selectivity towards 
these particular isoforms is similar to that shown in other studies using reporter 
assays (table 1.4). But this study also revealed that HDAC inhibitors have selectivity 
towards HDACs in certain complexes they are members of (see section 1.4.4 for 
details on the different complexes). The non-selective class I and II HDAC inhibitor 
valproate, in order of selectivity for the HDAC containing complexes, preferentially 
binds to HDAC1 and 2 in the CoREST and NuRD containing complexes over 
HDAC3 in the complex NCoR, but does not bind to HDAC1 and 2 in the Sin3 
complex. Whereas the non-selective HDAC inhibitors TSA and SAHA bind to 
HDACs in these four complexes equally. Likewise, the class I HDAC inhibitor 
apicidin does not preferentially bind to HDACs in either complex, but the class I 
HDAC1, 2 and 3 selective inhibitor MS-275, selectively binds to these isoforms in 
the NCoR, CoREST and NuRD (in order of selectivity) but not Sin3 complexes. 
How HDAC inhibitors, which selectively inhibit HDACs, have a preference for or 
can only bind to HDACs in certain HDAC-containing complexes is not understood. 
It has been suggested that the surface binding group/cap of the HDAC inhibitor 
confers selectivity to the specific complexes (Salisbury and Cravatt, 2007; 
Bantscheff et al., 2011). However, this hypothesis does not fit with the observations 
that SAHA and MS-275 despite having similar surface binding domains/caps (figure 
1.3) have very different complex selectivities and also SAHA and apicidin which 
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have very different surface binding domains, have the same complex selectivities. 
This study has raised an interesting point, that when using HDAC inhibitors which 
inhibit HDAC1 and 2, the effects observed are not simply from inhibiting these 
isoforms, but are also from differentially inhibiting the HDAC1 and 2 containing 
complexes. 
 
In addition to HDAC isoform selectivity, the binding kinetics of the different classes 
of HDAC inhibitors also differs, yet this is something that is often overlooked but 
may actually affect the physiological outcome of HDAC inhibition (Chou et al., 
2008; Bressi et al., 2010; Lauffer et al., 2013). The association rate and dissociation 
rates of the benzamide HDAC inhibitor MS-275 are several orders of magnitude 
slower compared to the hydroxamate HDAC inhibitor SAHA and as a consequence 
the length of time it takes benzamide HDAC inhibitors to bind to and inhibit 
HDACs, as well as the length of time the inhibitors are bound to them is significantly 
longer (Lauffer et al., 2013). To explain the slow binding kinetics of benzamide 
HDAC inhibitors, it has been shown that an internal hydrogen bond in the zinc-
binding domain of benzamide HDAC inhibitors, between the aniline amine and the 
amide carbonyl moieties, must be broken in order for the successful binding of 
benzamide inhibitors to a HDAC and coordination of the zinc ion in the active site 
(Bressi et al., 2010; Lauffer et al., 2013). This change in benzamide HDAC inhibitor 
structure must first take place in order for the inhibition of HDACs. The time it takes 
for this change to occur explains the slow binding kinetics of MS-275 and other 
benzamide HDAC inhibitors. The binding of hydroxamates such as SAHA to 
HDACs is much faster because structural rearrangements are not necessary for 
successful binding (Lauffer et al., 2013). A difference in a physiological response as 
a consequence of the different binding kinetics of hydroxamates and benzamides 
HDAC inhibitors is clearly demonstrated in the kinetics of acetylation of proteins 
over-time. The onset of histone acetylation and the time-dependent return of histone 
acetylation to the pre-HDAC inhibitor state are much slower with benzamide HDAC 
inhibitors compared to SAHA (Chou et al., 2008; Lauffer et al., 2013). These 
temporal differences in protein acetylation by these different classes of HDAC 
inhibitors, may affect the timings of functional effects, such as gene expression 
(Lauffer et al., 2013). Indeed, in cortical neurones, SAHA and MS-275 both increase 
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the expression of the neuroprotective and neurone-function enhancing protein 
BDNF, but do so at different times following treatment. SAHA rapidly induces the 
expression of BDNF during one hour, whereas BDNF upregulation following MS-
275 treatment is significantly delayed, with expression increasing between three and 
six hours post-treatment (Koppel and Timmusk, 2013). 
 
 
1.9. Effect of HDAC inhibition on gene expression in the brain 
 
As mentioned in section 1.2.1, histone acetylation and deacetylation are traditionally 
associated with active/activation of gene expression and an inactive/inactivation of 
gene expression respectively. Lopez-Atalaya et al. (2013) have mapped the 
acetylation of histone H3 at lysine 9 and 14 (H3K9 & 14), histone H4 at lysine 12 
(H4K12) and pan-acetylation of histone H2B (pan-H2B) for the whole-genome 
extracted from the mouse hippocampus in the basal state and in response to treatment 
of mice with the non-selective HDAC inhibitor TSA. In the basal state, all three 
acetylation marks are observed at the transcription start site (TSS), in introns and 
exons of genes (intragenic regions) and in non-transcribed DNA between genes 
(intergenic region). The abundance of these acetylated histone marks at TSSs and in 
the intragenic region of a gene correlates well with its level of expression. In the 
hippocampus of mice treated to TSA there was a significant but transient increase in 
global histone acetylation with an increase in the number of acetylation marks at 
H3K9 & 14, H4K12 and pan-H2B. Closer inspection of the topology of these 
changes reveals clear increases in histone acetylation at TSSs, intragenic regions and 
suspected gene expression enhancer regions but not intergenic regions. Genes in the 
hippocampus that are acetylated and actively expressed at the basal state undergo the 
greatest hyperacetylation in response to TSA, whereas poorly acetylated and low or 
non-expressed genes are largely unaffected. Furthermore, the overall impact of TSA 
on gene expression is actually very small, with changes in the expression of only 88 
genes and of these, around equal numbers are upregulated and down-regulated. 
These observations are consistent with other studies looking at the effects of HDAC 
inhibitors on global histone acetylation in non-neuronal cells (Van Lint et al., 1996; 
Bernstein et al., 2000; Marks, 2004; Peart et al., 2005; Reid et al., 2005; Halsall et 
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al., 2012). Furthermore, of the 88 genes that are affected in the mouse hippocampus, 
TSA increases the acetylation of histones in the TSS of both the up and down-
regulated genes. Together these findings contrast with the idea that histone 
acetylation is associated with active gene expression. The reasons behind these 
observations are poorly understood but a few possible explanations have been put 
forward, 1) HDAC inhibitors upregulate transcriptional repressor genes, which then 
down-regulate other genes, 2) HDAC inhibition causes the acetylation of non-histone 
substrates such as transcription factors, which positively or negatively regulate gene 
expression, 3) another explanation based on the fact that HDACs have been found to 
reside with HATs on active genes (Kurdistani et al., 2002; Wang et al., 2009b), is 
that HDACs deacetylate histones and reset the conformation of chromatin between 
rounds of transcriptional activation (Metivier et al., 2003; Kelly and Cowley, 2013; 
Dovey et al., 2010a). Therefore, preventing this resetting of chromatin structure with 
HDAC inhibitors will lead to the hyperacetylation of active genes and this may 
positively or negatively affect the transcription of those genes. 
 
 
1.10. HDAC inhibitors as neuroprotective agents to treat cerebral ischaemia 
 
There is a growing body of evidence to suggest a change in protein acetylation is part 
of the pathophysiology of neurodegenerative disease, brain insults and brain injuries.  
In the brains of rodents following ischaemia (Calderone et al., 2003; Ren et al., 2004; 
Faraco et al., 2006; Kim et al., 2007b; Wang et al., 2011a; Noh et al., 2012), in the 
spinal cord of a mouse model of motor neurone disease (Rouaux et al., 2003), in 
isolated cortical neurones following oxygen & glucose deprivation (OGD, 
Lanzillotta et al. (2013); Dmitriev and Papkovsky (2015)) or exposure to A 
(Rouaux et al., 2003) and in cerebellar granule neurones (CGNs) following exposure 
to the apoptotic stimuli of low extracellular K
+
 and glutamate excitotoxicity (Rouaux 
et al., 2003; Leng and Chuang, 2006), there is a consistent reduction in the 
acetylation of histones H3 and/or H4 (see figure 1.4 for an example). Potential 
causes of this deacetylation are changes in the expression of HDACs (see sections 
3.1.1 to 3.1.7) and/or HATs (Rouaux et al., 2003; Rouaux et al., 2007; Yildirim et 
al., 2014). 
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Figure 1.4. Histone acetylation levels decrease during neuronal apoptosis. Cerebellar 
granule neurones were maintained in survival conditions (high potassium, HK) or exposed to 
K
+
 deprivation (low potassium, LK) in order to trigger apoptosis. (A) The acetylation state of 
histones H3 (Ac-H3) and H4 (Ac-H4) during 6, 12 and 24 hours exposure to the apoptosis 
stimulus was monitored by Western blot analysis. Total cellular histone protein expression 
levels was analysed by Coomassie staining and was found to be unaffected during neuronal 
apoptosis. Values quoted to the right of the blots & gel indicate the molecular weight in kDa. 
(B) Histone acetylation is specifically decreased in neurones undergoing apoptosis. 
Representative fluorescence images of Hoechst nuclei staining and immunostaining for Ac-
H3 and Ac-H4 (indicated by cyanine 3 (CY3) labelling). Arrow heads indicate a reduction in 
histone acetylation in the condensed and fragmented nuclei of cells undergoing apoptosis. 
Scale bar 10 m. Figure adapted from Rouaux et al. (2003) with permission and under 
license granted by the publisher John Wiley and Sons (license number: 3772490615009, 
issued on the 19
th
 of December 2015). Copyright © 2003 European Molecular Biology 
Organization.  
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Cerebral ischaemia triggers the upregulation of the repressor element 1-silencing 
transcription factor (REST) in the rat hippocampus (Calderone et al., 2003; Noh et 
al., 2012) and rat cerebral cortex (Formisano et al., 2015). REST represses the 
expression of genes important for neuronal survival and function by recruiting the 
CoREST- and Sin3-HDAC1 & 2 containing repressor complexes to specific genes 
(Ooi and Wood, 2007). In cerebral ischaemia, REST and the multi-protein repressor 
complexes are found enriched at and inhibit the expression of many neuronal genes 
(Calderone et al., 2003; Formisano et al., 2015; Noh et al., 2012). Knockdown of 
REST, forced expression of a dominant negative competitor or combined 
knockdown of HDAC1 and 2, disinhibits REST-mediated repression of these genes 
and neurones are protected from ischaemia-induced death (Calderone et al., 2003; 
Formisano et al., 2015; Noh et al., 2012). 
 
In neuronal models of apoptosis, ischaemia, Alzheimer’s disease and motor neurone 
disease there is a consistent loss of CBP expression accompanied with histone 
deacetylation (Rouaux et al., 2003; Rouaux et al., 2007; Yildirim et al., 2014). 
Knocking down CBP in mouse cortical neurones exposed to OGD exacerbates 
neurone death (Yildirim et al., 2014) but overexpression of HATs CBP or p300 in 
neurones is neuroprotective (Rouaux et al., 2003). Moreover, CBP is actively 
upregulated in surviving neurones after ischaemia (Jin et al., 2001) and can be found 
enriched at the neuroprotective gene gelsolin (Yildirim et al., 2008; Yildirim et al., 
2014). Taken together, these data suggest CBP activity is important for neurone 
survival and increasing the activity of HATs in conditions where it is reduced may be 
of therapeutic benefit. In support of the role of protein deacetylation in the 
pathogenesis of cerebral ischaemia and preventing deacetylation or augmenting 
acetylation is a viable neuroprotective strategy; HDAC inhibitors have been shown 
to be neuroprotective in a variety of models relevant to this brain insult and injury. 
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1.10.1. A brief overview of the pathophysiology of cerebral ischaemia 
 
Cerebral ischaemia is caused by a reduction in blood flow to a region of the brain 
usually as a result of the occlusion of a cerebral artery. This leaves brain tissue 
unsupplied with oxygen and glucose, which causes cellular energy failure followed 
by a highly complex series of cellular, temporal and spatial events leading to neural 
cell and tissue dysfunction and death. This can be fatal to the individual, but those 
who survive the insult have permanent disabilities and neurological impairments 
reflective of the extent and location of the ischaemic damage in the brain. This 
ischaemic injury is temporal and spatial in nature. Within minutes there is rapid onset 
of tissue damage and death in the immediate region of the brain which the blocked 
blood vessel supplies. Here the cells that are damaged and are dying cannot be saved 
and this forms a lesion known as the ischaemic core. Over-time the pathogenesis 
spreads from the initial site to the surrounding tissue where energy metabolism is 
partially preserved. This forms a damaged and dying region called the penumbra 
(Barone and Feuerstein, 1999; Dirnagl et al., 1999; Lo et al., 2003). It is generally 
considered that there is a short therapeutic window to use pharmacological agents to 
prevent neural cell death and dysfunction in the penumbral region. 
 
In the ischaemic core, cellular energy failure prevents the maintenance of the finely 
balanced membrane potential, crucial for proper functioning and survival in neural 
cells. The Na
+
/K
+
-ATPase and the Ca
2+
-ATPase are energy-dependent pumps that 
maintain the membrane potential, but because of the reduction of adenosine 
triphosphate (ATP) synthesis during ischaemia, these pumps no longer function 
efficiently and neural cells depolarise due to Na
+
 and Ca
2+
 accumulation in the cell. 
This triggers excessive glutamate release into the extracellular space by synaptic 
vesicle release from neurones as well as the reversal of the sodium-dependent, 
electrochemical gradient coupled, excitatory amino acid transporters (EAATs) found 
in the membranes of neurones and astrocytes. An increase in the levels of 
extracellular glutamate then causes a phenomenon called excitotoxicity (Dirnagl et 
al., 1999; Lo et al., 2003). This involves over- and chronic-activation of the AMPA, 
N-Methyl-D-aspartic acid (NMDA), Kainate and metabotropic glutamatergic 
receptors and collectively this facilitates a further influx of Na
+
 and Ca
2+
 into the cell 
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and also the release of Ca
2+
 from intracellular stores. Described simply, this calcium 
overload causes neural cell death by activating proteases, lipases and endonucleases, 
which damage and break down the cell. Calcium overload also causes free radical 
production, which in turn leads to oxidative and nitrosative stress and this also 
damages DNA, proteins and lipids. As a consequence, the protective systems in 
neural cells within the ischaemic core are overwhelmed and cells die predominantly 
by necrosis and release their intracellular contents including toxic species into the 
extracellular space. These species then trigger the death of other neural cells, which 
leads to the exacerbation and spreading of injury and neural cell death (Dirnagl et al., 
1999; Lo et al., 2003). 
  
Neural cells in the surrounding penumbral region are confronted with propagating 
glutamate excitotoxicity, oxidative stress and toxic species from the ischaemic core, 
these damage cells and initiate delayed apoptotic cell death (Dirnagl et al., 1999; Lo 
et al., 2003). Furthermore, over the next few hours and days following the initial 
ischaemic attack, as the damage and death is spreading and accumulating, cellular 
damage, cells undergoing apoptosis, necrotic debris and spillage, and the production 
of inflammatory mediators by injured neural cells, all activate microglia which are 
the resident immune cells of the brain. In addition, ischaemic damage increases the 
permeability of the blood brain barrier, resulting in the infiltration of leukocytes, 
such as macrophages from the systemic circulatory immune system. Together, these 
innate immune cells accumulate in the ischaemic core and penumbra, and initiate an 
inflammatory response mediated by the NF- and MAPK (mitogen-activated 
protein kinase) signalling pathways. Upon activation of these pathways, these 
immune cells express and release of pro-inflammatory mediators including the 
cytokines; tumour necrosis factor-alpha (TNF-, interleukin-1 beta (IL-1 and 
interleukin-6 (IL-6) and produce oxidative and nitrosative species amongst other 
things. These inflammatory mediators can be toxic to neurones and other neural cells 
such as oligodendrocytes, leading to secondary neural cell damage and death and 
further amplification and spreading of the injury (reviewed by Barone and Feuerstein 
(1999); Ceulemans et al. (2010); Dirnagl et al. (1999); Lakhan et al. (2009); Lo et al. 
(2003); Wang et al. (2007); Zheng and Yenari (2004)). 
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Over-time, there are also changes in the expression of many genes in neural cells of 
the penumbral region in response to cerebral ischaemia, including immediate early 
response genes, pro- and anti-apoptotic genes, growth factors, pro-and anti-
inflammatory genes and many others (reviewed by Papadopoulos et al. (2000); Read 
et al. (2001)). These changes and the balance between pro-death and pro-survival 
gene expression contributes to the fate of neural cells in the penumbral region of the 
ischaemic brain. Therefore modulating these transcriptional programs may be a 
useful strategy to protect neural cells from ischaemia-induced damage and death. 
 
In summary, cerebral ischaemia causes a complex cascade of spatial and temporal 
events including glutamate excitotoxicity, oxidative stress, necrosis, apoptosis and 
neuroinflammation. The ideal treatment regime using pharmacological agents would 
target all of these pathophysiological mechanisms in order to protect neural cells of 
the penumbra. 
 
1.10.2. HDAC inhibitors are neuroprotective in in vivo models of cerebral ischaemia 
 
The neuroprotective effects of HDAC inhibitors in in vivo mouse and rat models of 
cerebral ischaemia (middle cerebral artery occlusion (MCAO) and four-vessel 
occlusion (4-VO)) have been extensively reviewed (Baltan et al., 2013; Langley et 
al., 2009; Schweizer et al., 2013; Shein and Shohami, 2011; Ziemka-Nalecz and 
Zalewska, 2014). In general, when either administered immediately at the time of, or 
post-treated up to 7 hours after the onset of ischaemia, HDAC inhibitors have a 
plethora of therapeutic effects. HDAC inhibitors significantly protect neurones and 
oligodendrocytes, reduce brain damage and infarct volume (Faraco et al., 2006; Kim 
et al., 2009; Kim et al., 2007b; Qi et al., 2004; Ren et al., 2004; Wang et al., 2011a; 
Wang et al., 2011b; Kim and Chuang, 2014; Lanzillotta et al., 2013; Liu et al., 2012; 
Murphy et al., 2014; Noh et al., 2012; Xuan et al., 2012), improve functional 
recovery (Faraco et al., 2006; Kim et al., 2009; Kim et al., 2007b; Liu et al., 2012; Qi 
et al., 2004; Ren et al., 2004; Wang et al., 2012; Xuan et al., 2012; Yildirim et al., 
2008), restore the integrity of the blood brain barrier (Wang et al., 2011b) and also 
improve blood flow in the ischaemic brain (Kim and Chuang, 2014; Wang et al., 
2012). In the majority of these studies, HDAC inhibition prevents ischaemia-induced 
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loss of histone acetylation and in some instances increases it above normal levels. 
Overall, there is a reported decrease in neural cell apoptosis, which coincides with 
increases in anti-apoptotic mediators including heat-shock protein 70 (HSP70, 
Faraco et al. (2006); Kim et al. (2007b); Ren et al. (2004)), gelsolin (Yildirim et al., 
2008) and B-cell lymphoma 2 (Bcl-2, Faraco et al. (2006); Kim et al. (2007b); Ren et 
al. (2004)), as well as a decrease in the expression of the apoptosis inducer p53 (Kim 
et al., 2007b) and a reduction in the activity of capsases (Kim and Chuang, 2014; Qi 
et al., 2004; Ren et al., 2004). There is also an anti-inflammatory effect, observed as 
a reduction in the expression of pro-inflammatory genes TNF- (Xuan et al., 2012), 
IL-1 (Xuan et al., 2012), inducible nitric oxide synthase (iNOS, Kim et al. (2007b)) 
and cyclooxygenase-2 (COX-2, Kim et al. (2007b)), and also a suppression of 
microglial activation and accumulation (Kim et al., 2007b; Kim and Chuang, 2014; 
Xuan et al., 2012). 
 
Despite these observations, the molecular mechanisms underlying them are not fully 
understood. Furthermore, an analysis of the global changes in the acetylome in 
response to cerebral ischaemia and HDAC inhibitor treatment has not been 
performed. It is important that this is not overlooked, because many of the reported 
neuroprotective effects of HDAC inhibitors could arise from an increase in the 
acetylation of non-histone proteins. The neuroprotective transcription factor, nuclear 
factor-like 2 (Nrf2) is an example. TSA is known to increase the acetylation of Nrf2, 
enhancing its transcriptional activity, which leads to an increase in the expression of 
neuroprotective antioxidant genes (Wang et al., 2011a). 
 
Because HDAC inhibitors in in vivo models of cerebral ischaemia target multiple 
pathophysiological components, the use of these compounds as therapeutic agents 
looks promising. Unfortunately, the majority of the in vivo studies performed to date 
have used the non-selective HDAC inhibitors SAHA, sodium butyrate, sodium 
phenylbutyrate, TSA and VPA. This means we do not know which HDAC or 
HDACs when inhibited are responsible for the neuroprotection observed and this 
also makes it difficult to isolate and determine the molecular mechanisms underlying 
this neuroprotection. Furthermore, clinically available non-selective HDAC 
inhibitors are associated with adverse side effects (see Schweizer et al. (2013) for a 
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review and see section 5.1), which also emphasises the need to identify the 
appropriate HDAC isoform(s) to inhibit. Lanzillotta et al. (2013) and Murphy et al. 
(2014) have made some progress with respect to this problem and show that the class 
I HDAC1, 2 and 3 inhibitor MS-275, is neuroprotective in the mouse MCAO model 
of cerebral ischaemia. This finding warrants further work to investigate the 
mechanisms underlying the neuroprotection provided by inhibiting HDACs 1, 2 and 
3, and to also determine which of these HDACs, upon inhibition, is responsible for 
this neuroprotective effect. 
 
1.10.3. HDAC inhibitors are neuroprotective in models of oxygen & glucose 
deprivation (OGD) 
 
During cerebral ischaemia, the fundamental pathological event that occurs is the 
starvation of neural cells of oxygen and glucose. This is often mimicked to simulate 
ischaemia-induced neural cell death in ex vivo nervous tissue and in vitro neural cell 
culture model systems. Using these systems, in comparison to in vivo models, allows 
for the studying of the responses of specific cell types, cell populations and their 
interactions during ischaemia, and upon pharmacological intervention in a more 
controlled and easy to manipulate environment. 
 
Histone deacetylase inhibitors exhibit neuroprotective effects in several ex vivo and 
in vitro models of OGD. When TSA is applied immediately after inducing OGD in 
organotypic slice cultures of rat hippocampus, this significantly reduces the amount 
of ischaemia-induced neurone cell death (Noh et al., 2012). HDAC inhibition also 
protects isolated neurone cultures from OGD. Pre-treating mouse or rat cortical 
neurones with TSA for one to twelve hours prior to exposing to OGD is 
neuroprotective (Meisel et al., 2006; Wang et al., 2011a). Here, TSA increases the 
acetylation of histone proteins and there is a positive correlation between surviving 
neurones and histone acetylation state (Meisel et al., 2006). On closer inspection, the 
acetylation of histones in the gene promoter for the neuroprotective protein gelsolin 
is enhanced by TSA treatment and this coincides with an increase in gelsolin 
expression (Meisel et al., 2006). In order to determine which specific HDAC 
isoforms must be inhibited to have neuroprotective effects, Lanzillotta et al. (2013) 
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and Formisano et al. (2015) have examined the effects of treating cortical neurones 
after OGD with the HDAC1, 2 and 3 selective inhibitor MS-275. Here, post-
treatment of MS-275 is neuroprotective and recovers an observed OGD-induced 
reduction in histone acetylation (Lanzillotta et al., 2013). From a neuroprotective 
mechanism standpoint, MS-275 or combined HDAC1 and 2 knockdown, increases 
the expression of the Na
+
/Ca
2+
 exchanger (NCX, Formisano et al. (2015)) and this 
may lead to neuroprotection by enhancing the extrusion of toxic intracellular calcium 
from neurones. 
 
Neurological recovery following cerebral ischaemia is dependent on the maintenance 
and repair of neurone axons and dendrites, connectivity between neurones and white 
matter integrity in the brain. Depriving mouse optic nerve cultures of oxygen and 
glucose is a useful model of ischaemia-induced white matter damage that allows for 
the studying of axon integrity and function following ischaemia. Pre-treating with 
HDAC inhibitors (TSA or MS-275) before inducing OGD, or administering them 
immediately after OGD, has a number of neuroprotective effects in this model of 
white matter. These include reducing glutamate release by neural cells, preventing 
ATP depletion and preserving mitochondrial function. These combined, protect 
oligodendrocytes, preserve axon integrity, maintain white matter cellular architecture 
and promote functional recovery of neurones (Baltan et al., 2011b; Murphy et al., 
2014). Similarly, Kim et al. (2010) show MS-275 improves mitochondrial transport 
and prevents neurite beading in the axons of cortical neurones exposed to the 
neurotoxins glutamate and TNF-. Furthermore, treating rat cortical neurones with 
VPA or TSA immediately after exposing to OGD, prevents neurone apoptosis and 
also partially recovers the number and extent of neurites over a period of seven days 
post-insult (Hasan et al., 2013). This coincides with an increase in histone 
acetylation, expression of genes involved in synaptic function (e.g. synaptophysin) 
and an increase in the expression of the neurotrophin BDNF (Hasan et al., 2013). 
Other studies have also shown VPA, SAHA, MS-275 or knockdown of HDAC1 
increases BDNF expression in rat cortical neurones (Koppel and Timmusk, 2013; 
Yasuda et al., 2009). 
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Together, these studies show that non-selectively inhibiting HDACs or selectively 
inhibiting class I HDACs 1, 2 and 3, prevents neurones and oligodendrocytes from 
undergoing OGD-induced death and also preserves and enhances neurone 
connectivity and function. 
 
1.10.4. HDAC inhibitors are neuroprotective in models of glutamate excitotoxicity, 
oxidative stress and apoptosis 
 
In cerebral ischaemia and in other brain conditions such as traumatic brain injury, 
Alzheimer’s disease, motor neurone disease, multiple sclerosis and Parkinson’s 
disease, neural cells die by apoptosis caused by processes such as glutamate 
excitotoxicity and oxidative stress (reviewed by Dong et al. (2009); Lau and 
Tymianski (2010)). In vitro and ex vivo models that mimic these pathophysiological 
events have also been used to investigate the neuroprotective effects of HDAC 
inhibitors. 
 
One such model of motor neurone disease involves treating rat spinal cord slice 
cultures to L-trans-Pyrrolidine-2,4-dicarboxylic acid (PDC) an inhibitor of EAATs 
1-5. Following this, there is a loss of motor neurones caused by glutamate 
excitotoxicity. In this model, pre-treating slices with VPA for seven days before 
exposing to PDC significantly protects motor neurones in the slice (Sugai et al., 
2004). HDAC inhibitors are also neuroprotective in isolated neuronal models of 
glutamate excitotoxicity. Pre-treating rat cortical neurones to HDAC inhibitors for 
three days protects from glutamate-induced excitotoxicity. Here, VPA increases 
histone acetylation at the promoter of and subsequently increases the expression of 
the neuroprotective protein HSP70 (Marinova et al., 2009). Other non-selective 
HDAC inhibitors sodium butyrate and TSA, as well as the selective class I HDAC 
inhibitors apicidin and MS-275, also increase HSP70 expression in cortical neurones 
(Marinova et al., 2009). Co-treatment of TSA, sodium butyrate, SAHA or apicidin at 
the same time as homocysteate (a glutamate analogue), protects cortical neurones 
from homocysteate-induced oxidative stress and apoptosis (Ryu et al., 2003; Sleiman 
et al., 2014). This neuroprotection is partly dependent on a HDAC inhibition induced 
increase in the acetylation and activity of the transcription factor Specificity protein 1 
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(Sp1, Ryu et al. (2003)). CGNs also die following exposure to high levels of 
glutamate or an inhibitor of the glutamate re-uptake transporters (SYM 2081). Pre-
treating CGNs for two to seven days with the non-selective HDAC inhibitors VPA, 
sodium butyrate, sodium phenylbutyrate or TSA, prior to the induction of glutamate 
excitotoxicity, prevents these neurones from undergoing cell death (Kanai et al., 
2004; Leng and Chuang, 2006). Glutamate excitotoxicity in CGNs results in a 
decrease in histone acetylation and HDAC inhibition restores this (Leng and Chuang, 
2006). More specifically, neuroprotection coincides with the hyperacetylation of 
histones in the promoter of the -synuclein gene and this correlates with an increase 
in the expression of this neuroprotective protein (Leng and Chuang, 2006).  
 
HDAC inhibition also protects isolated neurones from classical inducers of 
apoptosis. Non-selective HDAC inhibitors including TSA, SAHA and sodium 
butyrate when administered at the same time as the p53-dependent apoptosis 
inducing, DNA damaging agent camptothecin, prevents the apoptosis of isolated 
cortical neurones (Brochier et al., 2013; Uo et al., 2009). Furthermore, selective 
inhibition of HDACs 1, 2 & 3 with MS-275, prevents the accumulation of activated 
p53 and caspase 3 in cortical neurones exposed to camptothecin (Murphy et al., 
2014). Non-selective HDAC inhibitors also prevent the apoptosis of cortical 
neurones following exposure to p53-independent apoptosis inducing agents such as 
the protein kinase inhibitor staurosporine (Uo et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1    General Introduction 
43 
 
1.10.5. HDAC inhibition reduces neuroinflammation 
 
There is strong evidence to implicate microglia-mediated neuroinflammation in the 
pathogenesis of cerebral ischaemia (see section 1.10.1), traumatic brain injury, 
Alzheimer’s disease, motor neurone disease, multiple sclerosis and Parkinson’s 
disease (reviewed by Block and Hong (2005); Block et al. (2007); Glass et al. 
(2010); Smith et al. (2012)). It is generally considered that limiting the pro-
inflammatory phenotype of microglia will be beneficial in treating these brain insults 
and diseases. HDAC inhibitors have been shown to reduce neuroinflammation in 
rodent models of cerebral ischaemia (see section 1.10.2) and in other in vivo models 
where they are neuroprotective including traumatic brain injury, Alzheimer’s disease 
(amyloidosis model), multiple sclerosis and Parkinson’s disease (table 1.5). 
 
In a mouse model of traumatic brain injury, post-treatment of the non-selective 
HDAC inhibitor ITF2357 reduces microglia and macrophage accumulation in the 
hippocampus of damaged brains (Shein et al., 2009). Analysing the different 
microglial phenotypes in the corpus callosum following traumatic brain injury, the 
non-selective hydroxamate HDAC inhibitor Scriptaid, reduces the number of the 
neurotoxic pro-inflammatory M1-phenotype microglia but increases the number of 
anti-inflammatory neuroregenerative M2-phenotype microglia (Wang et al., 2015). 
This coincides with a reduction in the expression of the pro-inflammatory mediators 
TNF-, iNOS, nitric oxide (NO) and IL-6, and an increase in the expression of the 
anti-inflammatory cytokine interleukin-10 (IL-10) (Wang et al., 2015). This 
polarisation of inflammatory cells to an anti-inflammatory M2-phenotype following 
a reduction in the activity of HDACs has also been observed in macrophages. In 
these cells, deletion of HDAC3 leads to a gene expression program characteristic of 
the M2 phenotype (Mullican et al., 2011). Experimental autoimmune 
encephalomyelitis (EAE) and neuritis (EAN) are in vivo models of the chronic 
neuroinflammatory condition multiple sclerosis. In the encephalomyelitis model, 
TSA suppresses the infiltration of inflammatory cells in demyelinating spinal cords 
(Camelo et al., 2005). Also, in demyelinating sciatic nerves, a model of EAN, MS-
275 attenuates inflammatory cell infiltration and expression of pro-inflammatory 
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mediators IL-1, interferon gamma (IFN and iNOS, and also the extracellular 
matrix degrading protein; matrix metalloproteinase-9 (MMP-9, Zhang et al. (2010)). 
 
Looking at these in vivo models in isolation, it is difficult to interpret whether HDAC 
inhibitors reduce the inflammatory response because they protect neural cells and 
therefore reduce the stimulus for microglial activation, or if HDAC inhibitors 
directly affect the intracellular inflammatory pathways in microglia, or suppress 
neuroinflammation through both mechanisms. Many studies have now shown that 
HDAC inhibitors affect the inflammatory response of isolated microglia (table 1.5). 
In models physiologically relevant to cerebral ischaemia, pre-treatment of the HDAC 
inhibitors sodium phenylbutyrate or TSA has been shown to suppress pro-
inflammatory mediator expression, including TNF-, IL-1, IL-6 and iNOS in 
isolated microglia and astrocytes when exposed to OGD (Qi et al., 2004) or hypoxia 
(Niu et al., 2009). HDAC inhibitors also reduce the activation and inflammatory 
response of microglia isolated from several species in response to the generic 
inflammatory stimulus lipopolysaccharide (LPS). Kannan et al. (2013) show pre-
treatment of isolated mouse microglia cultures with SAHA or TSA for two hours 
prior to stimulating with LPS, increases histone acetylation and reduces the 
expression of LPS-induced pro-inflammatory mediators IL-6, TNF-, IL-1, iNOS 
and transforming growth factor-beta (TGF-. TSA pre-treatment also suppresses the 
activation of microglia, measured as a reduction in pro-inflammatory cell surface 
marker expression (Kannan et al., 2013). Likewise, in isolated human microglia 
cultures, pre-treatment of TSA for one hour prior to LPS stimulation also reduces IL-
1, TNF- and IL-6 expression (Suh et al., 2010). Also, pre-treatment of isolated rat 
microglia with sodium butyrate or TSA for one day prior to LPS, attenuates the 
expression of IL-6, TNF- and NO (Huuskonen et al., 2004). Co-treatment of mouse 
microglia and astrocyte co-cultures with LPS and the non-selective HDAC inhibitors 
ITF2357 or SAHA, increases histone acetylation and reduces the inflammatory 
response as indicated by a reduction in iNOS, COX-2, IL-1 and TNF-expression 
(Faraco et al., 2009). Furthermore, post-treatment of ITF2357 reduces the expression 
of iNOS and IL-1 in the striatum brain region of mice injected with LPS (Faraco et 
al., 2009).  
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Chronic neuroinflammation in cerebral ischaemia and other insults and 
neurodegenerative disease is thought be toxic to neurones. Therefore by inhibiting 
the inflammatory response of microglia, HDAC inhibitors may prevent neuronal 
death caused by neuroinflammation. In mesencephalic/midbrain neurone-glia 
cultures, LPS treatment induces the activation of microglia, expression of pro-
inflammatory mediators TNF- and nitrite and this causes the death of dopaminergic 
neurones (Peng et al., 2005). Not surprisingly, pre-treatment of these cultures with 
TSA or sodium butyrate for one day or VPA for two days prior to the LPS insult, 
suppresses the subsequent LPS-induced microglial activation and pro-inflammatory 
mediator expression resulting in the protection of dopaminergic neurones (Chen et 
al., 2007; Peng et al., 2005). 
 
To summarise so far, HDAC inhibitors are anti-inflammatory in in vivo models of 
brain insults, injuries and neurodegenerative disease, and several studies have shown 
non-selective HDAC inhibitors also suppress the inflammatory response of isolated 
microglia. However, there are other reports that show HDAC inhibitors enhance the 
inflammatory response of isolated microglia (table 1.5). Pre-treatment of sodium 
butyrate or TSA as mentioned, suppresses the inflammatory response of isolated rat 
microglia exposed to LPS, however surprisingly in the same study, pre-treatment of 
sodium butyrate prior to LPS exposure in mouse N9 immortalised microglia, 
augments pro-inflammatory mediator expression (Suuronen et al., 2003). The same 
laboratory also show that the LPS-induced expression of inflammatory mediators IL-
6 and NO in mouse N9 immortalised microglia cells is potentiated when either 
sodium butyrate (Huuskonen et al., 2004), TSA or VPA (Suuronen et al., 2003) are 
administered at the same time as LPS. Moreover, in isolated rat microglia exposed to 
LPS, the expression of IL-6 and the production of nitrite are increased by TSA or 
sodium butyrate treatment (Huuskonen et al., 2004; Suuronen et al., 2003). 
Furthermore, co-treatment of LPS and non-selective HDAC inhibitors TSA, SAHA 
and sodium butyrate potentiate the LPS evoked inflammatory response in rat 
hippocampal slice cultures (Huuskonen et al., 2004; Suuronen et al., 2003). Another 
study that has investigated the effects of HDAC inhibitors on the inflammatory 
response of isolated microglia from rats, shows that pre-treatment of VPA or sodium 
butyrate for thirty minutes prior to LPS exposure, increases histone acetylation and 
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potentiates the LPS-induced expression of pro-inflammatory prostaglandins and the 
enzymes that produce them (e.g. COX-2). The expression of other pro-inflammatory 
mediators such as IL-6, IL-1 and TNF- is also potentiated (Singh et al., 2014). 
These HDAC inhibitors also decrease the expression of the anti-inflammatory 
cytokine IL-10 (Singh et al., 2014).  
 
To date, all investigations of the effects of HDAC inhibitors on the inflammatory 
response of isolated microglia have used inhibitors that lack selectivity towards 
particular HDAC isoforms (table 1.4 and section 1.8). Therefore, the contrasting 
observations of anti- and pro-inflammatory effects upon treatment with these HDAC 
inhibitors may be a result of non-selective HDAC inhibition and variability in the 
balance between inhibiting HDACs that promote inflammation and inhibiting those 
that suppress it. It is important then, that we identify which HDAC isoforms are the 
appropriate ones to inhibit in microglia, in order to isolate the therapeutically 
beneficial anti-inflammatory and neuroprotective effect from a pro-inflammatory 
one, which could exacerbate neuronal injury. 
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Table 1.5. The effects of histone deacetylase inhibitors in experimental models of 
neuroinflammation. 
Model Stimulus HDAC inhibitors Treatment 
Anti or Pro-
inflammatory? 
Ref 
In
 v
it
ro
 
M
ic
ro
g
li
a 
LPS TSA Co- Pro 1 
LPS SB, VPA Pre-, Co- Anti & Pro 2 
Hypoxia SPB Pre- Anti 3 
LPS VPA Pre- Anti 5 
LPS SB, TSA, VPA Pre- Anti 6 
LPS ITF2357, SAHA Co- Anti 8 
LPS TSA, VPA Pre- Anti 10 
LPS or MPP+ SPB Pre- Anti 12 
LPS SAHA, TSA Pre- Anti 14 
LPS SB, VPA Pre-, Post- Pro 17 
In
 v
iv
o
 
Mouse EAE TSA Post- Anti 4 
Rat MCAO SB, VPA Post- Anti 7 
Mouse TBI ITF2357 Post- Anti 9 
Rat EAN MS-275 Post- Anti 11 
Mouse MPTP SPB Pre- Anti 12 
Rat 4-VO VPA Post- Anti 13 
Mouse Amyloidosis MS-275 Post- Anti 15 
Rat MCAO SB Post- Anti 16 
Mouse TBI SAHA, VPA, 
Scriptaid 
Post- Anti 18 
Abbreviations, 4-VO: Four-vessel occlusion model of cerebral ischaemia, EAE & EAN: 
Experimental autoimmune encephalomyelitis & neuritis respectively, LPS: 
Lipopolysaccharide, MCAO: Middle cerebral artery occlusion model of cerebral ischaemia, 
MPP+: 1-methyl-4-phenylpyridinium & MPTP: 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (neurotoxin models of Parkinson’s disease), OGD: Oxygen & glucose 
deprivation, SAHA: Suberoylanilide hydroxamic acid, SB: Sodium butyrate, SPB: Sodium 
phenylbutyrate, TBI: Traumatic brain injury, TSA: Trichostatin A & VPA: Valproate. 
References: 
1
Suuronen et al. (2003), 
2
Huuskonen et al. (2004), 
3
Qi et al. (2004), 
4
Camelo et 
al. (2005), 
5
Peng et al. (2005), 
6
Chen et al. (2007), 
7
Kim et al. (2007b), 
8
Faraco et al. (2009), 
9
Shein et al. (2009), 
10
Suh et al. (2010), 
11
Zhang et al. (2010), 
12
Roy et al. (2012), 
13
Xuan et 
al. (2012), 
14
Kannan et al. (2013), 
15
Zhang and Schluesener (2013), 
16
Kim and Chuang 
(2014), 
17
Singh et al. (2014) & 
18
Wang et al. (2015). 
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1.11. Aim of this study 
 
Non-selective and class I selective HDAC inhibitors are neuroprotective in in vivo 
models of cerebral ischaemia, other brain insults, brain injuries and 
neurodegenerative disease. However, the specific HDAC isoform(s) which when 
inhibited is/are responsible for this effect and the exact cellular and molecular 
mechanisms involved are not fully understood. The aim of this thesis is to use in 
vitro neural cell model systems and pharmacological and genetic tools to 1) 
determine the specific HDAC isoform(s) that should be selectively inhibited in order 
to have a neuroprotective effect and 2) to investigate the mechanisms underlying 
neuroprotection following this selective HDAC inhibition. 
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2.1. Primary rat cerebellar granule neurone (CGN) culture 
 
All work with animals was carried out in accordance with the UK Animals 
(Scientific Procedures) Act 1986. Seven-day old Wistar rats were sacrificed by 
cervical dislocation followed by decapitation as outlined in the Schedule 1 
guidelines. The brain was rapidly removed and placed into ice-cold 0.22 m filter-
sterilized (Millipore) Dissection Solution [calcium, magnesium and phenol red-free 
Hanks Balanced Salt Solution (HBSS, Sigma), 50U penicillin/50 g streptomycin 
(Sigma) and 10 mM HEPES (Sigma)]. From this point all work was performed in a 
Class II tissue culture hood.  
 
The cerebellum was dissected away from the cerebrum and transferred into fresh ice-
cold, filter-sterilized Dissection Solution. The meninges and vasculature were 
carefully removed using fine forceps before washing the cerebellum in fresh 
Dissection Solution. The cerebellum was subsequently mechanically and 
enzymatically dissociated, first using a sterile razor blade followed by incubation for 
15 minutes at 37°C in 10 mL of pre-warmed Trypsin Solution [HBSS, 50U 
penicillin/50 g streptomycin, 10 mM HEPES and 250 g/mL trypsin from bovine 
pancreas (Sigma)] with gentle agitation every 3 minutes.  
 
To terminate trypsin digestion, 10 mL of filter-sterilized and pre-warmed to 37°C 
Trypsin Inhibitor Solution [Dulbecco’s Modified Eagle’s Medium (DMEM, variant: 
high glucose (4500 mg/L), with sodium pyruvate and sodium bicarbonate but 
without L-glutamine, Sigma), 50U penicillin/50 g streptomycin, 10 mM HEPES, 
10% v/v horse serum (Sigma), 50 g/mL deoxyribonuclease I from bovine pancreas 
(DNase I, Sigma) and 1.5 mM MgSO4 (Sigma)] was added to the cell suspension 
which was then centrifuged at 1600 RPM/400 × g for 5 minutes at room temperature 
(Eppendorf Centrifuge 5702 with a A-4-38 rotor).  
 
The supernatant was discarded and using a P1000 pipette and tip, the cell pellet was 
re-suspended by triturating 15 times into 1 mL of filter-sterilized, pre-warmed to 
37°C DNase Solution [DMEM, 50U penicillin/50 g streptomycin, 10 mM HEPES, 
10% v/v horse serum, 50 g/mL DNase I, 1.5 mM MgSO4, 2 mM L-glutamine 
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(Sigma) and 19 mM KCl (Sigma)]. Another 1 mL of DNase Solution was added and 
the suspension was triturated 15 times using a sterile glass 230 mm Pasteur pipette 
(SLS). A further 3 mL of DNase Solution was added 3 times in 1 mL additions, with 
each addition followed by triturating 15 times with a glass Pasteur pipette. The cell 
suspension was filtered through a 40 m cell strainer (BD Bioscience) and the 
volume made up to 20 mL and then centrifuged at 1600 RPM/400 × g for 5 minutes 
at room temperature. The cell pellet was re-suspended in 1 mL of filter-sterilized, 
pre-warmed to 37°C Culture Medium A [DMEM, 50U penicillin/50 g 
streptomycin, 10 mM HEPES, 10% v/v horse serum, 2 mM L-glutamine and 19 mM 
KCl]. The number of cells was counted using a haemocytometer (Hawksley) and the 
cell suspension was diluted accordingly with Culture Medium A. 
 
For experiments using the YOYO®-1 & SYBR® Green I viability assay (described 
in section 2.5), the cell suspension was diluted to give 1.2×106 cells/mL and 
120,000 cells/well (100 L was taken) were seeded into poly-d-lysine coated, black-
walled, clear-bottomed 96-well plates (BD Bioscience). For immunocytochemistry 
assays, prior to CGN isolation, 13 mm glass coverslips (VWR) were autoclaved, 
placed into 24-well plates (Greiner) and incubated with 100 g/mL poly-d-lysine 
hydrobromide (Sigma, dissolved in sterile de-ionized H2O) overnight at 37°C in a 
humid atmosphere with 5% CO2. Each well was then washed 2 times with sterile de-
ionized H2O and air-dried before seeding cells. For 24-well plates, the cell 
suspension was diluted to give 1.44 × 106 cells/mL and 720,000 cells/well were 
seeded (500 L was taken). For oxygen glucose deprivation (OGD) experiments, 
prior to CGN isolation, wells of 4-well plates (Nunc) were coated with 100 g/mL 
poly-d-lysine overnight, then washed and air-dried as described before. For 4-well 
plates, the cell suspension was diluted to give 1.8× 106 cells/mL and 720,000 
cells/well were seeded (400 L was taken). For histone protein extractions, prior to 
CGN isolation, 6-well plates (Greiner) were also coated with 100 g/mL poly-d-
lysine overnight then washed and air-dried before seeding. For 6-well plates, the cell 
suspension was diluted to give 2.4 × 106 cells/mL and 3.6 × 106 cells/well were 
seeded (1.5 mL was taken).  
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After seeding the appropriate cell numbers in the appropriate volumes for each cell 
culture vessel, the cultures were incubated at 37°C in a humid atmosphere with 5% 
CO2. Twenty-four hours after seeding, the culture medium was topped up to double 
the volume in each well with fresh filter-sterilized, pre-warmed to 37°C Culture 
Medium A supplemented with 10 M cytosine -D-arabinofuranoside hydrochloride 
(ARAC, Sigma). After 2 days in vitro (DIV), 60% of the culture medium was 
replaced with fresh Culture Medium A supplemented with 10 M ARAC. On 3 and 
4 DIV, the cell cultures were supplemented with ARAC to maintain the 
concentration at 10 M. At 5 and 8 DIV, 60% of the culture medium was replaced 
with filter-sterilized, pre-warmed to 37°C Culture Medium B [DMEM, 50U 
penicillin/50 g streptomycin, 10 mM HEPES, 2% v/v B27 supplement (Gibco, Life 
Technologies), 2 mM L-glutamine and 19 mM KCl]. Cultures were kept for a 
maximum of 13 DIV. To monitor culture development, phase-contrast images were 
taken every 24 hours using an IncuCyte™ FLR microscope (10× objective lens) at 
37°C, in a humid atmosphere with 5% CO2. 
 
 
2.2. Immunocytochemistry of CGN cultures 
 
CGNs cultured on coverslips in 24-well plates were washed with 1 mL of sterile 
phosphate buffered saline (PBS, Oxoid) and fixed for 10 minutes with 350 L 4% 
w/v paraformaldehyde (PFA, dissolved in autoclaved PBS, Sigma) at room 
temperature. The PFA was removed and the fixed cells were washed 3 times with 1 
mL autoclaved PBS for 5 minutes each time. After the final wash, the PBS was 
discarded and the cells were permeabilised with 350 L of 0.25% v/v Triton X-100 
(Sigma, dissolved in autoclaved PBS) for 10 minutes at room temperature. The 
Triton solution was removed and the cells were washed again 3 times with PBS for 5 
minutes each time.  
The cells were then blocked with 350 L of 5% v/v goat serum (Sigma, dissolved in 
autoclaved PBS) for 30 minutes at room temperature. Each coverslip was removed 
from each well, placed face-up onto glass microscopy slides and the cells were 
incubated with 150 L of either of the following primary antibodies; Anti-NeuN 
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[1:100, mouse monoclonal (Millipore), dissolved in autoclaved PBS] or Anti-Glial 
Fibrillary Acidic Protein (GFAP) [1:400, mouse monoclonal (Sigma), dissolved in 
autoclaved PBS] overnight at 4°C. The primary antibody solution was then discarded 
and the cells were washed 3 times with autoclaved PBS for 5 minutes each time at 
room temperature. After the final wash, excess PBS was removed before incubating 
with 150 L of either of the following secondary antibodies Alexa Fluor® 633 Goat-
Anti-Mouse IgG [1:1000, Invitrogen, Life Technologies, dissolved in autoclaved 
PBS] or Alexa Fluor® 488 Goat-Anti-Mouse IgG [1:1000, Invitrogen, Life 
Technologies, dissolved in autoclaved PBS] for 1 hour, in the dark, at room 
temperature. The secondary antibody solution was then discarded and the cells were 
washed 3 times with PBS for 5 minutes each time at room temperature.  
Maintaining light exposure to a minimum, excess PBS was removed and a drop of 
4’, 6-diamidino-2-phenylindole (DAPI) with Vectashield (Vector Laboratories) was 
applied to each coverslip, the excess was removed and a larger coverslip was 
mounted on top and glued in place with UHU glue. Samples were stored at 4°C in 
the dark until imaging by confocal fluorescence microscopy. Four coverslips of 
CGNs were prepared per animal and this was repeated 3 times using 3 independent 
animals (n=3).  
Imaging of cells was performed using an upright-configured Zeiss LSM 510 
confocal microscope with a 20× objective lens. Images were taken using auto-
exposure/gain, a 2 m pinhole and at 405, 488 and 633 nm wavelengths to visualise 
DAPI+ (blue), GFAP+ (green) and NeuN+ (red) cells respectively. Four randomly 
selected non-overlapping images were taken from each coverslip, at 8-bit quality and 
1024 × 1024 resolution.  
To quantify the purity of CGN cultures, a 4 × 4 grid system (8000 m2 per grid 
square) was used and the number of DAPI+ cells and NeuN+ cells were counted 
within the grid for each image using the Cell Counter plugin in ImageJ. The number 
of NeuN+ cells (CGNs) was expressed as a percentage of the total number of cells 
(DAPI+) and results are presented as mean % CGNs ± SEM. 
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2.3. Induction of glutamate excitotoxicity and drug treatments in CGNs 
 
On 10 DIV, CGNs cultured in 96-well plates were treated to various conditions 
before measuring cell viability using the YOYO®-1 & SYBR® Green I viability 
assay as described in section 2.5.1, four wells were used per experimental condition 
per animal and this was repeated with 3 independent animals (n=3). CGNs cultured 
in 6-well plates were treated to various conditions described below, before extracting 
histone proteins as described in section 2.9, one well was used per experimental 
condition and this was repeated with 3 independent animals (n=3).  
 
2.3.1. Co-treatment experiments  
 
The culture medium was replaced with 75% fresh pre-warmed to 37°C Culture 
Medium B, 25% of the old Culture Medium B taken from the wells and the 
following conditions: vehicle control 0.1% v/v sterile dimethyl sulfoxide (DMSO), 1 
M SAHA (Cayman Chemicals, dissolved in DMSO) or 1 M MI192 (Professor 
Ronald Grigg, School of Chemistry, University of Leeds, UK, Boissinot et al. 
(2012), dissolved in DMSO). Glutamate excitotoxicity was induced with 100 M L-
glutamate (Sigma, dissolved in sterile de-ionized H2O) or with 500 M DL-threo--
Benzyloxyaspartic acid (DL-TBOA, Tocris Bioscience, dissolved in DMSO). At the 
same time as exposing to either of these neurotoxic insults, CGNs were treated with 
either vehicle control, both 30 M NBQX (Sigma, dissolved in sterile de-ionized 
H2O) and 10 M MK-801 (Sigma, dissolved in DMSO) an AMPA & Kainate and a 
NMDA glutamate receptor antagonist respectively, 200 M N-acetyl-Asp-Glu-Val-
Asp-al (ac-DEVD-al) a caspase 3 and 7 inhibitor (Sigma, dissolved in sterile de-
ionized H2O), 1 or 3 M SAHA, 1 mM valproate (VPA, Sigma, dissolved in DMSO) 
or 1 or 3 M MI192. CGNs were cultured at 37°C in a humid atmosphere with 5% 
CO2 for a further 24 or 72 hours after treatment.  
 
Another co-treatment paradigm used involved exposing CGNs to a short pulse of 
glutamate with or without HDAC inhibitors, followed by the removal of this and 
further treatment with HDAC inhibitors in the absence of glutamate. To do this, the 
culture medium was replaced with 75% fresh pre-warmed to 37°C Culture Medium 
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B, 25% of the old Culture Medium B taken from the wells and either vehicle control, 
or 100 M L-glutamate with either vehicle control, 1 M SAHA or 1 M MI192 for 
30 minutes. This was then removed and CGNs were treated with either vehicle 
control, 1 M SAHA or 1 M MI192 for a further 72 hours.  
 
2.3.2. Pre-treatment experiments  
 
The culture medium was replaced with 75% fresh pre-warmed to 37°C Culture 
Medium B, 25% of the old Culture Medium B taken from the wells and the 
following conditions: vehicle control 0.1% v/v DMSO, 1 M SAHA or 1 M 
MI192. CGNs were then cultured for 24 hours at 37°C in a humid atmosphere with 
5% CO2. After 24 hours of pre-treatment, the culture medium was replaced with 75% 
fresh pre-warmed to 37°C Culture Medium B, 25% of the old Culture Medium B 
taken from the wells and the following conditions: vehicle control 0.1% v/v sterile 
DMSO, or 100 M L-glutamate with vehicle control, 1 M SAHA or 1 M MI192. 
CGNs were cultured for a further 24 hours at 37°C in a humid atmosphere with 5% 
CO2. 
 
 
2.4. Induction of oxygen glucose deprivation (OGD) and drug treatments in CGNs 
 
CGNs cultured in 4-well plates for 10 DIV were exposed to oxygen glucose 
deprivation (OGD) and then treated to experimental conditions. One well was used 
per experimental condition, per animal and this was repeated using 3 independent 
animals (n=3). 
Immediately prior to OGD induction, 0.22 m filter-sterilized, modified glucose-free 
Earle’s Balanced Salt Solution (EBSS, [116 mM NaCl, 25 mM KCl, 1.8 mM CaCl2, 
0.8 mM MgSO4, 1 mM NaH2PO4 and 26.2 mM NaHCO3 (all from Sigma)]) was 
bubbled with 0.22 m filter-sterilized 95% N2 and 5% CO2 gas mixture (BOC) for 
60 minutes, with the pressure and flow regulators set at 1 bar pressure and at a 0.4 
L/min flow rate. After this time, the modified glucose-free EBSS was stored in an 
airtight tube and warmed to 37°C for 30 minutes. The OGD chamber (School of 
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Engineering, University of Leeds, UK) was also warmed to and maintained at 37°C 
throughout the experiment. 
OGD was performed under sterile conditions in a Class II tissue culture hood. The 
culture medium from CGNs cultured in 4-well plates was quickly removed, kept and 
stored at 37°C until later use. Then 800 L of oxygen depleted, pre-warmed to 37°C 
modified glucose-free EBSS was quickly added to each well. The plate was quickly 
transferred to the OGD chamber. The OGD chamber was sealed and flushed with 
0.22 m sterile filtered 95% N2 and 5% CO2 gas mixture for 2 minutes to expel 
atmospheric air, the pressure and flow regulators were set at 1 bar pressure and at a 1 
L/min flow rate. The atmosphere in the chamber was then maintained at 95% N2 and 
5% CO2 with the pressure and flow regulators set at 1 bar pressure and at a 0.4 L/min 
flow rate. A positive pressure was maintained so the total volume of 95% N2 and 5% 
CO2 inside the chamber was replaced approximately every minute. CGNs were 
exposed to OGD for 40 minutes. 
After exposing to OGD, the 4-well plate was removed from the chamber and the 
deoxygenated, modified glucose-free EBSS was replaced with 75% fresh pre-
warmed to 37°C Culture Medium B, 25% of the old Culture Medium B taken from 
the wells earlier and either vehicle control 0.1% v/v sterile DMSO or 1 M SAHA. 
In parallel to exposing CGN 4-well plate cultures to OGD, other cultures were not 
exposed to OGD, but were treated to 0.1% v/v sterile DMSO to serve as a no OGD 
control.  
After treatments, CGNs were cultured for a further 24 hours at 37°C in a humid 
atmosphere with 5% CO2. Following this, cell viability was measured using the MTT 
assay as described in section 2.5.2. 
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2.5. Assessment of CGN viability 
 
2.5.1. YOYO®-1 & SYBR® Green I assay 
 
To assess cell viability of CGNs, YOYO®-1 (Invitrogen, Life Technologies, 
dissolved in DMSO) a cell-impermeant nucleic acid fluorescent stain that labels the 
nuclei of dying and dead cells (Becker et al., 1994), was added to the existing culture 
medium in each well to give a final concentration of 200 nM. The cells were then 
incubated for 1 hour at 37°C in a humid atmosphere with 5% CO2.  
 
Imaging of stained cells was carried out using an IncuCyte™ FLR microscope (10× 
objective lens) at 37°C, in a humid atmosphere with 5% CO2. Images were taken in 
phase-contrast and green-fluorescence in the wavelength range of 450-490 nm to 
visualise YOYO®-1+ cells (green). Two non-overlapping images at 1280 × 1024 
resolution were taken per well. For a total cell count, all CGN nuclei were labelled 
by incubation with a 1:50,000 dilution of SYBR® Green I (Invitrogen, Life 
Technologies) a cell-permeant nucleic acid fluorescent stain for 30 minutes at 37°C 
in a humid atmosphere with 5% CO2. The cells were imaged at the same position in 
phase-contrast and green-fluorescence to visualise SYBR® Green I+ cells.  
 
The number of YOYO®-1+ cells and SYBR® Green I+ cells/well was quantified 
using an automated counting algorithm (Object Counting v2.0 and Edge Split v2.0, 
Essen BioScience) with a user defined segmentation fixed threshold of 150 AU and 
edge sensitivity of 1.00. Percentage cell viability was calculated by subtracting the 
number of YOYO-1+ (dying/dead cells) cells from the total number of cells 
(SYBR® Green I+). This value representing the number of viable cells (YOYO-1 
negative) was expressed as a percentage of total number of cells (SYBR® Green I+). 
Results are presented as mean % cell viability ± SEM. Statistical analysis was 
performed comparing the percentage cell viability for each condition using a one-
way ANOVA followed by the Bonferroni post hoc test at the 5% significance level 
(OriginPro, OriginLab) or using an unpaired Student’s t-test assuming equal variance 
at the 5% significance level (Microsoft Excel). 
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2.5.2. MTT assay 
 
To assess the viability of CGNs cultured in 4-well plates and treated as described in 
section 2.4, metylthiazolyldiphenyl-tetrazolium bromide (MTT) was added to the 
culture medium in each well to give a final concentration of 500 ng/mL. The cells 
were then incubated for 1 hour in the dark, at 37°C in a humid atmosphere with 5% 
CO2. The culture medium was then removed and the intracellular formazan crystals 
were dissolved with 100 L acidified isopropanol [90% isopropanol (Fisher 
Scientific), 40 mM HCl (Acros Organics) and 1% sodium dodecyl sulphate (SDS, 
Sigma)] by orbital shaking on rotating platform for 1 hour at room temperature. Once 
dissolved, the solution was triturated several times before transferring to a clear flat-
bottomed 96-well assay plate (Greiner). The absorbance of each well was measured 
at 570 nm (formazan) and 720 nm (background) wavelengths using a 
spectrophotometric plate reader (FLUOstar Omega, BMG Labtech). The background 
absorbance reading at 720 nm was subtracted from that at 570 nm and these values 
were expressed as a mean ± SEM % cell viability of the no OGD +vehicle control. 
Statistical analysis was performed with Microsoft Excel using an unpaired Student’s 
t-test assuming equal variance at the 5% significance level. 
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2.6. BV2 microglia cell culture  
 
BV2 murine microglia were routinely cultured in 78.5 cm
2 
cell culture treated Petri 
dishes (Greiner), with 10 mL Dulbecco’s Modified Eagle’s Medium (DMEM) high 
glucose AQmedia™ (Sigma) supplemented with 10% v/v foetal bovine serum (FBS, 
PAA Cell Culture Company) and 100U penicillin/100 g streptomycin (Sigma) at 
37°C in a humid atmosphere with 5% CO2. Cells were passaged at ~80% confluence, 
first, the cells were washed with 10 mL sterile PBS (room temperature,) then 
incubated with 1 mL of Trypsin-Ethylenediaminetetraacetic acid (EDTA) solution 
(pre-warmed to 37°C, 0.5 g/L porcine trypsin and 0.2 g/L EDTA, Sigma) for 3 
minutes at 37°C in a humid atmosphere with 5% CO2. The cells were resuspended in 
9 mL fresh culture medium (pre-warmed to 37°C) and this 10 mL was split 
appropriately into fresh culture medium in new Petri dishes. The Petri dishes were 
then topped-up with fresh culture medium to maintain a total volume of 10 mL. The 
cells were then cultured further until ~80% confluence and then were passaged again. 
BV2 microglia were cultured for a maximum of 25 passages. 
 
 
2.7. Induction of the inflammatory response and drug treatments in BV2 microglia 
 
BV2 microglia, were seeded into cell culture treated 24-well plates (Greiner) at a cell 
density of 175,000 cells/well in 1 mL of culture medium and into 6-well plates 
(Greiner) at a cell density of 350,000 cells/well or 500,000 cells/well with 3 mL 
culture medium. The cells were allowed to culture at 37°C in a humid atmosphere 
with 5% CO2 for 24 hours before changing the culture medium (pre-warmed to 37°C) 
and exposing to various treatments.  
 
2.7.1. Co-treatment experiments  
 
BV2 microglia seeded into 6-well plates at a cell density of 500,000 cells/well or 24-
well plates at a cell density of 175,000 cells/well, were treated to vehicle control 
0.1% v/v sterile DMSO, 500 nM apicidin (Sigma, dissolved in DMSO), 1 M 
MI192, 5 M MS-275 (Cayman Chemicals, dissolved in DMSO) and 1 M SAHA 
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with or without 500 ng/mL lipopolysaccharide (LPS, from Escherichia coli 0111:B4, 
LPS, Sigma, dissolved in autoclaved PBS) an inflammatory stimulant. BV2’s were 
also treated to 500 ng/mL LPS with either vehicle control, 5 M BAY 11-7082 
(BAY11, Sigma, dissolved in DMSO), 5 M Droxinostat (Sigma, dissolved in 
DMSO), 5 M Droxinostat & 1 M MI192 combined, or 5 mM VPA. The cells were 
then cultured for 6 or 24 hours after treatment at 37°C in a humid atmosphere with 
5% CO2. One well was used per experimental condition per passage number and this 
was repeated with 3 independent passage numbers (n=3). 
 
2.7.2. Pre-treatment experiments 
 
BV2 microglia seeded into 6-well plates at a cell density of 350,000 cells/well were 
treated to vehicle control 0.1% v/v sterile DMSO, 500 nM apicidin, 1 M MI192 or 
5 M MS-275 then cultured at 37°C in a humid atmosphere with 5% CO2 for 24 
hours. After 24 hours of pre-treatment, the culture medium (pre-warmed to 37°C) 
was replaced and the BV2’s were treated to vehicle control 0.1% v/v sterile DMSO 
alone or 500 ng/mL LPS with and without vehicle control, 500 nM apicidin, 1 M 
MI192 or 5 M MS-275 for a further 6 hours. One well was used per experimental 
condition per passage number and this was repeated with 3 independent passage 
numbers (n=3). 
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2.8. Transfecting BV2 microglia with small interfering RNA (siRNA)  
 
BV2 microglia, were seeded into cell culture treated 6-well plates at a cell density of 
350,000 cells/well. The cells were allowed to culture for 24 hours then washed with 
1 mL sterile PBS (at room temperature) and then maintained in 1 mL Opti-MEM® 
(pre-warmed to 37°C, Gibco, Life Technologies) at 37°C in a humid atmosphere 
with 5% CO2.  
 
Cells were transfected with 50 pmoles of Silencer® Select Negative Control siRNA 
(Ambion, Scrambled (Scr) siRNA) or Silencer® Select Pre-designed siRNA targeted 
against HDAC1 (id: s119557, Ambion) or HDAC2 (id: s67417, Ambion) as follows. 
Per well of a 6-well plate, 3 L of Lipofectamine™ 2000 (Invitrogen, Life 
Technologies) was added to 100 L of pre-warmed to 37°C Opti-MEM®. Also, 1 L 
of 50 M siRNA was added to 100 L of pre-warmed to 37°C Opti-Mem®. These 
mixtures were then gently mixed and then incubated for 5 minutes at room 
temperature before combining, gently mixing and incubating for 20 minutes at room 
temperature. Afterwards, the 200 L of siRNA and Lipofectamine™ 2000 mix was 
added to the 1 mL of Opti-MEM® in the well followed by gentle agitation and 
incubated at 37°C in a humid atmosphere with 5% CO2 for 4 hours. Similarly, BV2 
microglia were also transfected with 100 pmoles of Scr siRNA or 50 pmoles HDAC1 
siRNA with HDAC2 siRNA (a range of amounts 3, 5, 10, 30 & 50 pmoles) using 
Lipofectamine™ 2000 at a ratio of 3 L Lipofectamine™ per 50 pmoles of siRNA.  
 
After 4 hours incubation with the DNA-Lipofectamine™ 2000 complexes, this mix 
was removed and the cells were then cultured in 3 mL DMEM high glucose 
AQmedia™ supplemented with 1% v/v FBS and 100U penicillin/100 g 
streptomycin at 37°C in a humid atmosphere with 5% CO2 for 48 hours. After this 
time, some transfected cells were treated to 500 ng/mL LPS followed by culturing 
for a further 6 hours at 37°C in a humid atmosphere with 5% CO2. One well was 
used per transfection, per treatment and per passage number and this was repeated 
with 3 independent passage numbers (n=3). 
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2.9. Histone protein extraction 
 
For histone protein extraction, cells cultured in 6-well plates were washed with 1 mL 
sterile PBS which was then discarded and the cells were then scraped on ice into 1 
mL ice-cold sterile PBS and pelleted by centrifugation at 13,300 RPM/16,300 × g 
(GenFuge 24D Centrifuge, Progen) for 30 seconds at room temperature. The 
supernatant was discarded and the cell pellet was resuspended in a volume of ice-
cold Triton Lysis Buffer [0.5% v/v Triton X-100 (Sigma), 2 mM 
phenylmethylsulfonyl (PMSF, Apollo Scientific, dissolved in isopropanol), 0.02% 
w/v NaN3 (Sigma, dissolved in autoclaved de-ionized H2O) and autoclaved PBS] 
dependent on cell density (1 mL of lysis buffer was used per 1 × 107 cells). The 
suspension was incubated on ice for 10 minutes with vortexing every 3 minutes. 
Lysed cells were centrifuged at 8400 RPM/6600 × g for 10 minutes at 4°C 
(Eppendorf Centrifuge 5415R with a FA-45-24-11 rotor) to pellet the nuclei. The 
supernatant was discarded and the white nuclei pellet was resuspended in half the 
volume of ice-cold Triton Lysis Buffer used earlier then centrifuged once more at 
8400 RPM/6600 × g for 10 minutes at 4°C. The supernatant was once again 
discarded and the pellet was resuspended in 1 mL of ice-cold 200 mM HCl (Acros 
Organics, dissolved in autoclaved de-ionized H2O) per 4 × 10
7
 cells. Histone 
proteins were extracted overnight at 4°C, followed by centrifugation at 8400 
RPM/6600 × g for 10 minutes at 4°C then the supernatant containing histone 
proteins was taken and stored at -20°C until further analysis.  
 
The protein concentration of each sample was determined using the Bradford protein 
assay where 5 L of autoclaved de-ionized H2O (blank 1), bovine serum albumin 
(BSA, Sigma, dissolved in autoclaved de-ionized H2O) standards of a known 
concentration (0.25 to 2 g/L range), 2.5 L of 200 mM HCl plus 2.5 L of 
autoclaved de-ionized H2O (blank 2) or 2.5 L histone protein acid extract sample 
plus 2.5 L of autoclaved de-ionized H2O (dilution factor of 2) was added to 250 L 
of Bradford reagent (pre-incubated to room temperature, Sigma) and incubated for 
10 minutes at room temperature. These solutions were mixed gently and transferred 
to a clear flat-bottomed 96-well assay plate (Greiner) and absorbance was measured 
at 595 nm wavelength using a spectrophotometric plate reader (FLUOstar Omega, 
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BMG Labtech). A standard curve was produced of absorbance versus BSA 
concentration and the concentration of the histone protein acid extracts was 
determined using this curve. 
 
 
2.10. Whole cell protein extraction 
 
For whole cell protein extraction of BV2 microglia cells cultured and treated in 6-
well plates, cells were first washed with 1 mL sterile PBS and then scraped on ice 
into 250 L ice-cold Radioimmunoprecipitation (RIPA) Buffer [sterile 50 mM Tris-
HCL pH 8.0 (Sigma), sterile 1 mM EDTA pH 8.0 (Sigma), 1% Triton X-100, 0.1% 
sodium deoxycholate (Sigma), sterile 0.1% sodium dodecyl sulphate (SDS, Sigma), 
sterile 150 mM NaCl (Sigma), 0.02% w/v NaN3, 1 mM PMSF and autoclaved de-
ionized H2O]. The cell suspension was triturated 10 times using a pipette then 
incubated for 30 minutes on ice with vortexing every 10 minutes. The lysate was 
clarified by centrifugation at 12,000 RPM/13,400 × g for 20 minutes at 4°C 
(Eppendorf Centrifuge 5415R with a FA-45-24-11 rotor) and the supernatant 
containing proteins was collected and stored at -20°C until further analysis. 
 
The protein concentration of each sample was determined using the Bicinchoninic 
acid (BCA) protein assay (Sigma), 10 L of autoclaved de-ionized H2O (blank 1), 10 
L of BSA standard (0.25 to 1 g/L range), 3 L of RIPA Buffer (blank 2) plus 7 
L of autoclaved de-ionized H2O or 3 L of protein sample plus 7 L of autoclaved 
de-ionized H2O (dilution factor of 3.33) was added to wells of a clear flat-bottomed 
96-well assay plate followed by 200 L of BCA working reagent (50 : 1, BCA 
solution : 4% CuSO4, Sigma, pre-incubated to room temperature). The contents of 
the 96-well plate were mixed by trituration and the plate was covered and then 
incubated for 30 minutes at 37°C. The plate was gently agitated and then the 
absorbance of each well was measured at 562 nm wavelength using a 
spectrophotometric plate reader. A standard curve was produced of absorbance 
versus BSA concentration and the concentration of the whole cell protein extracts 
was determined using this curve and adjusted using the dilution factor. 
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2.11. Western blotting 
 
A volume of each histone protein acid extract sample or of each whole cell protein 
extract sample was take to give 10 g of protein. An appropriate volume of 
autoclaved de-ionized H2O and 5× Laemmli sample buffer [250 mM Tris-HCl pH 
6.8 (Sigma), 10% w/v SDS, 50% glycerol (Sigma), 500 mM dithiothreitol (DTT, 
Melford) and 0.2% w/v bromophenol blue (Sigma)] or 2× Laemmli sample buffer 
[100 mM Tris-HCl pH 6.8, 4% w/v SDS, 20% glycerol, 200 mM DTT, and 0.2% 
w/v bromophenol blue] was added to each 10 g sample to give 1× and a total 
volume of ≤20 L. These were boiled at 95°C for 5 minutes and then chilled on ice 
for 5 minutes.  
 
Samples underwent sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE, Mini-PROTEAN® Tetra Cell, Bio-Rad) alongside 10 L of Pre-
stained Protein Marker, Broad Range (with reference bands covering 7 to 175 kDa, 
New England Biolabs) or 10 L PageRuler™ Pre-stained Protein Ladder (with 
reference bands covering 10 to 170 kDa, Thermo Scientific). SDS-PAGE gels of 1.5 
mm thickness comprised of a 5% stacking gel and a 6, 10% or 15% resolving gel for 
whole cell protein extract samples, or a 15% resolving gel for histone protein acid 
extracts were used. Gel recipes are listed in table 2.1. Electrophoresis was performed 
at 150V in electrophoresis buffer [25 mM Tris (Sigma), 250 mM glycine (Fisher 
Scientific), 0.1% w/v SDS and de-ionized H2O]. Gels were run until the dye front 
had just migrated off the gel, the resolving gels were separated from the stacking gel 
and then underwent Western blotting.  
 
Gels were wet-transferred (XCell II™ Blot Module, Invitrogen, Life Technologies) 
onto Hybond-C Extra nitrocellulose membrane (Amersham) or Hybond-P 
polyvinylidene fluoride membrane (PVDF, Amersham). Before transferring, the 
nitrocellulose membranes were rinsed in de-ionized H2O then soaked in transfer 
buffer [48 mM Tris, 39 mM glycine and 20% methanol (Fisher Scientific)] for 30 
minutes, PVDF membranes were activated with 100% methanol for 1 minute, rinsed 
with de-ionized H2O and soaked in transfer buffer for 30 minutes. Wet-transfer was 
performed at 30V for 60 minutes in transfer buffer.  
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Table 2.1. SDS-PAGE Recipes. 
Constituent 5% Stacking gel 
Resolving gel 
6% 10% 15% 
Autoclaved DI-H2O 3.3 mL 4 mL 2.67 mL 1 mL 
30% Acrylamide
1
 1.02 mL 2 mL 3.33 mL 5 mL 
0.5 M Tris pH 6.8 1.5 mL - - - 
1 M Tris pH 8.8 - 3.8 mL 3.8 mL 3.8 mL 
SDS 60 L 100 L 100 L 100 L 
10% APS 60 L 100 L 100 L 100 L 
TEMED 6 L 8 L 8 L 8 L 
1
30% Acrylamide:Bis-acrylamide 29:1, Severn Biotech. All other constituents are from 
Sigma. Abbreviations, APS: Ammonium persulfate, DI: De-ionized, SDS: Sodium dodecyl 
sulphate, TEMED: Tetramethylethylenediamine. 
 
To confirm successful transfer of proteins, membranes were stained with Ponceau S 
solution (Sigma) for 5 minutes at room temperature. Protein bands were visualised 
and the membrane was rinsed with de-ionized H2O, destained with 100 mM NaOH 
(dissolved in autoclaved de-ionized H2O) for 60 seconds and washed in de-ionized 
H2O for 3 minutes on a rotating platform at room temperature. The membranes were 
then blocked with blocking solution [5% w/v non-fat dried milk powder (Oxoid), 
0.1% v/v Tween® 20 (Sigma) and autoclaved PBS] for 2 hours at room temperature 
or overnight at 4°C on a spiramix.  
 
Membranes were incubated with either of the following primary antibodies; Anti-
Histone H3 [1:1000, rabbit polyclonal (Millipore), dissolved in blocking solution 
+0.02% NaN3,], Anti-acetyl Histone H3 lysine 9 [1:1000, rabbit polyclonal 
(Millipore), dissolved in blocking solution +0.02% NaN3], Anti-acetyl Histone H4 
pan-lysine [1:10,000, rabbit polyclonal (Millipore), dissolved in blocking solution 
+0.02 NaN3], Anti-acetyl Tubulin [1:2000, mouse monoclonal (Sigma), dissolved in 
blocking solution +0.02% NaN3], Anti-HDAC1 [1:2000, rabbit polyclonal (Abcam), 
dissolved in blocking solution +0.02% NaN3], Anti-HDAC2 [1:2000, rabbit 
polyclonal (Abcam), dissolved in blocking solution +0.02% NaN3], Anti-HDAC3 
[1:2000, rabbit polyclonal (Abcam), dissolved in blocking solution +0.02% NaN3], 
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Anti-acetylated lysine (Ac-K
2
-100) [1:1000, rabbit monoclonal (Cell Signaling), 
dissolved in 5% w/v BSA, Tris Buffered Saline (137 mM NaCl and 20 mM Tris, pH 
7.6, TBS) and 0.1% v/v Tween® 20], or Anti--actin [1:10,000, mouse monoclonal 
(Sigma), dissolved in blocking solution +0.02% NaN3] for 1 hour at room 
temperature or overnight at 4°C on a spiramix.  
 
Membranes were then washed 3 times with PBS-tween [0.1% v/v Tween® 20 
dissolved in PBS] or with TBS-tween [0.1% v/v Tween® 20 dissolved in TBS] on a 
spiramix for 15 minutes each time. Membranes were then incubated with the 
appropriate secondary antibody; Goat-Anti-Rabbit IgG-horseradish peroxidase 
(HRP) linked [1:2000, dissolved in blocking solution, (Cell Signaling)] or Goat-Anti-
Mouse IgG-HRP linked [1:2000, dissolved in blocking solution, (Cell Signaling)] for 
1 hour at room temperature on a spiramix followed by washing 3 times with PBS-
tween or TBS-tween as before. Membranes were then incubated for 5 minutes at 
room temperature with an enhanced chemiluminescence (ECL) substrate 
(Amersham) and were either exposed to photographic film which was subsequently 
developed and fixed in the dark using a Xograph Imaging System Compact X4, or 
the membranes were directly photographed using a Fujifilm LAS-3000 imaging 
system (Exposure Type: Precision, Sensitivity: High) or scanned with a LI-COR 
cDigit® Scanner (Sensitivity: High).  
 
Following visualisation, membranes were washed once with PBS-tween or TBS-
tween for 15 minutes and stripped of bound primary and secondary antibodies if 
necessary. During stripping, the membranes were rolled in a hybridisation tube and 
oven with pre-warmed to 50°C stripping buffer [62.5 mM Tris-HCl pH 6.8, 2% w/v 
SDS, 0.4% v/v -mercaptoethanol (Sigma) and de-ionized H2O] for 30 minutes at 
50°C. The membranes were then washed 3 times with PBS-tween or TBS-tween for 
15 minutes each time and blocked with blocking solution. Membranes were then re-
probed with appropriate primary and secondary antibodies and visualised as 
described earlier.  
 
Photographic films were digitally scanned in grey-scale at 1200 dots per inch (DPI) 
and the intensity of bands was determined using ImageJ (Miller, 2010; Rasband, 
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1997-2014). Images acquired using the Fujifilm LAS-3000 were saved in grey-scale 
at 72 DPI and the intensity of bands was determined using the Aida Image Analyzer 
v4.15 software (Raytest) with background correction. Membranes scanned with the 
cDigit® were quantified using Image Studio Lite v4.0 (LI-COR) with background 
correction. All bands were normalised to the -actin or total Histone H3 loading 
control as appropriate. 
 
 
2.12. Ribonucleic acid (RNA) extraction, reverse transcription and quantitative PCR 
 
RNA was extracted from BV2 microglia cells cultured and treated in 6-well plates. 
The culture medium was removed and the cells were washed with 1 mL sterile PBS 
before scraping into 500 L of ice-cold TRI Reagent® (Sigma). Each sample was 
triturated 10 times using a pipette and incubated for 5 minutes at room temperature 
followed by the addition of 100 L of chloroform (Arcos Organics). The samples 
were vortexed for 15 seconds, incubated for a further 5 minutes at room temperature 
then centrifuged at 13,000 RPM/16,000 × g for 10 minutes at 4°C (Eppendorf 
Centrifuge 5415R with a FA-45-24-11 rotor). The clear aqueous layer containing 
RNA was carefully removed (250 L) into a new 1.5 mL microcentrifuge tube and 
then 250 L of ice-cold isopropanol was added and the samples were then briefly 
vortexed and incubated overnight at -80°C to precipitate the RNA. 
 
To pellet the precipitated RNA, the frozen samples were centrifuged at 13,000 
RPM/16,000 × g for 30 minutes at 4°C. The supernatant was removed and the 
pellets were washed with 500 L ice-cold 75% ethanol (Sigma), vortexed and 
centrifuged at 13,000 RPM/16,000 × g for 10 minutes at 4°C. The supernatant was 
again removed, the pellets were centrifuged dry at 13,000 RPM/16,000 × g for 5 
minutes at 4°C, residual ethanol was removed and the pellets were air-dried for 5 
minutes at room temperature then resuspended in ice-cold 50 L Tris-EDTA (TE, 
pH 7.5, Invitrogen, Life Technologies). To dissolve the RNA pellet in the TE, the 
samples were gently mixed, incubated at 55°C for 5 minutes, chilled on ice for 5 
minutes followed by gentle mixing again. Samples were stored at -20°C until further 
analysis.  
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The concentration of each RNA sample was determined in duplicate using a 
NanoDrop 2000c (Thermo Scientific). The absorbance at 260 nm wavelength was 
measured of the TE (blank) and each RNA sample. Using the formula, 1 A260 = 40 
g/mL, the average RNA concentration of each sample was determined. The 
absorbance at 280 nm wavelength (maximum absorbance of protein, A280) was also 
measured and the A260/A280 value was calculated as a measure of the RNA purity of 
the sample. Samples with a ratio between 2.0 and 2.2 were then reverse transcribed 
to produce cDNA. 
 
An appropriate volume of RNA to give 2.5 g was primed for reverse transcription 
at 65°C for 5 minutes with 1.25 L of Oligo(dT)15 primers (0.5 g/L, Promega), 
1.25 L of Random primers (0.5 g/L, Promega) and autoclaved de-ionized H2O to 
make the reaction volume 32.5 L. The samples were then chilled on ice for 1 
minute before adding 17.5 L of reverse transcription mastermix [10 L of 5×M-
MLV Reverse Transcriptase 5× reaction buffer (Promega), 5 L of 20 mM 
deoxynucleoside triphosphate (dNTP) mix containing 5 mM of each dNTP 
(deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate (dGTP), 
deoxycytidine triphosphate (dCTP) and deoxythymidine triphosphate (dTTP), 
Bioline), 1.25 L of RNasin® Plus ribonuclease (RNase) Inhibitor (40 U/L, 
Promega) and 1.25 L of M-MLV Reverse Transcriptase, RNase H Minus (200 
U/L, Promega)] to make the final reaction volume 50 L. These were then 
incubated at 37°C for 60 minutes, chilled on ice for 1 minute and stored at -20°C 
until further analysis. 
 
Quantitative PCR (qPCR) reactions were carried out in duplicate using a Rotor Gene 
6000 PCR Analyser (Corbett). Each reaction comprised of 50 or 100 ng of sample 
cDNA (1 and 2 L of reverse transcribed sample respectively), 300 nM of 
forward/sense primer (0.6 L of 100 mM stock), 300 nM of reverse/anti-sense 
primer (0.6 L of 100 mM stock), 10 L 2×SensiMix™ SYBR® & Fluorescein (to 
give 1×, Bioline) and autoclaved de-ionized H2O to make the total reaction volume 
to 20 L. All sequences of primers used in this study are listed in table 2.2. A RNA 
control (no reverse transcription) and an autoclaved de-ionized H2O (no template) 
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control was run for each primer set. The hot-start DNA polymerase was activated by 
holding the samples at 95°C for 10 minutes and the PCR was run for 45 cycles of 
95°C for 10 seconds, 60°C for 15 seconds and 72°C for 30 seconds. This was 
followed by a melt curve to check for specific amplification by each primer set and 
the absence of primer dimers. To generate the melt curve the temperature was 
ramped from 55°C to 95°C rising by 1°C per step and waiting 5 seconds between 
each step.  
 
Table 2.2. List of qPCR primers. 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
IL-6 CCCAACTTCCAATGCTCTCC ACAGTGAGGAATGTCCACAAAC 
iNOS CAGCTGGGCTGTACAAACCTT CATTGGAAGTGAAGCGTTTCG 
TNF- TGAACTTCGGGGTGATCG GGGCTTGTCACTCGAGTTTT 
U6 CTCGCTTCGGCAGCACA AACGCTTCACGAATTTGCGT 
 
Transcript levels were analysed by real time analysis of SYBR® Green fluorescent 
reporter dye intercalation into amplified double stranded DNA. Qualitative analysis 
of transcript levels was performed using the 2
-Ct 
method (Ct = Ct,sample - 
Ct,house-keeping gene, Livak and Schmittgen (2001)) with the house-keeping gene U6. 
Results are presented as mean relative expression or as a relative mean percentage of 
an appropriate experimental condition ± standard error of the mean (SEM). 
Statistical analysis was performed as described by Lew (2007). The absolute Ct 
values for each experimental condition vs. an appropriate condition were compared 
using a one-way repeated measures analysis of variance (ANOVA) followed by the 
Dunnet post hoc test at the 5% significance level (performed using OriginPro, 
OriginLab) or a paired Student’s t-test at the 5% significance level (performed using 
Microsoft Excel). 
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2.13. Enzyme linked immunosorbent assays (ELISAs) 
 
Cell culture supernatants were taken from BV2 microglia cells cultured and treated 
in 24-well plates. The 1 mL of culture medium was carefully removed from each 
well, transferred to a 1.5 mL microcentrifuge tube, centrifuged for 30 seconds at 
13,300 RPM/16,300 × g (GenFuge 24D Centrifuge, Progen) to pellet any detached 
cells then 950 L was carefully removed and placed into a new 1.5 mL 
microcentrifuge tube. Supernatants were stored at -20°C until analysis.  
 
The concentration of secreted mouse IL-6 protein was determined by a 96-well plate 
format ELISA following the manufacturer’s instructions (Invitrogen, Life 
Technologies). The ELISA consisted of a chromogen blank, standards of known IL-6 
concentrations (0 to 500 pg/mL rangeInvitrogen, Life Technologies) and low and 
high controls of IL-6 known to be within the measurable range of the assay 
(Invitrogen, Life Technologies). The cell culture supernatant samples were diluted 
10-fold (in provided diluent buffer, Invitrogen, Life Technologies). All controls, 
standards and samples were run in duplicate.  
 
The assay procedure was as follows, 100 L of the controls, standards and diluted 
samples were added to appropriate wells pre-coated with a monoclonal antibody 
specific for mouse IL-6The plate was incubated for 2 hours at room temperature. 
The plate was then decanted and washed as follows, 400 L of 1× Wash Buffer was 
added to each well, incubated for 30 seconds, decanted once more then blotted dry 
onto tissue paper 10 times. This washing step was performed a total of 4 times. Then, 
100 L of mouse IL-6 Biotin Conjugate solution (Invitrogen, Life Technologies) was 
added to each well (excluding the chromogen blank), followed by incubation for 30 
minutes at room temperature. The wells were subsequently washed 4 times as 
described before, followed by incubation with 100 L of Streptavadin-HRP 
(Invitrogen, Life Technologies) for 30 minutes at room temperature. The plates were 
again washed 4 times before incubating with 100 L of Stabilised Chromogen 
(Invitrogen, Life Technologies) for 30 minutes at room temperature. Stop solution 
(100 L, Invitrogen, Life Technologies) was added directly to the Stabilised 
Chromogen in each well, the plate was gently agitated and the absorbance at 450 nm 
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wavelength was measured using a spectrophotometric plate reader (FLUOstar 
Omega, BMG Labtech).  
 
A standard curve was produced of absorbance versus IL-6 concentration and the 
concentration of IL-6 in the cell culture supernatant samples was determined using 
this curve and adjusted using the dilution factor of 10. Results are presented as a 
mean IL-6 protein (pg/mL) ± SEM. Statistical analysis comparing the absolute 
absorbance values for each experimental condition was performed using an unpaired 
Student’s t-test assuming equal variance at the 5% significance level. 
 
 
2.14. Measuring protein synthesis in BV2 microglia 
 
BV2 microglia cultured for 24 hours in 6-well plates at a cell density of 500,000 
cells/well and 24-well plates at a cell density of 175,000 cells/well, were treated to 1) 
500 ng/mL LPS and either vehicle control 0.1% v/v sterile DMSO, 1 M SAHA or 
500 nM apicidin, or 2) 500 ng/mL LPS with 1 g/mL cycloheximide (CHX) and 
either vehicle control, 1 M SAHA or 500 nM apicidin for 3 hours in total.  
 
Protein synthesis was assessed in the treated 24-well plates using a Click-iT® Plus 
O-propargyl-puromycin Protein Synthesis Assay Kit (Molecular Probes, Life 
Technologies). Briefly, after 2.5 hours of the aforementioned drug treatments, Click-
iT® O-propargyl-puromycin was added directly to each well to give a final 
concentration of 20 M. The BV2 microglia were cultured at 37°C in a humid 
atmosphere with 5% CO2 for the remaining 30 minutes (3 hours drug treatment in 
total). The culture medium was then removed, the cells were washed with 1 mL 
sterile PBS, followed by fixation with 100 L of 4% w/v paraformaldehyde (PFA, 
dissolved in autoclaved PBS) for 15 minutes at room temperature. The cells were 
then permeabilised with 100 L of 0.5% v/v Triton X-100 (dissolved in autoclaved 
PBS) for 15 minutes at room temperature. The cells were washed 2 times with 1 mL 
autoclaved PBS and processed further following the manufacturer’s instructions. 
Imaging of labelled cells was carried out using the IncuCyte™ FLR with a 10× 
objective lens taken in phase-contrast and green-fluorescence to visualise the OPP+ 
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cells/the cells that are undergoing protein synthesis. Nine non-overlapping images at 
1280 × 1024 resolution were taken per well. The settings for each image, per well, 
per condition were kept constant. 
 
In parallel to the protein synthesis assay, RNA was extracted from BV2 microglia 
cultured in 6-well plates and treated to the aforementioned conditions. The RNA was 
reverse transcribed and the cDNA generated underwent qPCR analysis as described 
in section 2.12. 
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3.1. Introduction 
 
The mechanisms that induce neuronal death in brain insults such as cerebral 
ischaemia, as well as injuries such as traumatic brain injury and neurodegenerative 
diseases such as Alzheimer’s, multiple sclerosis, motor neurone disease and 
Parkinson’s disease, lead to neuronal death through either necrosis or apoptosis. In in 
vivo models of cerebral ischaemia, histone deacetylase (HDAC) inhibitors are 
neuroprotective, neuro-restorative and improve neurological outcome (see section 
1.10.2). However, the molecular mechanisms underlying these effects are not well 
understood. One way to investigate the mechanisms underlying neuroprotection seen 
in vivo, is to study the effects of inhibiting HDACs in isolated neurones challenged 
with neurotoxic insults. As discussed earlier in sections 1.10.3 and 1.10.4, non-
selective and class I selective HDAC inhibitors protect cortical neurones and CGNs 
from a variety of neurotoxic insults including OGD, glutamate excitotoxicity, 
oxidative stress and classical apoptosis inducers such as low extracellular K
+
, DNA 
damaging agents and protein kinase inhibitors. However, in contrast to these 
observations, other studies have reported that applying these HDAC inhibitors to 
neurones independent of an insult, or at the same time as exposing to the 
aforementioned insults, can also cause neurotoxicity and exacerbate neuronal death 
(Bollino et al., 2015; Boutillier et al., 2003; Gaub et al., 2010; Rouaux et al., 2004; 
Salminen et al., 1998; Vashishta and Hetman, 2014). It is generally considered that 
selectively inhibiting the HDACs responsible for producing a neuroprotective effect 
and not inhibiting HDACs, which are important for neurone function and survival, 
will prevent this non-selective HDAC inhibitor mediated neurotoxicity. Furthermore, 
selectively inhibiting particular HDACs will also allow for more focused 
experiments to be performed in order to understand the molecular mechanisms 
involved in the protection of neurones upon inhibition of the appropriate HDAC(s). 
However, as will now be presented, choosing the most appropriate HDACs to inhibit 
is not that simple, because the role of each of the HDAC isoforms in neuronal death 
and neurone survival processes is not clear. 
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3.1.1. The role of HDAC1 in neurone survival and death 
 
The role HDAC1 in neurone survival and death is disputed. As already mentioned in 
section 1.7.1, mice overexpressing HDAC1 have no abnormalities in brain structure, 
cellular architecture or neurone numbers (Guan et al., 2009). Despite this, other 
studies show that HDAC1OE causes neurotoxicity in isolated rat cortical and 
cerebellar granule neurone (CGN) cultures (Bardai et al., 2012). In this study, the 
neurotoxic effect of HDAC1 activity is dependent on an interaction with HDAC3 
(Bardai et al., 2012). Consistent with an increase in HDAC1 expression being 
neurotoxic, the same study observed HDAC1 to be upregulated in both the cortex 
and hippocampus of the p25/Cdk5 mouse model of Alzheimer’s disease (Bardai et 
al., 2012). These two brain areas are known to degenerate in this condition. HDAC1 
has also been found to be upregulated in experimental models relevant to cerebral 
ischaemia including in the mouse brain following MCAO (Baltan et al., 2011a) and 
in white matter tracts deprived of oxygen and glucose (mouse optic nerve OGD 
model, Baltan et al. (2011a)). Furthermore, in the corpus callosum of mice following 
cuprizone-induced axonal demyelination, in the brains of patients with multiple 
sclerosis and in a mouse cerebellar organotypic slice culture model of inflammatory 
demyelination, there is a consistent abnormal localisation and accumulation of 
HDAC1 in the cytoplasm and axons of neurones (Kim et al., 2010). Using cortical 
neurones to investigate this observation further, it was shown that neuronal HDAC1, 
in response to neurotoxic stimuli such as glutamate and TNF-, undergoes 
translocation to the cytoplasm and axons, where it accumulates and inhibits axonal 
transport (Kim et al., 2010). This leads to the formation of protein aggregates, which 
cause neurite beading, swelling and irreversible axon transections (Kim et al., 2010). 
This axonal damage can be prevented by inhibiting HDACs 1, 2 & 3 with MS-275, 
or knocking down HDAC1 but not HDAC2, 3, 4, 6 or 8 (Kim et al., 2010). 
 
Contrary to the work by Montgomery et al. (2009), which shows HDAC1KO mice 
have no obvious brain abnormalities, and the aforementioned studies that suggest an 
increase in HDAC1 activity promotes neurotoxicity, other studies have shown 
HDAC1 activity is important for neurone survival and increasing it has 
neuroprotective effects. Unlike Bardai et al. (2012), Kim et al. (2008) found HDAC1 
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to not be upregulated in the brains of p25/Cdk5 mice, rather HDAC1 activity is 
reduced (Kim et al., 2008). The same group have also shown HDAC1 levels are not 
affected in the brains of patients with Alzheimer’s disease either (Graff et al., 2012). 
One study shows HDAC1 expression and therefore activity is also reduced in the 
mouse brain following MCAO-induced cerebral ischaemia (Chen et al., 2012c). Kim 
et al. (2008) show that a reduction in HDAC1 expression in cortical neurones causes 
neurotoxicity. Here, HDAC1KD causes double-strand DNA breaks, aberrant 
expression of cell-cycle genes and these ultimately trigger neuronal death. Consistent 
with this, HDAC1OE is neuroprotective in the p25/Cdk5 mouse model of 
Alzheimer’s disease and in the rat bilateral common carotid artery occlusion 
(BCCAO) model of cerebral ischaemia (Kim et al., 2008). More recently, the same 
laboratory show HDAC1 is required for successful DNA repair in mouse cortical 
neurones (Wang et al., 2013b). Here, knockdown of HDAC1 prevents the repair of 
double-strand DNA breaks whereas HDAC1OE enhances it. During DNA repair 
signalling, HDAC1 is found to interact with the Fused-in-Sarcoma (FUS) protein 
which is recruited to sites of DNA damage in neurones and is important in detecting 
and activating DNA repair processes (Wang et al., 2013b). 
 
3.1.2. The role of HDAC2 in neurone survival and death 
 
HDAC2 is found to be upregulated in the post-mortem brain of patients with 
Alzheimer’s disease and in the p25/Cdk5 mouse model of this neurodegenerative 
condition. This increase is thought to contribute to the cognitive decline associated 
with Alzheimer’s disease (Graff et al., 2012). An upregulation of HDAC2 has also 
been observed in other neurodegenerative and neurotoxic conditions. HDAC2 
expression is increased in the motor cortex of the post-mortem brain of patients with 
motor neurone disease (Janssen et al., 2010) and in the ischaemic mouse brain 
following MCAO (Baltan et al., 2011a). It is not known if the upregulation of 
HDAC2 causes the neuronal loss in these conditions, but HDAC2 expression is also 
increased in isolated mouse hippocampal neurones exposed to oxidative stress 
conditions (Graff et al., 2012) and a recent study shows that knocking down HDAC2 
protects CGNs from this insult (Peng et al., 2015). Taken together, these studies 
imply that HDAC2 may also be involved in regulating neuronal apoptosis. 
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3.1.3. The role of HDAC3 in neurone survival and death 
 
HDAC3 is also involved in regulating neurone survival and death. One of the earliest 
studies suggested HDAC3 was important in neurone survival and the active process 
of HDAC3 degradation by caspase enzymes was important during low K
+
 induced 
CGN apoptosis. Mechanistically, the loss of HDAC3 during neurone death relieves 
the repression on the apoptosis-inducing gene E2F-1 (Boutillier et al., 2003; 
Panteleeva et al., 2004). More recently, another study revealed that knockout of 
HDAC3 in mouse Purkinje neurones of the cerebellum, has deleterious effects 
resulting dendritic pruning, neurone death and motor impairments in mice 
(Venkatraman et al., 2014). 
 
Contrary to the aforementioned studies, there are others that show HDAC3 activity, 
is involved in neuronal death. Bardai and D'Mello (2011) found that knocking down 
HDAC3 in isolated rat cortical neurones or CGNs protects against apoptosis induced 
by either homocysteate or low extracellular  K
+
 respectively. Also, overexpressing 
HDAC3 in healthy neurones causes neurotoxicity (Bardai and D'Mello, 2011). 
HDAC3 mediated neurotoxicity is dependent on HDAC3 interacting with HDAC1 
and also its phosphorylation by glycogen synthase kinase 3 beta (GSK3 a kinase 
which itself is implicated in neurodegenerative diseases (Bardai et al., 2012). 
HDAC3 is found to be upregulated in neurones that are dying following nerve crush. 
Here, increased HDAC3 expression followed by nuclear translocation is correlated 
with widespread deacetylation of histones and presumably aberrant gene expression 
in dying neurones following axon damage (Pelzel et al., 2010). HDAC3 is not 
upregulated in the cortex of the post-mortem brain of Alzheimer’s disease patients or 
in the cortex or hippocampus of p25/Cdk5 mice (Graff et al., 2012) but its expression 
is increased in the brains of mice following cerebral ischaemia (Baltan et al., 2011a; 
Chen et al., 2012c) and in cortical neurones exposed to OGD (Chen et al., 2012c). 
Consistent with the role of HDAC3 in causing neuronal death, knocking down 
HDAC3 in cortical neurones is neuroprotective against OGD (Chen et al., 2012c). 
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3.1.4. The role of HDAC4 in neurone survival and death 
 
Like HDAC1 and HDAC3 discussed earlier, the role of HDAC4 in neurone survival 
and death is disputed. Bolger and Yao (2005) report that during low K
+
 induced 
apoptosis or glutamate excitotoxicity, HDAC4 in isolated mouse CGNs, translocates 
to the nucleus and represses the activity of the pro-survival transcription factors 
MEF-2 and CREB. Knocking down HDAC4 is neuroprotective in this context, 
whereas overexpression of HDAC4 in the nucleus of healthy neurones is neurotoxic. 
HDAC4 also translocates to the nucleus of isolated rat cortical neurones following 
the induction of cell death due to oxidative stress (Yang et al., 2011). Once in the 
nucleus, HDAC4 interacts with and inhibits another pro-survival transcription factor 
peroxisome proliferator-activated receptor gamma (PPAR, Yang et al. (2011)). In 
this study, knocking down HDAC4 also protects cortical neurones from oxidative 
stress induced neuronal death (Yang et al., 2011). 
 
However, in disagreement with the evidence suggesting HDAC4 activity causes 
neurone cell death, other studies suggest HDAC4 activity is important for neurone 
survival and is neuroprotective. In contradiction to the work by Bolger and Yao 
(2005), Majdzadeh et al. (2008) report that overexpression of HDAC4 (HDAC4OE) 
is neuroprotective and protects isolated rat CGNs from low K
+
 induced apoptosis, rat 
cortical neurone cultures from 6-hydroxy dopamine-induced apoptosis and mouse 
hippocampal neurone-like cells (HT22 neuroblastoma cell-line) from homocysteate-
induced oxidative stress. Additionally, forced expression of HDAC4 in rat neurone-
like cells (differentiated pheochromocytoma PC-12 cell-line) is neuroprotective 
against OGD and this is correlated with a decrease in expression of high-mobility 
group protein 1 (HMG-1), a mediator of tissue damage following acute injury (He et 
al., 2013). Consistent with HDAC4 being important for neurone survival, HDAC4 
mRNA and protein expression levels are significantly reduced in these rat neurone-
like cells following OGD and also in the ischaemic brains of rats during MCAO (He 
et al., 2013). Surprisingly, in the latter model, there is no change in the levels of 
HDAC1, 2 or 3 as reported by others (see sections 3.1.1, 3.1.2 and 3.1.3).  
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3.1.5. The role of HDAC5 in neurone survival and death 
 
Knockout of HDAC5 in healthy mice does not affect hippocampal integrity or 
survival as measured by immunoreactivity for neurones, axons and synapses (Agis-
Balboa et al., 2013). However, in models relevant to cerebral ischaemia, HDAC5 
levels are significantly reduced in the ischaemic brains of mice and rats following 
MCAO (He et al., 2013; Chen et al., 2012c) and in rat neurone-like cells 
(differentiated pheochromocytoma PC-12 cell-line) after OGD (He et al., 2013). The 
underlying cause of this reduction and the consequence of this change is not clear. 
HDAC5OE in rat neurone-like cells exposed to OGD is neuroprotective (He et al., 
2013) and HDAC5OE in the nucleus of isolated rat cortical neurones protects against 
glutamate excitotoxicity (Wei et al., 2015). Wei et al. (2015) also report that HDAC5 
is phosphorylated in neurones undergoing apoptosis and is exported out of the 
nucleus. This loss of nuclear HDAC5 may lead to neuronal death through a de-
repression of apoptosis-inducing genes. Together these studies show a reduction in 
HDAC5 levels and activity in the nucleus is detrimental to neurones and enhancing 
its activity through overexpression is neuroprotective.  
 
In a different study, HDAC5OE in isolated rat CGNs is neurotoxic in the absence of 
a neurotoxic stimulus (Linseman et al., 2003). Furthermore, unlike cortical neurones, 
when CGNs are undergoing apoptosis, HDAC5 is dephosphorylated and undergoes 
nuclear translocation, where it inhibits the pro-survival transcription factor MEF-2 
(Linseman et al., 2003). 
 
3.1.6. The role of HDAC6 in neurone survival and death 
 
In isolated rat cortical neurones, an upregulation of HDAC6 coincides with neuronal 
commitment to apoptosis upon homocysteate-induced oxidative stress (Rivieccio et 
al., 2009) and OGD (Yuan et al., 2015; Chen et al., 2012c). Knocking down or 
inhibiting HDAC6 is neuroprotective in both neurotoxic insults. The molecular 
mechanisms underlying neuroprotection are not known. The neuroprotective effect 
following HDAC6 inhibition comes as a surprise because HDAC6 in addition to 
regulating intracellular transport mechanisms, is important for the clearance of 
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misfolded proteins (Boyault et al., 2007; Iwata et al., 2005; Kawaguchi et al., 2003). 
These proteins are known to accumulate and aggregate as a result of damage by 
oxidative stress, which then causes neuronal dysfunction and neurotoxicity in 
conditions such as Alzheimer’s disease. In addition to protecting neurones, knocking 
down HDAC6 also facilitates neurite outgrowth, which in-turn helps re-establish 
neuronal networks that have been damaged and lost following an insult (Rivieccio et 
al., 2009).  
 
3.1.7. The role of HDAC7 in neurone survival and death 
 
Little is known about the function of HDAC7 in the developed brain, but one report 
shows HDAC7 is important for neurone survival (Ma and D'Mello, 2011). Knocking 
down HDAC7 is neurotoxic in isolated rat CGNs and HDAC7 protein is dramatically 
reduced during low K
+
 induced apoptosis of CGNs and glutamate excitotoxicity in 
hippocampal neurone-like cells (HT22 neuroblastoma cell-line). Consistent with the 
role of HDAC7 in neurone survival, overexpressing this isoform in CGNs and 
cortical neurones prevents apoptosis induced by low K
+
 and homocysteate 
respectively. HDAC7 promotes neurone survival by repressing the expression of c-
Jun a transcription factor implicated in neuronal death. Together, these findings 
suggest under normal circumstances HDAC7 activity is important for neurone 
survival, but in neurones primed to die, HDAC7 levels are reduced and the 
associated neurone survival activities are lost (Ma and D'Mello, 2011).  
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3.1.8. Chapter aim 
 
Several studies have shown selectively inhibiting class I HDACs 1, 2 & 3 protects 
isolated neurones from neuronal death caused by OGD (Formisano et al., 2015; 
Lanzillotta et al., 2013) and oxidative stress (Sleiman et al., 2014), as well as 
preventing axon damage when neurones are exposed to glutamate & TNF- (Kim et 
al., 2010). The inhibition of HDAC2 may underlie the neuroprotective effects seen 
with class I HDAC inhibitors in neurones. Therefore, this isoform is a plausible 
candidate to selectively inhibit with pharmacological agents, to promote 
neuroprotection whilst minimising the risk of causing neurotoxicity from inhibiting 
other HDACs. Currently available HDAC inhibitors do not exclusively inhibit 
HDAC2 and inhibit HDAC1 and/or HDAC3 with similar pharmacological properties 
(table 1.4). The most selective HDAC inhibitor for HDAC2 is MI192, which has 
selectivity towards HDAC2 & 3 over HDAC1 (see section 1.8). In this chapter, the 
efficacy of selective HDAC2 & 3 inhibition to protect neurones from neurotoxicity 
was examined. To do this, CGNs were isolated and cultured, then neuronal cell death 
was induced by exposing them to 1) glutamate excitotoxicity, which is a major 
pathophysiological event in cerebral ischaemia, as well as traumatic brain injury, 
multiple sclerosis, Alzheimer’s disease and motor neurone disease (reviewed by 
Dong et al. (2009); Lau and Tymianski (2010)), or 2) oxygen glucose deprivation 
(OGD), the initiating pathophysiological event in cerebral ischaemia. 
 
 
3.2. HDAC inhibitors do not protect CGNs from glutamate excitotoxicity 
 
CGNs were isolated from seven-day-old rats and cultured for ten days in vitro (DIV) 
before experimentation. After 10 DIV, the cultures had developed a stable 
morphology and neuronal network (figure 3.1) and of this cell population 91.7 ± 
0.315% of the cells were identified as being CGNs (figure 3.2A & C). The remaining 
8.3% of the cell population included astrocytes, as indicated by the presence of cells 
which were highly branched and positive for the astrocyte marker GFAP (figure 
3.2B). 
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Figure 3.1. Development of cerebellar granule neurones (CGNs) during culture. 
Representative phase-contrast images show the morphological changes of CGNs every 24 
hours over a period of 13 days in vitro (DIV). Scale bar 100 m. 
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Figure 3.2. Purity of cerebellar granule neurone (CGN) cultures. Representative 
fluorescence immunocytochemistry images showing; (A) all cells (DAPI+, blue), CGNs 
(NeuN+, red) and a merged image of the two (magenta) at 1 day in vitro (DIV) and 10 DIV, 
arrow heads indicate non-neurone cells (NeuN-), and (B) all cells (DAPI+, blue) and 
astrocytes (GFAP+, green) at 10 DIV. Scale bar 15 & 50 m for (A) & (B) respectively. (C) 
Quantification of (A), purity of CGN cultures at 1 and 10 DIV is expressed as mean 
percentage CGNs (NeuN+ cells) ± SEM, n=3. 
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To determine neurone viability, CGNs were incubated with the cell death stain 
YOYO®-1, which is a nucleic acid dye that works on the basis that dying and dead 
cells have increased membrane permeability so accumulate the stain, whereas intact-
viable cells are impermeable to the stain (Becker et al., 1994). Images were taken of 
the cells by fluorescence microscopy and then all the cells were stained with the cell-
permeable nucleic acid dye SYBR Green I and imaged once more. The number of 
YOYO®-1+ cells and SYBR® Green I+ cells were quantified from the fluorescent 
images and percentage cell viability was calculated. 
 
Glutamate excitotoxicity was induced in CGNs by administering 100 M L-
glutamate (as used by Ankarcrona et al. (1995); Du et al. (1997); Leng and Chuang 
(2006)). After 24 hours of treatment, there was a significant reduction in cell 
viability of 44.69 ± 2.56% (P=8.44 × 10
-11
 compared to the vehicle control, figure 
3.3A & 3.3B). This cell death was significantly suppressed by co-administering both 
30 M NBQX an AMPA & Kainate glutamate receptor antagonist, and 10 M MK-
801 a NMDA glutamate receptor antagonist. These drugs restored cell viability to 
90.96 ± 1.46% (P=2.88 × 10
-10
 compared to glutamate +vehicle, figure 3.3A & 
3.3B). Glutamate excitotoxicity causes neurone death through necrosis and apoptosis 
(Ankarcrona et al., 1995; Du et al., 1997). Necrotic cell death is an uncontrolled 
event resulting from an intense stimulus, which causes overwhelming cell stress and 
damage. Apoptosis on the other-hand is a controlled intracellular signalling cascade, 
which is triggered by the cell in response to detecting damage or when the cell is 
unable to perform its normal function. Apoptosis involves a complex intracellular 
pathway involving many proteins but importantly the proteolytic enzymes caspases 3 
& 7. In CGNs, administering 200 M N-acetyl-Asp-Glu-Val-Asp-al (ac-DEVD-al) a 
caspase 3 & 7 inhibitor at the same time as L-glutamate did not protect CGNs from 
glutamate excitotoxicity (P=1.74 × 10
-10
 compared to the vehicle control, figure 
3.3B). It was assumed the caspase inhibitor was working because, when used in a 
parallel experiment (see figure 3.5), caspase inhibition was able to protect CGNs 
from neurotoxicity induced by another stimulus. Because caspases, which are 
essential for apoptosis were not involved in glutamate-induced neuronal death during 
24 hours, this implied that these neurones were not dying from apoptosis and were 
likely to be undergoing necrotic cell death. 
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To examine the effects of HDAC inhibition on this glutamate-induced cell death, 
first the effect of HDAC inhibitors in healthy CGN cultures was examined. CGNs 
were treated to 1 M of the non-selective HDAC inhibitor SAHA or 1 M of the 
HDAC2 & 3 selective inhibitor MI192 and after 24 hours cell viability of neurones 
exposed to these HDAC inhibitors was 89.6 ± 0.687% and 90.34 ± 0.339% 
respectively (figure 3.3B). These viabilities were not significantly different from the 
vehicle control, therefore non-selective HDAC inhibition and selective inhibition of 
HDAC2 & 3 did not induce neurotoxicity in this time frame. Treatment of CGNs 
with either HDAC inhibitor for 24 hours robustly increased the acetylation of histone 
H3 at lysine 9 (acH3K9, figure 3.3C) and pan-acetylation of histone H4 (acH4, 
figure 3.3C). Despite HDAC inhibition having a positive effect on histone 
acetylation, treatment of 1 M SAHA, 1 mM VPA (a non-selective HDAC inhibitor) 
or 1 M MI192 at the same time as glutamate, did not protect CGNs from glutamate-
induced cell death after 24 hours, with cell viabilities of 48.6 ± 1.72% (P=8.18 × 10
-
11
 compared to the vehicle control), 45.03 ± 2.55% (P=2.89 × 10
-11
 compared to the 
vehicle control) and 51.01 ± 3.047% (P=1.41 × 10
-10
 compared to the vehicle 
control) respectively (figure 3.3B). Administering 3 M SAHA or 3 M MI192 at 
the same as glutamate did not protect CGNs after 24 hours either (figure 3.3B). Also, 
SAHA or MI192 did not protect CGNs from glutamate-induced cell death after 
treating for 72 hours, with cell viabilities of 53.5 ± 3.58% (P=3.71 × 10
-4
 compared 
to the vehicle control) and 46.9 ± 6.43% (P=1.24 × 10
-4
 compared to the vehicle 
control) respectively (figure 3.4A). 
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Figure 3.3. Histone deacetylase inhibitors do not protect rat cerebellar granule neurones 
(CGNs) from excitotoxicity when administered at the same time as glutamate for 24 hours.  
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Figure 3.3 continued… CGNs after 10 days in vitro (DIV) were treated to vehicle (0.3% v/v 
DMSO), 1 M SAHA or 1 M MI192. To induce glutamate excitotoxicity and examine the 
effects of pharmacological interventions on this, CGNs were exposed to 100 M L-
glutamate and simultaneously treated with either vehicle, both 30 M NBQX and 10 M 
MK-801 (glutamate receptor antagonists), 200 M ac-DEVD-al (a caspase inhibitor), 1 or 3 
M SAHA, 1 mM VPA or 1 or 3 M MI192 for 24 hours. Cell viability was then 
determined by fluorescence microscopy. (A) Representative images of phase contrast and 
fluorescently labelled dying/dead CGNs (YOYO®-1+, green) and all CGNs (SYBR® Green 
I+) after 24 hours of excitotoxicity induced by glutamate with either vehicle or glutamate 
receptor antagonists. Scale bar 50 m. (B) The number of YOYO®-1 and SYBR® Green I 
positive CGNs were quantified from all images across all conditions and data shown are 
mean percentage cell viability ± SEM. All experiments were performed n=3. ***P<0.001 vs. 
vehicle, ###P<0.001 vs. glutamate +vehicle. (C) CGNs were treated to vehicle, 1 M SAHA 
or 1 M MI192 for 24 hours followed by histone protein extraction and Western blot to 
analyse acetylated histone H3 at lysine 9 (acH3K9) and pan-acetylated histone H4 (acH4). 
Total histone H3 was used as the loading control. 
 
One of the reasons why HDAC inhibitors do not protect CGNs from glutamate-
induced excitotoxicity, when administered at the same time as glutamate, may be 
because the neurotoxic insult is continually present. When glutamate is added to 
CGN cultures, if this is in excess and is not transported into and then metabolised by 
neurones and contaminating astrocytes, and/or there is no glutamate receptor 
desensitisation, then toxic levels of glutamate in the media will persist. This will 
chronically stimulate neuronal glutamate receptors, which would maintain a constant 
state of depolarisation and calcium overload; processes that trigger cellular damage 
and neuronal cell death. This could mean that any protective mechanisms induced by 
HDAC inhibitors may be antagonised or are always overwhelmed by the insult. Also, 
because there is no point in time where CGNs are not being challenged by glutamate, 
there is no opportunity for the intracellular environment to return to normal and for 
HDAC inhibitor induced repair mechanisms to repair damage and have a 
neuroprotective effect. To examine if HDAC inhibitors are neuroprotective against a 
brief pulse of glutamate, CGNs were exposed to 100 M L-glutamate for 30 minutes 
in the presence of either the vehicle control, 1 M SAHA or 1 M MI192. These 
treatments were then removed and CGNs were treated to either the vehicle control, 1 
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M SAHA or 1 M MI192 for a further 72 hours. It was noticed that the viability of 
CGNs in the control condition (79.9 ± 0.170%) was reduced compared to previous 
experiments. This was presumably because of the treatment paradigm itself, which 
involved more handling and manipulating of the neurone cultures outside of optimal 
culture conditions compared to other treatment regimes. Thirty minutes of glutamate 
exposure followed by 72 hours of culture in the absence of glutamate, induced 42.1 ± 
0.892% cell death (P=2.86 × 10
-14
 compared to the vehicle control, figure 3.4B). 
SAHA or MI192 when given at the same time as the glutamate pulse and for 72 
hours after this, did not protect CGNs from the initial insult or induce repair 
mechanisms that promoted neurone survival (figure 3.4B). Cell viabilities following 
SAHA and MI192 treatment were 36.8 ± 0.478% (P=2.16 × 10
-14
 compared to the 
vehicle control) and 38.9 ± 0.713% (P=3.95 × 10
-14
 compared to the vehicle control) 
respectively (figure 3.4B). 
 
To protect against glutamate-induced neuronal death, HDAC inhibitors may need to 
be pre-treated before an insult to allow time for the neuroprotective molecular 
changes to take place. To test this hypothesis, CGNs were pre-treated with either the 
vehicle control, 1 M SAHA or 1 M MI192 for 24 hours before exposing to L-
glutamate for a further 24 hours (figure 3.4C). Pre-treating with the vehicle control 
followed by glutamate exposure induced, 46.7 ± 2.72% cell death (P=5.8 × 10
-8
 
compared to the vehicle control). Both HDAC inhibitors when administered before 
the insult, failed to protect CGNs from glutamate-induced cell death with cell 
viabilities of 24.5 ± 1.802% and 41.9 ± 3.401% respectively (P=6.5 × 10
-10
 and 
P=1.87 × 10
-8
 compared to the vehicle control respectively). Pre-treatment of SAHA 
for 24 hours significantly exacerbated glutamate-induced cell death (P=1.54 × 10
-4
 
compared to glutamate +vehicle). This effect was not due to exposure to SAHA on 
its own for 24 hours because this had no effect on CGN viability (figure 3.3B), nor 
was it due to the co-treatment paradigm or the length of time CGNs were exposed to 
SAHA because when these neurones were treated to this HDAC inhibitor alongside 
L-glutamate for 24 or 72 hours, the cell death induced (44.07 ± 1.72% and 53.5 ± 
3.58% for 24 and 72 hours respectively) was not significantly different to that caused 
by glutamate +vehicle (44.7 ± 2.56% and 53.8 ± 2.55% for 24 and 72 hours 
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respectively). This suggests SAHA pre-treatment causes CGNs to be more 
susceptible to neurotoxicity by glutamate. 
 
 
 
 
Figure 3.4. Histone deacetylase inhibitors (HDACi) do not protect rat cerebellar granule 
neurones (CGNs) from glutamate excitotoxicity when treated for longer, treated after a short 
pulse of glutamate or when pre-treated before glutamate. (A) CGNs after 10 days in vitro 
(DIV) were exposed to 100 M L-glutamate and simultaneously treated with either vehicle 
(0.1% v/v DMSO), 1 M SAHA or 1 M MI192 for 72 hours. (B) CGNs were treated to 100 
M L-glutamate with either vehicle, 1 M SAHA, 1 M MI192 for 30 minutes. This was 
then removed and CGNs were treated to either vehicle, 1 M SAHA, 1 M MI192 for a 
further 72 hours. (C) CGNs were treated to vehicle, 1 M SAHA, 1 M MI192 for 24 hours 
followed by exposure to 100 M L-glutamate with either the vehicle control or the HDAC 
inhibitors for a further 24 hours. For each panel, cell viability was determined by 
fluorescence microscopy and data shown are mean percentage cell viability ± SEM. All 
experiments were performed n=3. ***P<0.001 vs. vehicle, ###P<0.001 vs. glutamate 
+vehicle. 
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Rather than a sudden and overwhelming neurotoxic stimulus as modelled when 
applying glutamate directly to CGNs, it may be that HDAC inhibitors are only 
neuroprotective when the induction of cell death is slower and/or is through the 
apoptotic cell death pathway. To model a slower induction of glutamate 
excitotoxicity and one with an apoptotic component which HDACs such as HDAC2 
may positively regulate and/or HDAC inhibitors can protect against, CGNs were 
treated for 24 hours with 500 M DL-threo--Benzyloxyaspartic acid (DL-TBOA) a 
blocker of excitatory amino acid re-uptake transporters (EAATs 1-5, Shigeri et al. 
(2001); Shimamoto et al. (1998)). It was expected that during this time, glutamate 
would gradually accumulate in the culture medium as CGNs released this 
neurotransmitter but were unable to re-uptake it. This glutamate, after a period of 
time, would reach levels sufficient to induce neurotoxicity and so the cell would have 
the time to detect the cellular damage caused by excitotoxicity and initiate 
appropriate repair mechanisms or apoptosis. This temporally dependent insult would 
better mimic the cell death induced by glutamate excitotoxicity in the penumbral 
brain region in in vivo models of cerebral ischaemia (Dirnagl et al., 1999). 
Furthermore, as the induction of apoptosis would be relatively slow, there may be a 
therapeutic window where HDAC inhibitors may act to have a neuroprotective effect 
by preventing the damage, which would trigger apoptosis and/or by inhibiting the 
apoptotic-signalling cascade itself. 
 
After 24 hours exposure to DL-TBOA, cell viability was significantly reduced to 
58.2 ± 3.12% (P=1.17 × 10
-7
 compared to the vehicle control, figure 3.5A & 3.5B). 
This DL-TBOA induced cell death could be significantly suppressed by co-
administering both 30 M NBQX and 10 M MK-801 (glutamate receptor 
antagonists) with cell viability restored to 84.2 ± 2.17% (P=3.051 × 10
-6
 compared to 
DL-TBOA, figure 3.5A & 3.5B), which was not significantly different to vehicle 
control (P=0.845). Neuronal death induced by DL-TBOA in CGNs was through an 
apoptotic pathway as predicted; with treatment of a caspase inhibitor (ac-DEVD-al) 
at the same time as DL-TBOA suppressing neuronal death (viability of CGNs was 
restored to 73.3 ± 2.47%, P=5.72 × 10
-4
 compared to DL-TBOA +vehicle, P=1.42 × 
10
-3
 compared to the vehicle control, figure 3.5A & 3.5B). However, when isolated 
CGNs were exposed to DL-TBOA and at the same time either 1 M SAHA, 1 mM 
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VPA or 1 M MI192, these HDAC inhibitors did not protect CGNs from DL-TBOA 
induced apoptosis with cell viabilities of 53.2 ± 2.41% (P=1.66 × 10
-7
 compared to 
the vehicle control), 56.5 ± 4.19% (P=5.76 × 10
-7 
compared to the vehicle control) 
and 57.9 ± 2.503% (P= 9.704 × 10
-7 
compared to the vehicle control) respectively 
(figure 3.5B).  
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Figure 3.5. Histone deacetylase inhibitors do not protect rat cerebellar granule neurones 
(CGNs) from glutamate excitotoxicity induced by inhibiting glutamate re-uptake 
transporters.  
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Figure 3.5 continued… CGNs after 10 days in vitro (DIV) were treated for 24 hours to 
vehicle (0.6% v/v DMSO) or 500 M DL-TBOA (a blocker of excitatory amino acid re-
uptake transporters, EAATs) with either vehicle, both 30 M NBQX and 10 M MK-801 
(glutamate receptor antagonists), 200 M ac-DEVD-al (a caspase inhibitor) or the HDAC 
inhibitors SAHA, VPA, or MI192. Cell viability was then determined by fluorescence 
microscopy. (A) Representative images of phase contrast and fluorescently labelled 
dying/dead CGNs (YOYO®-1+, green) and all CGNs (SYBR® Green I+) after 24 hours of 
treatment with DL-TBOA and vehicle, glutamate receptor antagonists or a caspase inhibitor. 
Scale bar 50 m. (B) The number of YOYO®-1 and SYBR® Green I positive CGNs were 
quantified from all images across all conditions and data shown are mean percentage cell 
viability ± SEM. All experiments were performed n=3. **P<0.01 & ***P<0.001 vs. vehicle, 
###P<0.001 vs. DL-TBOA +vehicle. 
 
 
3.3. HDAC inhibitors do not protect CGNs from oxygen glucose deprivation (OGD) 
 
In the models of glutamate excitotoxicity used in this chapter, treatment of HDAC 
inhibitors did not prevent necrotic or apoptotic cell death caused by this insult. 
Therefore, the effect of HDAC inhibitors on neurone survival was investigated using 
another model system of cerebral ischaemia; oxygen and glucose deprivation (OGD). 
A reduction in the supply of oxygen and glucose to a region of the brain is the 
fundamental pathophysiological event that causes neuronal death in cerebral 
ischaemia. To induce OGD, CGNs cultured for 10 DIV were exposed to 
deoxygenated culture medium and incubated at 37°C in an atmosphere composed of 
95% N2 and 5% CO2 for 40 minutes (exposure time was based on the findings 
reported by Kalda et al. (1998) and preliminary work looking at a time series of 
OGD exposures (30 to 90 mins), n=1 data not shown). After this, the deoxygenated 
medium was changed to normal culture medium with either the vehicle control or 1 
M SAHA and then the CGNs were cultured for a further 24 hours, a period of time 
termed the reperfusion period (as performed by Kalda et al. (1998); Scorziello et al. 
(2001); Scorziello et al. (2004)). Then, cell viability was determined using the MTT 
assay. Depriving CGNs of oxygen and glucose significantly reduced cell viability by 
44.73 ± 12.5% (P=0.00937 compared to the no OGD control, figure 3.6). 
Administering SAHA immediately after exposing to OGD for 40 minutes, did not 
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prevent neuronal death after 24 hours of reperfusion (cell viability was 59.6 ± 8.33%, 
P= 0.00313 compared to the no OGD control, figure 3.6). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Inhibiting histone deacetylases does not protect rat cerebellar granule neurones 
(CGNs) from oxygen glucose deprivation (OGD)-induced death. CGNs after 10 days in vitro 
(DIV) were exposed OGD for 40 minutes followed by reperfusion in normal culture 
conditions with either the vehicle control (0.1% v/v DMSO) or 1 M SAHA for a further 24 
hours. Cell viability was determined by MTT assay and data shown are mean cell viability 
expressed as a percentage of the no OGD control ± SEM. All experiments were performed 
n=3. **P<0.01 vs. no OGD control. 
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3.4. Discussion 
 
3.4.1. HDAC inhibitors do not protect neurones from glutamate-induced death 
 
Glutamate excitotoxicity causes neuronal death through necrosis or apoptosis 
(Ankarcrona et al., 1995; Du et al., 1997). In this study, inhibiting caspases 3 & 7, 
which are enzymes essential for apoptosis, did not protect CGNs from glutamate-
induced neuronal death (figure 3.3B). This suggests the predominant mode of cell 
death induced by glutamate exposure was not apoptotic but necrotic. It may be 
possible, through the use of HDAC inhibitors, to change the expression of specific 
genes thus proteins, in order to reduce the responsiveness of neurones to glutamate, 
reduce the susceptibility of neurones to excitotoxicity, or induce mechanisms that 
repair neurones from damage and therefore prevent the commitment to necrosis. 
However, administering HDAC inhibitors SAHA, VPA or MI192 at the same time as 
exposing CGNs to glutamate, did not protect these neurones (figure 3.3B, 3.4A & 
3.4B). If changes in the acetylation of proteins such as histones and transcription 
factors, then changes in the transcription, translation and expression of genes upon 
HDAC inhibition are important for neuroprotection, it is likely that a certain length 
of time is required for these changes to take place following treatment with a HDAC 
inhibitor. This may be longer than the time it takes for the toxic effects of glutamate 
to cause neuronal damage and evoke necrotic cell death. Indeed, the amount of cell 
death induced when CGNs were exposed to just 30 minutes of glutamate followed by 
further culture without it (figure 3.4B) was not significantly different to the amount 
of cell death induced when CGNs were constantly exposed to glutamate for 24 and 
72 hours (figure 3.3B & 3.4A). This suggests glutamate rapidly activates cell death 
processes during the first 30 minutes of exposure. Taking this fast kinetics into 
consideration, it is not too surprising that treatment of HDAC inhibitors at the same 
time as exposing to glutamate did not prevent CGNs undergoing glutamate-induced 
necrosis. 
 
Based on the molecular mechanisms known to be involved in glutamate 
excitotoxicity (see section 1.10.1), some of the changes in gene expression that have 
been reported to occur in neurones and the central nervous system (CNS) following 
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HDAC inhibition, which might protect neurones from this insult include an increase 
in the expression of the glutamate re-uptake transporter EAAT2 (Baltan et al., 2011b; 
Yoo and Ko, 2011). This may enhance the uptake of glutamate from the extracellular 
space and reduce glutamate-induced activation of glutamate receptors. HDAC 
inhibition can also trigger an upregulation of calpastatin an inhibitor of the 
proteolytic calcium-dependent enzyme calpain 1 (Seo et al., 2013) and an increase in 
the expression of the Na
+
/Ca
2+
 exchanger (Formisano et al., 2015), which may 
prevent the rise in intracellular calcium to the levels that are toxic to neurones. 
HDAC inhibition has also been shown to increase the expression of antioxidant 
enzymes in neurones and the brain including Glutathione peroxidase 1 (Camelo et 
al., 2005) and NADPH (nicotinamide adenine dinucleotide phosphate) 
dehydrogenase (Wang et al., 2011a). Together these changes in gene expression may 
prevent and reduce cellular damage caused by excitotoxicity. In order to change the 
expression of these genes, CGNs may need to be pre-treated with HDAC inhibitors 
to allow for the expression levels of these and other neuroprotective proteins to reach 
or surpass a threshold in order to protect from excitotoxicity. In support of this idea, 
pre-treatment of non-selective HDAC inhibitors VPA, TSA or sodium butyrate for 
two to seven days before exposing to glutamate, has been shown to protect CGNs 
from excitotoxicity (Leng and Chuang, 2006). Based on this, to investigate if 
selective HDAC2 & 3 inhibition prior to glutamate exposure was neuroprotective, 
CGNs were pre-treated with the SAHA or MI192 for 24 hours and then exposed to 
glutamate in the presence of the HDAC inhibitor. Following this, it was found that 
neither HDAC inhibitor protected CGNs from this insult. In fact, pre-treatment of the 
non-selective HDAC inhibitor SAHA, exacerbated/increased the susceptibility of 
CGNs to glutamate-induced CGN death (figure 3.4C).  
 
This toxicity as-well as that seen by others when using non-selective HDAC 
inhibitors (Bollino et al., 2015; Boutillier et al., 2003; Gaub et al., 2010; Rouaux et 
al., 2004; Salminen et al., 1998; Vashishta and Hetman, 2014), could be caused by 
inappropriately inhibiting HDAC isoforms, which are important for neurone function 
and survival, or HDACs that when inhibited increase the susceptibility of neurones 
to toxicity. Therefore, it is important to selectively inhibit the appropriate HDAC 
isoforms to prevent the neurotoxicity associated with non-selective HDAC 
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inhibition. Consistent with this idea, pre-treatment of CGNs to MI192 did not 
exacerbate glutamate-induced CGN death. This suggests that the neurotoxic effect of 
SAHA is caused by an inappropriate inhibition of HDAC isoforms other than 
HDAC2 & 3 such as HDAC1, 5 and 8 (see table 1.4 and sections 3.1.1 and 3.1.5).  
 
The absence of a neuroprotective effect following pre-treatment with MI192 could 
be for several reasons. The first is that HDAC2 & 3 activity is not involved in the 
induction and progression of necrotic cell death, therefore HDAC inhibitors do not 
prevent and protect from such activity. The second reason is that pre-treatment of 
MI192 for 24 hours is not a long enough period of time for appropriate 
neuroprotective changes to become established. The third could be that selective 
inhibition of HDAC2 & 3 before the insult is insufficient to cause necessary 
molecular changes to protect CGNs, therefore inhibiting other isoforms on their own 
or together with HDAC2 & 3 is required for a neuroprotective effect. However this is 
unlikely because specific knockdown of either HDAC2 (Peng et al., 2015) or 
HDAC3 (Bardai and D'Mello, 2011) before an insult has been shown to prevent 
CGNs undergoing apoptosis. 
 
In search of a more appropriate model of excitotoxicity to use to examine possible 
neuroprotective effects of selective HDAC2 & 3 inhibition in neurones, it was 
important to bear in mind that glutamate excitotoxicity in the brain, following a 
cerebral ischaemic attack consists of two phases. The first is an overwhelming insult 
to neurones in the brain region starved of blood and this area of damage is known as 
the ischaemic core and here neurones die by necrosis (discussed in section 1.10.1, 
Dirnagl et al. (1999)). This first phase was modelled when CGNs were exposed to 
glutamate. The second phase of glutamate excitotoxicity occurs within several hours 
as the pathogenesis evolves and is triggered by the slow propagation of glutamate 
into the surrounding brain tissue known as the penumbral region. Here neuronal 
death is predominantly apoptotic (discussed in section 1.10.1, Dirnagl et al. (1999)). 
It is this apoptotic cell death and brain region, which is considered preventable and 
salvageable by using neuroprotective agents respectively. Therefore an in vitro 
model system that closely represents the death of penumbral neurones when exposed 
to glutamate excitotoxicity in vivo, is not a model where neurones get a single and 
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overwhelming “hit” of toxic glutamate, but rather a model where neurones are 
exposed to a progressive accumulation of glutamate which causes cellular damage 
and triggers apoptotic cell death. 
 
3.4.2. HDAC inhibitors do not protect CGNs from apoptosis caused by glutamate 
excitotoxicity when administered at the same time as exposing to the insult 
 
One way to induce progressive glutamate accumulation in vitro is to treat neurones 
to an inhibitor of glutamate re-uptake transporters such as DL-TBOA or SYM 2081 
(Kanai et al., 2004). In this study, DL-TBOA triggered glutamate excitotoxicity and 
induced apoptotic cell death of CGNs. This was indicated by significant 
neuroprotection with the treatment of glutamate receptor antagonists and ac-DEVD-
al an inhibitor of the apoptosis-inducing enzymes caspase 3 & 7 (figure 3.5A & 
3.5B). However, treating CGNs to either SAHA or MI192 at the same time as 
exposing to DL-TBOA did not prevent this neuronal apoptosis. This rules out a 
mechanism whereby HDACs are mediators of the apoptotic cascade triggered by 
glutamate excitotoxicity.  
 
Other studies have shown that treating CGNs with non-selective HDAC inhibitors 
initiates anti-apoptotic mechanisms such as an increase in the expression of anti-
apoptotic genes Bcl-2 (Leng and Chuang, 2006) and HSP70 (Marinova et al., 2009). 
For non-selective HDAC inhibitors and possibly HDAC2 & 3 selective inhibitors to 
evoke these and other mechanisms to prevent DL-TBOA induced apoptosis, it is 
likely that CGNs must be exposed to these inhibitors for an appropriate length of 
time prior to exposure of the insult. With respect to the length of time required to 
have this neuroprotective effect, Kanai et al. (2004) report that three days is the 
minimum but seven days is the optimum amount of time to pre-treat with VPA, 
sodium butyrate & TSA in order to protect CGNs from apoptosis induced by 
inhibiting glutamate re-uptake transporters. Also, non-selective HDAC inhibitors 
need to be pre-treated for two or more days to protect CGNs and cortical neurones 
from subsequent glutamate-induced excitotoxicity (Leng and Chuang, 2006; 
Marinova et al., 2009). Pre-treating with HDAC inhibitors may prevent the apoptosis 
of CGNs exposed to DL-TBOA, but this hypothesis was not investigated 
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experimentally. Nevertheless, it is likely that pre-treatment of non-selective HDAC 
inhibitors will not prevent DL-TBOA induced glutamate excitotoxicity anyway, but 
will exacerbate it as seen in figure 3.4C. 
 
The requirement for a prolonged pre-treatment of several days to protect neurones 
from glutamate excitotoxicity, is unusual given that the same HDAC inhibitors can 
protect neurones from other apoptosis inducing insults such as DNA damaging 
agents, oxidative stress, OGD and low extracellular K
+
 without requiring days of pre-
treatment to have a neuroprotective effect (see section 1.10.3 & 1.10.4). This 
suggests HDAC inhibitors may be having different effects to protect neurones from 
these other apoptosis-inducing insults compared to glutamate excitotoxicity and 
these effects may be time-dependent. For example, unlike glutamate excitotoxicity, 
HDACs may be actively involved in causing neuronal apoptosis in these other 
neurotoxic insults (see sections 3.1.1 to 3.1.7). Therefore inhibiting them would 
prevent this directly, without requiring other slower molecular changes to take place. 
Because the literature suggests that a prolonged pre-treatment is only required to 
protect neurones from neuronal death caused by excitotoxicity and not other stimuli, 
this raises doubts over the validity of this model system. It is unclear if the 
neuroprotective mechanisms that occur during this prolonged pre-treatment time 
frame represent the mechanisms involved when HDAC inhibitors are 
neuroprotective in other in vitro models and more importantly, neuroprotective in ex 
vivo and in vivo models when administered either immediately before or sometime 
after the onset of the neurotoxic insult (see sections 1.10.2, 1.10.3 and 1.10.5 for 
examples). 
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3.4.3. HDAC inhibitors do not protect CGNs from oxygen glucose deprivation 
(OGD)-induced death when administered immediately after OGD 
 
One model of neurotoxicity where non-selective HDAC inhibitors have been shown 
to be neuroprotective, when either given shortly before or immediately after a 
neurotoxic insult, is when cortical neurones are exposed to OGD (Hasan et al., 2013; 
Lanzillotta et al., 2013; Meisel et al., 2006; Wang et al., 2011a). Recently the class I 
selective HDAC inhibitor MS-275 has also been shown to protect cortical neurones 
from OGD-induced death when administered immediately after OGD (Formisano et 
al., 2015). 
 
The ability of HDAC inhibitors to protect CGNs from OGD-induced death has not 
been investigated before. Using these neurones, the aim was to establish an OGD 
model system where as the literature suggests, non-selective HDAC inhibitors are 
neuroprotective against OGD. Then this system would be used to determine which 
HDAC isoforms when inhibited are important for this effect and to investigate the 
molecular mechanisms involved. However, having established a paradigm to cause a 
similar amount of OGD-induced death of CGNs compared to the studies with 
cortical neurones, it was found that despite these other studies showing non-selective 
HDAC inhibitors are neuroprotective when administered immediately after exposing 
cortical neurones to OGD, the same treatment regime did not protect CGNs from this 
insult (figure 3.6). As hypothesised earlier when discussing the ineffectiveness of 
HDAC inhibitors to protect CGNs from glutamate excitotoxicity, the inability of 
HDAC inhibitors to protect from OGD may also be because of the mode of cell 
death induced. If OGD predominantly caused necrosis, then for HDAC inhibitors to 
induce mechanisms that protect from or repair the initiating damaging, it is likely 
that they will need to be administered for an appropriate amount of time before the 
insult. If OGD caused apoptosis, then HDACs were not involved in the induction and 
progression of the apoptotic cell death pathway in CGNs. However, having not 
examined the effectiveness of caspase inhibitors or glutamate receptor antagonists to 
prevent OGD-induced CGN death, it is impossible to confirm at this time what mode 
of cell death was induced and what pathophysiological molecular mechanisms were 
involved. 
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3.5. Conclusion 
 
In conclusion, treatment of CGNs with either non-selective HDAC inhibitors or a 
selective HDAC2 & 3 inhibitor did not protect from glutamate-induced necrotic cell 
death when given at the same time as glutamate, or pre-treated for 24 hours 
beforehand. Also, these HDAC inhibitors did not prevent the apoptosis of CGNs 
when administered at the same time as inhibiting glutamate re-uptake transporters. 
Furthermore, non-selective HDAC inhibitors when given immediately after OGD did 
not prevent CGNs undergoing OGD-induced neuronal death. It is possible that pre-
treating CGNs with HDAC inhibitors for an extended period may prevent neuronal 
death caused by glutamate excitotoxicity and OGD, but this remains to be 
determined. However, it is questionable whether the effects of HDAC inhibitors 
during a prolonged pre-treatment regime, represents the neuroprotective mechanisms 
involved when HDAC inhibitors are neuroprotective post-insult in ex vivo and in 
vivo models. 
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Investigating the effects of inhibiting HDACs  
on the inflammatory response of microglia
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4.1. Introduction 
 
Histone deacetylase inhibitors are neuroprotective, neuro-restorative and improve 
neurological outcome in in vivo models of cerebral ischaemia and other brain insults 
and neurodegenerative diseases. HDAC inhibitors may do this through a number of 
mechanisms including direct effects in neurones, but as discussed in the previous 
chapter, the effect of HDAC inhibitors in isolated neurones is controversial. HDAC 
inhibitors could have neuroprotective effects in vivo by acting in other neural cells 
such as suppressing the inflammatory response of microglia, the innate immune cells 
of the brain, and as a consequence inhibit the neurotoxicity associated with 
neuroinflammation. Based on this, the effect of selective HDAC inhibition on the 
inflammatory response of microglia has been examined in this chapter. To date, 
every study that has looked at the effects of HDAC inhibition in microglia has used 
non-selective HDAC inhibitors (table 1.5). Therefore we do not know which HDAC 
isoforms are the important ones to inhibit and how this suppresses 
neuroinflammation. In order to identify which HDAC isoforms may be suitable to 
selectively inhibit to suppress the inflammatory response in microglia, I turned to 
studies that have investigated the effects of selective HDAC inhibitors in innate 
immune cells, which normally reside outside of the CNS (table 4.1). This analysis 
strongly suggested examining the effects of selectively inhibiting class I HDACs or 
HDAC6 in microglia. In isolated macrophages from mice, MS-275 a selective 
inhibitor of class I HDACs 1, 2 & 3 (table 1.4), significantly reduces the LPS-
induced expression of iNOS and production of nitrite (Jeong et al., 2014) and 
expression of the pro-inflammatory cytokines TNF- and IL-1 (Zhang and 
Schluesener, 2013). Consistent with this, combined knockdown of HDACs 1, 2 & 3 
has the same anti-inflammatory effect (Jeong et al., 2014). One study found that 
MI192 a HDAC2 & 3 selective inhibitor (see section 1.8) also inhibits the expression 
of pro-inflammatory mediators such as TNF-, IL-6 and IFN in human peripheral 
blood mononuclear cells (PBMCs) exposed to LPS (Gillespie et al., 2011). More 
specifically, knocking down HDAC3 in murine macrophages suppresses LPS-
induced interferon beta (IFN) and IL-6 expression (Chen et al., 2012a) and 
following a more comprehensive analysis, knocking out HDAC3 in macrophages, 
has been shown to reduce the expression of approximately 45% of the genes that are 
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increased in response to LPS (Chen et al., 2012a). Very little is known about the 
cellular functions of the class I HDAC, HDAC8, but recent data suggests this 
isoform may be involved in regulating the inflammatory response of innate immune 
cells. Selective inhibition of this isoform with a novel hydroxamate HDAC8 inhibitor 
(ITF3056, IC50 of 285 nM for HDAC8, 2 M for HDAC1, >3 M for HDAC2, 3, 6, 
10 & 11 and >10 M for HDAC4, 5, 7 & 9, Li et al. (2015)) attenuates LPS-induced 
IL-1, TNF- and IL-6 expression in human PBMCs (Li et al., 2015). Selective 
inhibition of HDAC8 and HDAC6 with Tubastatin (IC50 of 15 nM for HDAC6, 854 
nM for HDAC8, 16.4 M for HDAC1 and >30 M for HDAC2-5, 7 & 9-11, Butler 
et al. (2010)) also suppresses pro-inflammatory mediator expression in mononuclear 
cells and macrophages (Vishwakarma et al., 2013).  
 
Taken together, these data show that selective inhibition of class I HDACs or 
HDAC6 inhibits the inflammatory response of cells of the innate immune system 
outside of the CNS. On the basis of these findings, it is possible that selective 
inhibition or specific knockdown of these HDAC isoforms has the same anti-
inflammatory effect in activated microglia. This hypothesis is supported by studies 
which have shown the selective class I HDAC inhibitor MS-275 is neuroprotective in 
rodent models of cerebral ischaemia (Lanzillotta et al., 2013; Murphy et al., 2014), 
experimental autoimmune neuritis (Zhang et al., 2010) and amyloidosis (Zhang and 
Schluesener, 2013) all of which have a neuroinflammatory component. To 
investigate if selectively inhibiting class I HDACs or HDAC6 suppresses the 
inflammatory response of microglia, the immortalised murine BV2 microglia cell-
line was used and the inflammatory response of these microglial cells was activated 
with LPS. 
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Table 4.1. The effect of HDAC inhibitors on the inflammatory response of 
monocytes and macrophages. 
HDAC inhibitors Treatment 
Anti or Pro-
inflammatory? 
Ref 
ITF2357, SAHA Pre Anti- 1 & 2 
TSA Co Anti- & Pro- 3 
SAHA, TSA Pre, Co Anti- 4 
MS-275, SAHA Pre Anti- 5 
TSA, SPB Co Anti- 6 
MS-275, SAHA, SB, TSA Co Anti- & Pro- 7 
MI192, TSA Co Anti- 8 
HDAC3KD Pre Anti- 9 
SAHA, Tubastatin Pre Anti- 10 
MS-275 Post Anti- 11 
MS-275, HDAC1, 2 & 3 cKD Pre Anti- 12 
ITF2357, ITF3056 Pre Anti- 13 
In all studies, the inflammatory response of monocytes and macrophages was activated with 
lipopolysaccharide (LPS). Abbreviations, cKD: Combined knockdown, HDAC3KD: 
HDAC3 knockdown, SAHA: Suberoylanilide hydroxamic acid, SB: Sodium butyrate, SPB: 
Sodium phenylbutyrate. References: 
1
Leoni et al. (2002), 
2
Leoni et al. (2005), 
3
Aung et al. 
(2006), 
4
Bode et al. (2007), 
5
Choo et al. (2010), 
6
Grabiec et al. (2010), 
7
Halili et al. (2010), 
8
Gillespie et al. (2011), 
9
Chen et al. (2012a), 
10
Vishwakarma et al. (2013), 
11
Zhang and 
Schluesener (2013), 
12
Jeong et al. (2014), 
13
Li et al. (2015). 
 
The BV2 microglia cell-line is a suitable model system because like isolated primary 
microglia or during neuroinflammation in vivo, when BV2 microglia are activated by 
physiologically relevant inflammatory stimuli such as LPS (Blasi et al., 1990; 
Bocchini et al., 1992; Gresa-Arribas et al., 2012; Henn et al., 2009; Horvath et al., 
2008; Lund et al., 2005), IFN (Gresa-Arribas et al., 2012; Henn et al., 2009), 
hypoxia (Zhou et al., 2013), OGD (Li et al., 2013), A (He et al., 2011) and MPP+ 
(1-methyl-4-phenylpyridinium, a neurotoxin model of Parkinson’s disease, Roy et al. 
(2012)), these microglia cells produce cytokines including IL-1, IL-6 and TNF-, 
as well as other pro-inflammatory substances such as COX-2, iNOS, nitrite and 
others. Furthermore, similar to the effects of neuroinflammation in vivo and in co-
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culture models of isolated primary microglia and neurones, activation of the 
inflammatory response of BV2 microglia when co-cultured with neurones, causes the 
production of pro-inflammatory mediators, which induce neuronal death (Gresa-
Arribas et al., 2012; Yu et al., 2008). The magnitude of the inflammatory response of 
BV2 microglia in response to inflammatory stimuli has been compared with that of 
primary isolated microglia. Horvath et al. (2008) report that the amount of each pro-
inflammatory mediator expressed by BV2 cells in response to LPS is less compared 
to primary microglia; however this study has a major caveat in that it compared 
mouse BV2 cells with rat primary microglia and so these differences may be because 
of a difference in species. A later study comparing mouse BV2 microglia with mouse 
primary microglia, showed that in response to LPS +IFN, the amount of TNF- 
expression is equal between the two cell types, whereas primary microglia express 
significantly more IL-6 and COX-2 than BV2’s, but BV2 microglia express a greater 
amount of iNOS and thus produce more nitrosative stress-inducing species in 
response to LPS +IFN compared to primary microglia (Gresa-Arribas et al., 2012). 
Although there are differences in the amount expressed for each pro-inflammatory 
mediator, the underlying mechanisms of microglial activation and downstream 
signalling which induce pro-inflammatory expression in BV2 microglia and primary 
microglia is most likely the same. Consistent with this, treating BV2 microglia with a 
HDAC inhibitor (sodium phenylbutyrate) known to suppress the inflammatory 
response of primary microglia (see section 1.10.5), also suppresses the inflammatory 
response of BV2 microglial cells (Roy et al., 2012). This suggests the anti-
inflammatory mechanisms involved and therefore the inflammatory signalling 
pathways in BV2 microglia and primary microglia are the same. In addition to 
expressing pro-inflammatory mediators, BV2 microglia also retain the ability to 
migrate towards stimuli (Horvath et al., 2008) and phagocytose physiologically 
relevant materials such as microorganisms (Blasi et al., 1990; Bocchini et al., 1992), 
necrotic and apoptotic cells (Hirt and Leist, 2003) and A (Fleisher-Berkovich et al., 
2010).  
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4.1.1. Chapter aim 
 
Using the BV2 murine microglia model system, which shares many characteristics of 
primary microglia, the effect of selectively inhibiting class I HDACs and HDAC6 on 
the inflammatory response of microglia and the mechanisms underlying this effect 
were investigated. 
 
 
4.2. Non-selective HDAC inhibitors suppress pro-inflammatory cytokine expression 
in microglia 
 
The cytokines IL-6 and TNF- are classical markers and participants of the 
inflammatory response of isolated microglia and neuroinflammation in vivo. 
Measuring the changes in the levels of these cytokines has often been used as an 
indicator of the effects of HDAC inhibitors on the inflammatory response (see 
sections 1.10.5 and 4.1). The expression of these two cytokines in BV2 microglia 
following stimulation with LPS (500 ng/mL, as used by Gibson et al. (2012)) for 6 
hours was determined by qPCR. After LPS exposure, IL-6 mRNA expression was 
robustly increased by 50990 ± 5190% and TNF- mRNA by 3380 ± 271% compared 
to un-stimulated microglia (figure 4.1A). After 24 hours of LPS stimulation, the 
amount of IL-6 protein secreted by BV2 microglia into the cell culture supernatant 
was examined and was found to have increased to a concentration of 5406 ± 439 
pg/mL (figure 4.1C, measured by an ELISA). The amount of IL-6 protein secreted 
by un-stimulated microglia was too low to be detected. 
 
Activation of the transcription factor NF- is one of the major signalling pathways 
involved in generating the inflammatory response of innate immune cells upon 
exposure to LPS or other inflammatory stimuli. In part, NF- is responsible for 
inducing the expression of many pro-inflammatory mediators including IL-6 and 
TNF-. To serve as an anti-inflammatory positive control, the activation of NF- 
was inhibited using the drug BAY11-7082 (BAY11) and the effects of this on LPS-
induced IL-6 and TNF- mRNA was measured. When BV2 microglia were 
stimulated with LPS for 6 hours, but in the presence of 5 M BAY11, the expression 
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of both IL-6 and TNF- mRNA was significantly reduced by 75.4 ± 6.032% 
(P=0.00686) and 34.01 ± 2.44% (P=0.0118) compared to the expression in LPS 
+vehicle respectively (figure 4.1B). 
 
Non-selective HDAC inhibitors such as VPA of the short-chain fatty acid class and 
SAHA of the hydroxamate class (see section 1.8) have been shown to either 
attenuate or potentiate the inflammatory response of isolated primary microglia (see 
section 1.10.5 and table 1.5) and other innate immune cells (see table 4.1). The effect 
of these two HDAC inhibitors on the inflammatory response in BV2 microglia was 
investigated (figure 4.1B). The expression of both pro-inflammatory cytokines IL-6 
and TNF- in BV2 microglia in response to LPS stimulation for 6 hours were 
significantly reduced, not increased, in the presence of either 1 M SAHA (IL-6 
mRNA by 84.1 ± 1.63% (P=0.00375) and TNF- by 59.7 ± 3.19% (P=0.00143)), or 
5 mM VPA (IL-6 mRNA by 89.7 ± 1.59% (P=0.0272) and TNF- by 77.9 ± 2.50% 
(P=0.0214)). Furthermore, the amount of IL-6 protein secreted by BV2 microglia 
during 24 hours when stimulated with LPS in the presence of SAHA was also 
significantly reduced by 85.6% (P=1.50 × 10
-6
) compared to LPS +vehicle (figure 
4.1C).  
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Figure 4.1. Non-selective histone deacetylase (HDAC) inhibitors suppress pro-inflammatory 
cytokine expression in microglia. (A) BV2 microglia were stimulated with 500 ng/mL 
lipopolysaccharide (LPS) for 6 hours and the mRNA expression of interleukin-6 (IL-6) and 
tumour necrosis factor alpha (TNF-) was measured by quantitative PCR. Transcript levels 
were normalised to U6 and data shown are mean mRNA expression levels expressed as a 
percentage of the expression in the vehicle control ± SEM. (B) Effects of the NF- 
inhibitor BAY11-7082 (5 M, BAY11) and the non-selective HDAC inhibitors SAHA (1 
M) and valproate (5 mM, VPA) on LPS-induced cytokine expression in (A). LPS and 
vehicle (0.1% v/v DMSO) or drugs were administered at the same time and RNA was 
extracted after 6 hours. Transcript levels for each treatment were normalised to U6 and data 
shown are mean mRNA expression levels expressed as a percentage of the expression in 
LPS +vehicle ± SEM. (C) BV2 microglia were treated with 500 ng/mL LPS and either 
vehicle or 1 M SAHA for 24 hours followed by measurement of IL-6 secretion into the cell 
culture supernatant using an ELISA. Data shown are mean IL-6 protein (pg/mL) ± SEM. In 
all experiments, n=3. *P<0.05, **P<0.01 and ***P<0.001 vs. LPS +vehicle. 
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4.3. Selective inhibition of HDAC1, 2 & 3 or HDAC2 & 3, but not HDAC6 & 8 
suppresses pro-inflammatory cytokine expression in microglia 
 
When BV2 microglia were stimulated with 500 ng/mL LPS in the presence of the 
class I selective HDAC inhibitor apicidin (500 nM), the inflammatory response was 
significantly suppressed. This was indicated by a significant reduction in the 
expression of IL-6 mRNA (by 82.7 ± 2.26%, P=0.00405) and TNF- mRNA (by 
50.26 ± 4.48%, P=0.00355) compared to that in LPS +vehicle (figure 4.2A). 
Furthermore, apicidin significantly suppressed LPS-induced IL-6 protein secretion 
during 24 hours of treatment (89.75% reduction, P=6.96 × 10
-7
, figure 4.2B). This 
finding showed that inhibiting at least one of the class I HDACs suppresses the 
inflammatory response of microglia.  
 
HDAC inhibitors with selectivity towards the class I HDAC8 and the class IIb 
HDAC6 are anti-inflammatory in LPS activated mononuclear cells from the 
peripheral innate immune system (table 4.1). To examine if this is also the case in 
microglia, BV2 microglia were stimulated with LPS in the presence of Droxinostat, a 
hydroxamate HDAC inhibitor selective for HDAC6 & 8 (IC50 of 2.47 M for 
HDAC6, 1.46 M for HDAC8, 16.9 M for HDAC3 and >20 M for HDAC1 & 2, 
Wood et al. (2010)). Then, the inflammatory response was measured by looking at 
changes in the expression of IL-6 and TNF-. It was found that when BV2 microglia 
were co-treated to LPS and 5 M Droxinostat for 6 hours, the LPS-induced 
expression of the pro-inflammatory cytokines IL-6 and TNF- was unaffected (103.4 
± 10.6% and 99.5 ± 4.605% compared to LPS with vehicle respectively, figure 
4.2A). Despite having no effect on the inflammatory response, Droxinostat was 
functional in BV2 microglia and robustly increased the acetylation of -tubulin, a 
protein, which is uniquely targeted for deacetylation by HDAC6 (Hubbert et al. 
(2002), figure 4.2F). This suggested inhibition of HDAC6 & 8 does not suppress the 
inflammatory response of microglia. 
 
Based on this, to determine which of the remaining class I HDACs, HDAC1, 2 & 3 
should be inhibited to suppress pro-inflammatory mediator expression in microglia; 
the effect of MI192 a HDAC2 & 3 selective inhibitor (see section 1.8) was 
Chapter 4    Results II 
108 
 
investigated. Treatment of BV2 microglia with 1 M MI192 at the same time as LPS 
for 6 hours, had no effect on the LPS-induced expression of IL-6 and TNF- mRNA 
(figure 4.2A). Furthermore, treatment of either SAHA or apicidin at the same time as 
LPS for 6 hours significantly reduced the LPS-induced expression of iNOS mRNA 
(46 ± 1.41%, P=0.0394 and 52.9 ± 3.34%, P=0.0366 of LPS with vehicle 
respectively, figure not shown), however treatment of MI192 did not (93.7 ± 6.59% 
of LPS with vehicle, figure not shown). SAHA and VPA may reduce the expression 
of pro-inflammatory cytokines by inhibiting a combination of HDACs, which MI192 
and Droxinostat on their own do not. This hypothesis was examined by stimulating 
BV2 microglia for 6 hours with LPS in the presence of both 1 M MI192 and 5 M 
Droxinostat together. Theoretically this would lead to the selective inhibition of 
HDAC2, 3, 6 and 8. Nevertheless, combining these two HDAC inhibitors did not 
significantly affect the inflammatory response in BV2 microglia (figure 4.2A). 
 
Interestingly, when looking at the morphology of BV2 microglia following LPS 
treatment for 6 hours with or without the HDAC inhibitors SAHA, apicidin and 
MI192, there were clear changes in cell morphology when the microglia were treated 
with a HDAC inhibitor that suppressed the expression of pro-inflammatory cytokines 
(SAHA and apicidin) compared to microglia treated to LPS with vehicle or MI192. 
In the LPS and vehicle condition, BV2 microglia were mostly spherical, but 
following SAHA or apicidin treatment, the majority of the cells had flattened and 
had become bipolar in shape (figure 4.2C). This is indicative of a reduction in 
proliferation and/or change to a resting state/non-pro-inflammatory phenotype 
(Pottler et al., 2006; Zierler and Kerschbaum, 2005). Consistent with the absence of 
any changes in inflammatory mediator expression, MI192 treatment had no 
discernible effect on BV2 microglia morphology (figure 4.2C). 
 
When the acetylation of histone proteins was assessed, both SAHA and apicidin 
within 6 hours, robustly increased histone H3 acetylation at lysine 9 (acH3K9) and 
also histone H4 acetylation (acH4) to a similar extent (figure 4.2D). Treatment with 
MI192 increased histone acetylation by 6 hours compared to the vehicle control, but 
did not increase it to the same extent as the other two HDAC inhibitors (figure 4.2D). 
An analysis of the timings of histone hyperacetylation by these HDAC inhibitors 
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over a period of 24 hours revealed that SAHA and apicidin increased the acetylation 
of histone H4 within the first hour of treatment and this was maintained over 24 
hours (figure 4.3A & 4.3B). However, MI192 and MS-275, gradually increased 
histone acetylation over time (figure 4.3C & 4.3D). Consistent with other studies 
(see section 1.8), the data presented here suggests that the onset of HDAC inhibition 
and therefore protein acetylation by inhibiting HDACs with benzamide HDAC 
inhibitors such as MI192 and MS-275 is much slower compared to the hydroxamate 
HDAC inhibitor SAHA and the cyclic tetrapeptide HDAC inhibitor apicidin. As a 
consequence, specific proteins that become acetylated following HDAC inhibition, 
which are responsible for the suppression of pro-inflammatory mediator expression, 
may not become acetylated during 6 hours of MI192 treatment. To allow time for 
binding to and inhibition of HDACs and the acetylation of the necessary proteins, the 
effect on the inflammatory response after pre-treating with benzamide HDAC 
inhibitors was investigated next. BV2 microglia were pre-treated for 24 hours with 
apicidin or the benzamide HDAC inhibitors MI192 or MS-275, followed by 
activation with the inflammatory stimulant LPS for a further 6 hours (figure 4.2E). 
Pre-treatment of 500 nM apicidin significantly reduced LPS-induced IL-6 mRNA 
expression by 98.8 ± 0.313% (P=0.002016) and TNF- mRNA expression by 72.9 ± 
2.039% (P=8.25 × 10
-5
). Following pre-treatment of 1 M MI192, LPS-induced 
expression of IL-6 and TNF- was significantly reduced by 82.08 ± 1.46% 
(P=0.01087) and 24.1 ± 1.093% (P=0.0448) respectively. Similarly, pre-treatment of 
BV2 microglia with 5 M MS-275 (a HDAC1, 2 & 3 selective inhibitor, table 1.4) 
before stimulating with LPS also significantly reduced the LPS-induced expression 
of IL-6 (by 96.8 ± 0.646%, P=0.00213) and TNF- (by 87.8 ± 0.695%, P=1.79 × 10-
5
) mRNA.  
 
To summarise, the data presented thus far suggested that combined inhibition of 
class I HDACs 1, 2 & 3 or HDAC2 & 3 but not HDAC6 & 8, was sufficient to 
suppress the expression of pro-inflammatory mediators IL-6 and TNF- in BV2 
microglia stimulated with LPS. 
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Figure 4.2. Selective inhibition of HDAC1, 2 & 3 or HDAC2 & 3, but not HDAC6 & 8 
suppresses pro-inflammatory cytokine expression in microglia.  
 
 
 
Chapter 4    Results II 
111 
 
Figure 4.2 continued… (A) BV2 microglia were treated for 6 hours with 500 ng/mL 
lipopolysaccharide (LPS) with either vehicle (0.1% v/v DMSO), 500 nM apicidin (a cyclic 
tetrapeptide HDAC1, 2, 3 & 8 selective inhibitor), 1 M MI192 (a benzamide HDAC2 & 3 
selective inhibitor), 5 M Droxinostat (a hydroxamate HDAC6 & 8 selective inhibitor) or 
combined treatment of MI192 and Droxinostat. The mRNA expression of the cytokines 
interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-) was then measured by 
quantitative PCR. Transcript levels for each treatment were normalised to U6 and data 
shown are mean mRNA expression levels expressed as a percentage of the expression in 
LPS +vehicle ± SEM. (B) BV2 microglia were treated with 500 ng/mL LPS and either 
vehicle or 500 nM apicidin for 24 hours followed by measurement of IL-6 protein secreted 
into the cell culture supernatant using an ELISA. Data shown is mean IL-6 protein (pg/mL) 
± SEM. (C) Representative phase-contrast images of the effects of HDAC inhibitors on BV2 
microglia morphology after 6 hours of co-treatment with LPS. Scale bar 50 m. (D) 
Representative Western blots of histone H3 lysine 9 acetylation (acH3K9) and histone H4 
acetylation (acH4) in BV2 microglia after treatment with 1 M SAHA, 1 M MI192 or 500 
nM apicidin for 6 hours. Total histone H3 was used as the loading control. (E) BV2 
microglia were pre-treated for 24 hours with either vehicle, 500 nM apicidin, 1 M MI192 or 
5 M MS-275 (a benzamide HDAC1, 2 & 3 selective inhibitor), then stimulated with LPS 
for a further 6 hours. The expression of IL-6 and TNF- mRNA was then measured and 
expressed as in (A). (F) Representative Western blots of acetylated -tubulin (ac--tubulin) 
in BV2 microglia after treatment with 5 M Droxinostat (Drox) for 6 hours. -actin was 
used as the loading control. In all experiments, n=3, *P<0.05, **P<0.01 and ***P<0.001 vs. 
LPS +vehicle. 
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Figure 4.3. Time-course of histone H4 acetylation (acH4) following treatment with HDAC 
inhibitors of different pharmacophore groups. BV2 microglia were treated to vehicle (0.1% 
v/v DMSO), or a (A) hydroxamate (1 M SAHA), (B) a cyclic tetrapeptide (500 nM 
apicidin), or benzamide HDAC inhibitors (C) 1 M MI192, (D) or 5 M MS-275 over a 24 
hour period. Total histone H3 was used as the loading control. 
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4.4. HDAC2 knockdown suppresses pro-inflammatory cytokine expression in 
microglia 
 
To determine if the inhibition of HDAC2 on its own is enough to suppress the 
expression of pro-inflammatory mediators in BV2 microglia, HDAC2 was knocked 
down (HDAC2KD) and the effect of this on the inflammatory response was 
examined. To knockdown HDAC2, BV2 microglia were transfected with siRNA 
targeted against HDAC2 mRNA. Forty-eight hours post-transfection, the expression 
of HDAC1, 2 and 3 proteins was determined by Western blot (figure 4.4A & 4.4B). 
HDAC2 was found to be significantly reduced by 68.7 ± 3.44% (P=0.0114) 
compared to the expression in the scrambled siRNA control (Scr siRNA). There was 
no effect of HDAC2KD on the expression of HDAC1 (109.4 ± 1.57% of Scr siRNA) 
or HDAC3 (99.5 ± 11.8% of Scr siRNA). To examine if HDAC2KD had any effect 
on the inflammatory response of BV2 microglia, following knockdown cells were 
stimulated with 500 ng/mL LPS for 6 hours. Then, the expression of LPS-induced 
pro-inflammatory cytokines IL-6 and TNF- was assessed by qPCR (figure 4.4C). It 
was found that knocking down HDAC2 significantly suppressed the expression of 
IL-6 mRNA by 48.2 ± 1.25% (P=0.00668) and TNF- mRNA by 22 ± 3.57% 
(P=0.0134) compared to Scr siRNA +LPS. 
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Figure 4.4. HDAC2 knockdown suppresses pro-inflammatory cytokine expression in BV2 
microglia. (A) Representative Western blots of HDAC1, 2 and 3 proteins expressed in BV2 
microglia following transfection with scrambled (Scr) or HDAC2 siRNA for 48 hours. -
actin was used as the loading control. (B) Quantification of (A), band intensities were 
normalised to -actin and data shown are relative mean HDAC expression levels expressed 
as a percentage of the expression in the Scr siRNA control ± SEM, n=3, *P<0.05 vs. Scr 
siRNA. (C) BV2 microglia transfected with Scr or HDAC2 siRNA for 48 hours were 
stimulated with 500 ng/mL lipopolysaccharide (LPS) for 6 hours. Then, the mRNA 
expression of the cytokines interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-) 
was measured by quantitative PCR. Transcript levels for each treatment were normalised to 
U6 and data shown are relative mean mRNA expression levels expressed as percentage of 
the expression in Scr siRNA +LPS ± SEM, n=3, *P<0.05 and **P<0.01 vs. Scr siRNA 
+LPS. 
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4.5. HDAC1 knockdown suppresses pro-inflammatory cytokine expression in 
microglia 
 
The non-selective HDAC inhibitors SAHA and VPA and the class I selective HDAC 
inhibitors apicidin and MS-275 all suppress the expression of pro-inflammatory 
mediators in BV2 microglia stimulated with LPS. They may do this by inhibiting 
HDAC1 as well as HDAC2. To determine if the inhibition of HDAC1 on its own is 
enough to suppress the expression of pro-inflammatory mediators in BV2 microglia, 
HDAC1 was knocked down (HDAC1KD) and the effect of this on the inflammatory 
response was examined. To knockdown HDAC1, BV2 microglia were transfected 
with siRNA targeted against HDAC1 mRNA. Forty-eight hours post-transfection, 
the expression of HDAC1, 2 and 3 proteins was determined by Western blot (figure 
4.5A & 4.5B). HDAC1 protein was found to be significantly reduced by 62.56 ± 
4.52% (P=0.000134) compared to the expression in the scrambled siRNA control 
(Scr siRNA). Following HDAC1KD, HDAC2 protein was found to be significantly 
upregulated (194 ± 7.49% of Scr siRNA, P=0.000773) but there was no change in 
the expression of HDAC3 (101.4 ± 4.79% of Scr siRNA). To examine if HDAC1KD 
with the accompanying increase in HDAC2 levels had any effect on the 
inflammatory response, forty-eight hours post-transfection, BV2 microglia were 
stimulated with 500 ng/mL LPS for 6 hours and the mRNA expression of pro-
inflammatory cytokines IL-6 and TNF- was assessed by qPCR (figure 4.5C). 
HDAC1KD and the accompanying upregulation of HDAC2 did not affect the LPS-
induced mRNA expression of IL-6 and TNF-, which were 116 ± 7.73% and 112 ± 
6.84% of the expression in Scr siRNA +LPS respectively. 
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Figure 4.5. HDAC1 knockdown causes a compensatory upregulation of HDAC2 and has no 
effect on pro-inflammatory cytokine expression in BV2 microglia. (A) Representative 
Western blots of HDAC1, 2 and 3 proteins expressed in BV2 microglia following 
transfection with scrambled (Scr) or HDAC1 siRNA for 48 hours. -actin was used as the 
loading control (B) Quantification of (A), band intensities were normalised to -actin and 
data shown are relative mean HDAC expression levels expressed as a percentage of the 
expression in the Scr siRNA control ± SEM, n=3, ***P<0.01 vs. Scr siRNA. (C) BV2 
microglia transfected with Scr or HDAC1 siRNA for 48 hours were stimulated with 500 
ng/mL lipopolysaccharide (LPS) for 6 hours. Then, the mRNA expression of the cytokines 
interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-) was measured by quantitative 
PCR. Transcript levels for each treatment were normalised to U6 and data shown are relative 
mean mRNA expression levels expressed as percentage of the expression in Scr siRNA 
+LPS ± SEM, n=3, ***P<0.001 vs. Scr siRNA +LPS. 
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It was hypothesised that the upregulation of HDAC2 following HDAC1KD counter-
acted an anti-inflammatory effect mediated by a reduction in HDAC1 expression and 
activity. To investigate this, the inflammatory response of BV2 microglia was 
examined after knocking down HDAC1 whilst simultaneously preventing the 
upregulation of HDAC2. To do this, cells were transfected with both HDAC1 and 
HDAC2 siRNA. Forty-eight hours post-transfection, the expression of HDAC1, 2 
and 3 proteins was determined by Western blot (figure 4.6A & 4.6B). HDAC1 
protein was significantly reduced by 63.5 ± 2.36%, (P=0.004026 compared to Scr 
siRNA) and the upregulation of HDAC2 was prevented (89.7 ± 6.23% which was 
not significantly different from Scr siRNA). The expression of HDAC3 was not 
significantly altered (116 ± 4.77% of Scr siRNA). BV2 microglia were then 
stimulated with LPS for 6 hours. Now, a reduction in HDAC1 expression without the 
upregulation of HDAC2, significantly reduced LPS-induced expression of IL-6 
mRNA by 34.8 ± 2.95% (P=0.0153) and TNF- mRNA by 35.7 ± 4.8% (P=0.0169) 
compared to the expression in Scr siRNA +LPS (figure 4.6C). 
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Figure 4.6. Knocking down HDAC1 whilst preventing the accompanying upregulation of 
HDAC2, suppresses pro-inflammatory cytokine expression in BV2 microglia. (A) 
Representative Western blots of HDAC1, 2 and 3 proteins expressed in BV2 microglia 
following transfection with scrambled (Scr) or combined HDAC1 & HDAC2 siRNA for 48 
hours. -actin was used as the loading control. (B) Quantification of (A), band intensities 
were normalised to -actin and data shown are relative mean HDAC expression levels 
expressed as a percentage of the expression in the Scr siRNA control ± SEM, n=3, **P<0.01 
vs. Scr siRNA. (C) BV2 microglia transfected with Scr or HDAC1 & HDAC2 siRNA for 48 
hours were stimulated with 500 ng/mL lipopolysaccharide (LPS) for 6 hours. Then, the 
mRNA expression of the cytokines interleukin-6 (IL-6) and tumour necrosis factor alpha 
(TNF-) was measured by quantitative PCR. Transcript levels for each treatment were 
normalised to U6 and data shown are relative mean mRNA expression levels expressed as 
percentage of the expression in Scr siRNA +LPS ± SEM, n=3, *P<0.05 vs. Scr siRNA 
+LPS. 
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4.6. Exploration of the mechanisms underlying the anti-inflammatory effects of 
HDAC inhibition in microglia 
 
Through the use of selective HDAC inhibitors and knocking down specific HDAC 
isoforms it was established that inhibiting the activity of HDAC1 and/or 2 suppresses 
the expression of pro-inflammatory mediators in activated BV2 microglia. The focus 
of the study turned to exploring potential mechanisms by which the inhibition of 
these two isoforms produced this anti-inflammatory phenotype. 
 
One mechanism could be that HDAC inhibitors prevent an increase in HDAC 
activity associated with an LPS-induced upregulation of HDAC1 and 2. To 
investigate this hypothesis, BV2 microglia were stimulated with 500 ng/mL LPS for 
6 hours and the expression of HDAC1, 2 and 3 proteins was determined by Western 
blot. This analysis showed that LPS treatment did not alter HDAC expression (figure 
4.7A & 4.7B) and suggested that HDAC upregulation is not involved in the 
inflammatory response of BV2 microglia during the 6 hours of LPS stimulation.  
 
 
 
 
 
Chapter 4    Results II 
120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Lipopolysaccharide (LPS) treatment does not affect the expression of HDAC1, 2 
or 3 in BV2 microglia. (A) BV2 microglia were treated with 500 ng/mL LPS for 6 hours 
followed by Western blot for HDAC1, 2 & 3. -actin was used as the loading control. (B) 
Quantification of (A), band intensities were normalised to -actin and data shown are 
relative mean HDAC expression levels expressed as percentage of the expression in the 
vehicle control ± SEM, n=3. 
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Another way inhibition of HDAC1 and/or 2 may be anti-inflammatory could be 
through increasing histone acetylation and the expression of genes encoding anti-
inflammatory proteins. To investigate if the synthesis of new proteins is required for 
the anti-inflammatory effects of HDAC inhibitors, BV2 microglia were treated for 1 
or 3 hours with LPS with or without the protein synthesis inhibitor cycloheximide (1 
g/mL, CHX) and in the presence of either vehicle, 1 M SAHA or 500 nM 
apicidin. A protein synthesis determination assay was performed and cells that were 
able to synthesise proteins incorporated O-propargyl-puromycin into newly 
synthesised peptides, which could be subsequently labelled with a green fluorescent 
dye and visualised by fluorescence microscopy. At both time points, CHX treatment 
robustly reduced protein synthesis in all treatments as indicated by a reduction in the 
intensity of green fluorescence in cells (figure 4.8A). After treating BV2 microglia 
for 3 hours, the LPS-induced expression of IL-6 mRNA was analysed by qPCR 
(figure 4.8B). Both SAHA and apicidin treatment after 3 hours, significantly reduced 
the expression of LPS-induced IL-6 by 81.7 ± 2.59% (P=7.32 × 10
-5
) and 84.7 ± 
1.084% (P=6.22 × 10
-5
) respectively. Protein synthesis inhibition by CHX did not 
prevent the suppression of IL-6 mRNA expression by SAHA (100.68 ± 9.80% of 
LPS +SAHA) or apicidin (107.3 ± 9.20% of LPS +Apicidin). This data rules out a 
mechanism whereby HDAC inhibitors mediate anti-inflammatory effects through 
increasing protein expression. Conversely, HDAC inhibitors may be anti-
inflammatory by suppressing the synthesis of proteins important for inducing the 
expression of pro-inflammatory mediators. However, global protein synthesis 
inhibition in BV2 microglia did not prevent the production of IL-6 mRNA in 
response to LPS stimulation (107.6 ± 9.69% of the expression in LPS with vehicle), 
therefore did not recapitulate the effects of HDAC inhibitors on the expression of 
pro-inflammatory mediators. This rules out a mechanism whereby HDAC inhibitors 
are anti-inflammatory by inhibiting protein synthesis. 
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Figure 4.8. Histone deacetylase inhibitors do not induce novel protein synthesis to suppress 
pro-inflammatory cytokine expression in microglia.  
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Figure 4.8 continued… BV2 microglia were treated for 1 or 3 hours with 500 ng/mL 
lipopolysaccharide (LPS) with or without 1 g/mL cycloheximide (a protein synthesis 
inhibitor, CHX) and in the presence of either vehicle (0.1% v/v DMSO), 1 M SAHA or 500 
nM apicidin. (A) Representative green fluorescent and phase contrast images of each 
treatment. Cells that are positive for green fluorescence have synthesised new proteins 
during the treatment period. Scale bar 50 m. (B) After 3 hours of treatment, the mRNA 
expression of the cytokine interleukin-6 (IL-6) was measured by quantitative PCR. 
Transcript levels for each treatment were normalised to U6 and data shown are mean mRNA 
expression levels expressed as a percentage of the expression in LPS +vehicle ± SEM, n=3, 
***P<0.001 vs. LPS +vehicle. 
 
In addition to increasing the acetylation of histone proteins, HDAC inhibitors have 
the potential to increase the acetylation of all proteins that make-up the acetylome. 
The identity and function of proteins that make-up the acetylome in microglia is 
unknown but it is likely that some of these are involved in or can regulate the 
inflammatory response. One way of visualising the changes in the acetylome after 
treating cells with HDAC inhibitors is to perform a Western blot to identify all 
lysine-acetylated proteins in the cell. Comparing the acetylome of BV2 microglia 
treated with HDAC inhibitors that suppress the inflammatory response within a 
given time frame with the acetylome of BV2 microglia treated with a HDAC 
inhibitor that does not, may reveal the acetylation of specific proteins responsible for 
suppressing the inflammatory response. As shown earlier, during 6 hours of 
treatment, SAHA and apicidin both suppress the LPS-induced expression of pro-
inflammatory mediators in BV2 microglia. However, during 6 hours of treatment 
MI192 is unable to suppress the inflammatory response of BV2 microglia. This 
suggests that during the first 6 hours of treatment, HDAC inhibitors that are anti-
inflammatory increase the acetylation of specific proteins that suppress the 
inflammatory response whereas MI192 does not. In support of this, it has already 
been shown that SAHA and apicidin increase the acetylation of histone proteins to a 
greater extent compared to MI192 (figure 4.2D), so a similar comparison was 
performed to look for differences in the acetylation state of non-histone proteins in 
microglia treated with these HDAC inhibitors (figure 4.9). 
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Following treatment of LPS and either vehicle, 1 M SAHA, 500 nM apicidin or 1 
M MI192 for 6 hours, it was observed that all three HDAC inhibitors increased the 
acetylation of proteins in BV2 microglia compared to LPS +vehicle. SAHA 
treatment caused an increase in acetylation of a protein with an approximate 
molecular weight of 55 kDa and this protein was not hyperacetylated following 
treatment with apicidin or MI192. This band is likely to be -tubulin, which has the 
same molecular weight and is uniquely deacetylated by HDAC6 (Hubbert et al., 
2002), a target of the non-selective HDAC inhibitor SAHA but not apicidin or 
MI192 (see section 1.8). Two proteins were observed to be hyperacetylated 
following treatment of SAHA or apicidin but not in MI192. One protein was 
observed between molecular weight markers 55 and 72 kDa (indicated by the red 
box in figure 4.9) and the other between markers 26 and 34 kDa (indicated by the 
green box in figure 4.9). The acetylation of these two proteins may be important for 
the anti-inflammatory effects of SAHA and apicidin during 6 hours of treatment. The 
possible identity and function of these proteins will be discussed later. 
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Figure 4.9. Changes in the acetylome in BV2 microglia following treatment with histone 
deacetylase inhibitors. BV2 microglia were treated for 6 hours with 500 ng/mL 
lipopolysaccharide (LPS) and vehicle (0.1% v/v DMSO), or 1 M SAHA or 500 nM 
apicidin (API) which are anti-inflammatory during this timeframe, or 1 M MI192 which is 
not anti-inflammatory during this timeframe.  Whole-cell lysates were subjected to Western 
blotting and probed with an antibody recognising acetylated lysine residues (acK), -actin 
was used as a loading control. Coloured boxes indicate differences in acetylated proteins 
between SAHA and both apicidin & MI192 (yellow) and between MI192 and both SAHA & 
apicidin (red and green). 
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4.7. Discussion                                       
 
4.7.1. Inhibition of either HDAC1 or HDAC2 suppresses the inflammatory response 
of microglia 
 
In this chapter, the effects of various HDAC inhibitors on the inflammatory response 
of activated BV2 microglia were investigated. It was found that selective inhibition 
of class I HDACs 1, 2 and 3 suppresses the inflammatory response of these cells as 
indicated by a reduction in the expression of pro-inflammatory mediators IL-6 and 
TNF-. This is consistent with the anti-inflammatory effects of inhibiting these 
HDAC isoforms in other innate immune cells such as mononuclear cells and 
macrophages (see section 4.1 and table 4.1). Taken together, this suggests the role of 
these three HDACs in the inflammatory response is conserved and the inhibition of 
these HDACs may lead to the acetylation of the same proteins in all innate immune 
cells, which when acetylated inhibits the inflammatory response. Having identified 
HDAC1, 2 & 3 as targets to suppress pro-inflammatory mediator expression in 
microglia, the effect of knocking down these HDACs was investigated with the aim 
to identify the isoform important for this response. Knocking down HDAC2 
significantly suppressed the expression of pro-inflammatory mediators in activated 
BV2 microglia whereas HDAC1KD had no effect. As a consequence of knocking 
down HDAC1 there was a significant upregulation of HDAC2 but no change in 
HDAC3. This upregulation also occurs in immortalised murine macrophages 
following HDAC1KD (Jeong et al., 2014) and in peripheral nerves (Jacob et al., 
2011) and embryonic stem cells (Dovey et al., 2010b) from HDAC1KO mice. 
Knocking down HDAC2 in BV2 microglia had no consequential effect on the 
expression of either HDAC1 or HDAC3 and this is consistent with the effects of 
knocking out HDAC2 in mouse embryonic stem cells (Dovey et al., 2010b). 
However, other studies have shown that like HDAC2 when HDAC1 is silenced or 
knocked out, HDAC1 is upregulated following HDAC2KD in immortalised murine 
macrophages (Jeong et al., 2014), as well as in peripheral nerves (Jacob et al., 2011) 
and in the brains of HDAC2KO mice (Guan et al., 2009). The mechanisms 
underlying the upregulation of HDAC1 or 2 in response to a loss in the other are not 
fully understood. It has been suggested that HDAC1 can negatively regulate the 
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expression of HDAC2 (Jeong et al., 2014). This is based on the observation that 
histones in the promoter of the HDAC2 gene become hyperacetylated in HDAC1-
deficient cells (Lagger et al., 2002). However, Dovey et al. (2010b) report that 
despite measuring an increase in HDAC2 protein levels in HDAC1KO cells, there 
was no change in the expression of HDAC2 at the mRNA level and propose that the 
increase in HDAC2 protein in the absence of HDAC1, is through enhancement of 
mRNA translation, or an increase in HDAC2 protein stability. The reason why 
HDAC1 is not upregulated following HDAC2 knockdown in BV2 microglia, or 
HDAC2 knockout in embryonic stem cells, but is upregulated in other cells and 
tissues is currently not known. It is possible that the compensatory upregulation of a 
HDAC isoform following the loss of another, depends on the expression of this other 
HDAC falling below a certain threshold, or the levels being reduced for a certain 
length of time (as demonstrated by Jacob et al. (2011)). Moreover, the residual 
activity of the remaining HDAC and multi-protein complexes, the ability of one 
HDAC to regulate the expression of another, may also contribute to whether a 
HDAC is upregulated or not and all these mechanisms may be dependent on the 
particular cell type and circumstance. 
 
Because knocking down HDAC2 suppressed pro-inflammatory mediator expression, 
one might hypothesise that an upregulation of HDAC2 is pro-inflammatory. 
However, when HDAC2 was upregulated following knockdown of HDAC1 there 
was no effect on the expression of the pro-inflammatory mediators measured. One 
possible explanation is that a pro-inflammatory effect of HDAC2 upregulation was 
being counteracted by an anti-inflammatory effect of HDAC1KD. An alternative 
explanation is that the induction of HDAC2 expression following HDAC1KD is not 
pro-inflammatory, but the upregulation of HDAC2 and increase in activity may 
compensate for the reduction in HDAC1 expression and loss of activity, and 
therefore prevent an anti-inflammatory effect mediated by a loss of HDAC1. This 
latter hypothesis was based on the observations reported in other studies which show 
in some circumstances HDAC1 and HDAC2 are functionally redundant. This means 
these two isoforms can perform the same function in certain cellular processes and 
when one is reduced, the upregulation of the other is able to compensate for this loss 
of activity and prevent phenotypic changes. This functional redundancy of HDAC1 
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and 2 has been observed during brain development in mice where individual 
knockout of either HDAC1 or 2 has no effect on the development of the brain, but 
when both HDAC isoforms are simultaneously knocked out there is a significant 
reduction in neural cell viability and impairment in neural cell differentiation and 
brain histoarchitecture (Montgomery et al., 2009). Furthermore, in peripheral nerves 
from HDAC1KO and HDAC2KO mice, HDAC2 and HDAC1 are upregulated in 
these two knockout mice respectively and when this upregulation is prevented there 
are changes in the expression of genes which were previously unobserved (Jacob et 
al., 2011). The authors of this study go on to propose that when a HDAC becomes 
upregulated, this HDAC compensates for a loss in activity of the other and prevents 
changes in the expression of specific genes (Jacob et al., 2011). Similarly, in BV2 
microglia, when the upregulation of HDAC2 upon HDAC1KD was prevented, there 
was an anti-inflammatory effect when HDAC1 was knocked down as indicated by 
the suppression of pro-inflammatory mediator expression in activated cells. Together 
the data presented indicates that both HDAC1 and HDAC2 can regulate the 
inflammatory response of microglia and inhibition of either, when there is no change 
in the expression of the other, is anti-inflammatory in these cells.  
 
I propose that in BV2 microglia the activity of the upregulated HDAC2 compensates 
for a loss in HDAC1 expression and activity. In support of this, both HDAC1 and 
HDAC2 are members of the same multi-protein complexes (see section 1.4.4) and 
when either is reduced, the other isoform if upregulated, is incorporated into the 
CoREST, NuRD and Sin3 multi-protein complexes in its place (Dovey et al., 2010b; 
Guan et al., 2009). It is possible that the functional redundancy and compensatory 
action of these two HDAC isoforms is mediated by the interchangeable incorporation 
of these HDACs into the same specific functional multi-protein complex. In BV2 
microglia, when HDAC1 is knocked down, the upregulated HDAC2 may be 
incorporated into a specific multi-protein complex in place of the lost HDAC1 and 
because of this, the number of functional complexes, which would otherwise be 
reduced if there was no upregulation, is maintained. These complexes, of which a 
greater number now contain HDAC2 instead of HDAC1, are still functional and can 
appropriately and sufficiently deacetylate proteins involved in, or that regulate the 
inflammatory response. Because there is not a reduction in the activity of these 
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specific complexes there is no shift towards the acetylation of specific proteins, 
which upon acetylation no longer promote the inflammatory response or when 
acetylated actively suppress it. This hypothesis could explain why an anti-
inflammatory phenotype is not produced when HDAC1 is knocked down and 
HDAC2 is upregulated and implies that in regulating the inflammatory response of 
BV2 microglia, HDAC1 & 2 through a complex they share perform the same 
function. Therefore, it doesn’t matter which of the two isoforms is inhibited, an anti-
inflammatory effect is dependent on a reduction in the number and activity of 
specific functional multi-protein complexes which HDAC1 and 2 are 
interchangeable members of and which are recruited to and deacetylate specific 
protein substrates. This implies that inhibition of either one of these isoforms in 
isolation would be sufficient to suppress the inflammatory response of innate 
immune cells. In support of this, MI192 which is selective for HDAC2 over HDAC1 
(see section 1.8) suppresses the inflammatory response in BV2 microglia (figure 
4.2E) and in peripheral monocytes (Gillespie et al., 2011). In these instances, one 
would have to assume that selectively inhibiting HDAC2 with MI192 does not cause 
an upregulation of HDAC1 and an associated compensatory effect because of this. 
 
In immortalised murine macrophages, the compensatory effect associated with an 
upregulated class I HDAC following knockdown of others also extends to HDAC3. 
Here, knockdown of HDAC1 leads to an upregulation of HDAC2 and vice versa. 
When the authors knocked down both HDAC1 & 2 to levels below those found 
endogenously (rather than knocking down one HDAC and preventing the 
upregulation of the other as performed in this thesis), this caused an increase in the 
levels of HDAC3. In this scenario, it was only when all three isoforms were knocked 
down, that an anti-inflammatory phenotype was observed (Jeong et al., 2014). It is 
surprising that this upregulated HDAC3 had a compensatory effect because HDAC3 
is a member of a different multi-protein complex to HDAC1 and 2. Yet HDAC3 
upregulation and an increase in the activity of HDAC3-containing complexes must 
be sufficient to maintain the acetylation state of a specific protein or proteins, which 
if hyperacetylated would lead to an inhibition of the inflammatory response. This 
implies that this substrate(s) can be deacetylated by all three of these HDACs and the 
specific multi-protein complexes they are members of. Therefore, it is possible that 
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inhibiting HDAC3 on its own may also reduce the inflammatory response of BV2 
microglia. In support of this, other studies have shown that knocking down or 
knocking out HDAC3 in macrophages (Chen et al., 2012a), in human embryonic 
kidney (HEK)-293 cells and murine embryonic fibroblasts (Ziesche et al., 2013) 
before activating the inflammatory response with appropriate stimuli, significantly 
suppresses the expression of pro-inflammatory genes in those cells. At present, there 
is no direct evidence to suggest HDAC3 is involved in the inflammatory response of 
microglia or that the selective HDAC3 inhibition using a pharmacological agent or 
HDAC3KD can suppress it. However, the non-selective or class I selective HDAC 
inhibitors which suppressed the expression of pro-inflammatory mediators in BV2 
microglia, all inhibit HDAC3 and the inhibition of this isoform as well as inhibition 
of HDAC1 and/or 2, could contribute to the anti-inflammatory phenotype observed.  
 
As proposed earlier, in BV2 microglia and other innate immune cells, HDAC1 and 
HDAC2 may deacetylate the same protein substrate(s) and in doing so regulate the 
inflammatory response. It is important to note that in other cellular processes outside 
of those discussed; the upregulation of one of these two isoforms following the loss 
of the other is not always compensatory. A notable example of this in the field of 
neuroscience is how HDAC1 upregulation in HDAC2KO mice does not compensate 
for a loss in HDAC2 activity because these mice exhibit a phenotype of improved 
learning and memory (Guan et al., 2009). Also, in mouse embryonic stem cells, 
despite an upregulation of HDAC2 after knocking out HDAC1 the specific 
acetylation of histone H3 at lysine 56 is increased (Dovey et al., 2010b). These two 
studies as well as others suggest that in some circumstances one HDAC isoform 
dominates the other when deacetylating a specific protein substrate, or that not all 
proteins that are regulated by acetylation, are targeted by both HDAC1 and 2, and 
these two isoforms have a degree of substrate specificity. How this substrate 
specificity and lack of it in different cellular processes is brought about is an 
interesting question for further study. One obvious way HDACs 1 and 2 could 
deacetylate the same substrates and therefore both regulate the same cellular process 
is because they are both able to form part of the same multi-protein complex either 
together or individually and it is this specific complex, rather than the particular 
HDAC isoform, which is targeted to a substrate. So in BV2 microglia, one particular 
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complex regardless of which or the combination of HDACs 1 & 2 are present is 
recruited to and deacetylates a particular protein substrate, which in turn regulates 
the inflammatory response. On the other-hand, substrate specificity of HDAC1 and 2 
could be mediated through one HDAC being present in one complex, which the other 
HDAC is not and these complexes target specific protein substrates. An example of 
this has been seen in embryonic mouse cells where HDAC1 is found in the Sin3 
complex to a greater extent than HDAC2 (Dovey et al., 2010b). This Sin3 complex 
containing only HDAC1 may be how this isoform regulates a specific function in 
embryonic stem cells. Together this poses an interesting question for further research 
with respect to identifying the HDAC1 and/or 2 containing multi-protein complex 
that when inhibited is responsible for the suppression of pro-inflammatory mediator 
expression in BV2 microglia. Bantscheff et al. (2011) have reported that VPA and 
MS-275, two HDAC inhibitors which are anti-inflammatory in microglia (figure 
4.1B and 4.2E respectively), do not inhibit HDAC1 or HDAC2 in the Sin3 multi-
protein complex, but inhibit these HDAC isoforms in the CoREST and NuRD 
complexes. Furthermore, Guan et al. (2009) show that following HDAC2KO in the 
mouse brain, HDAC1 is upregulated and this isoform then becomes incorporated into 
the Sin3 and NuRD complexes but not the CoREST complex. Based on these data, 
one could hypothesise a role of the NuRD complex or a yet to be identified complex 
in regulating the inflammatory response in microglia. 
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4.7.2. How is histone deacetylase inhibition anti-inflammatory?  
 
This chapter has presented evidence that shows the inhibition of class I HDACs and 
more specifically HDAC1 and/or HDAC2, has anti-inflammatory effects in 
microglia. The underlying mechanisms of this response remain to be fully elucidated, 
but this thesis has begun to answer this question by investigating if the following 
mechanisms are involved: 
 
1) An increase in the acetylation of histone proteins which leads to an increase 
in the expression of anti-inflammatory proteins, 
2) An increase in the acetylation of non-histone proteins which regulate the 
inflammatory response. 
 
Firstly, inhibiting HDACs increases histone acetylation in BV2 microglia and this 
may lead to an increase in the expression of genes, particularly those encoding 
proteins that suppress the inflammatory response. However, SAHA and apicidin 
suppressed LPS-induced mRNA expression of the pro-inflammatory cytokine IL-6 in 
BV2 microglia when protein synthesis was simultaneously inhibited. This 
phenomenon has also been observed in human HeLa cells where non-selective 
HDAC inhibition suppressed TNF- induced IL-8 mRNA expression when protein 
synthesis was inhibited with cycloheximide (Furumai et al., 2011). Also, inhibiting 
protein synthesis in BV2 microglia did not prevent the LPS-induced expression of 
IL-6 mRNA. Together these data rule out a mechanism whereby HDAC inhibitors 
are anti-inflammatory through increasing the expression of existing or new proteins 
or by inhibiting protein synthesis in general. A more likely mechanism is that HDAC 
inhibition increases the acetylation of other pre-existing proteins, which in-turn 
regulates the inflammatory response. 
 
There is experimental evidence in the literature that shows HDAC inhibitors inhibit 
the inflammatory response by reducing the activity of the transcription factor NF-. 
Furumai et al. (2011) reported that in HeLa cells stimulated with the inflammatory 
stimulus TNF-, non-selectively inhibiting HDACs with TSA, significantly 
suppressed the transcriptional activity of NF-, reduced its recruitment to and 
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binding at the gene promoter of the pro-inflammatory cytokine IL-8, reduced the 
recruitment of RNA polymerase II to the IL-8 gene promoter and ultimately reduced 
the transcription and expression of this cytokine. Although not examined by Furumai 
et al. (2011), it is possible that NF- recruitment is also reduced at other NF- 
dependent pro-inflammatory genes that are suppressed by HDAC inhibitors, such as 
IL-6 and TNF-. A key mechanism by which NF- activity is regulated is through 
acetylation and deacetylation of specific lysine residues in the subunits that come 
together to form this transcription factor. Therefore inhibiting HDACs will lead to 
the increase in the acetylation of these lysine residues and affect the activity of NF-
. Specifically, class I HDACs are responsible for deacetylating NF-, HDAC3 
deacetylates the RelA[p65] subunit of NF-at lysine residues 122, 123, 314 and 
315 and as discussed in section 1.2.3, the acetylation of these lysine residues reduces 
the transcriptional activity of NF- (Kiernan et al., 2003; Ziesche et al., 2013). 
Therefore, HDAC3 by removing these acetyl groups from these lysine residues may 
facilitate NF- dependent transcription of pro-inflammatory genes in response to 
inflammatory stimuli. Consistent with this idea, acetylation mimicking RelA[p65] 
mutants at the lysine residues mentioned (Ziesche et al., 2013) or selective 
knockdown or knockout of HDAC3 (discussed in sections 4.1 and 4.7.1), reduce the 
expression of pro-inflammatory mediators in activated cells. Furthermore, 
HDAC3KD reduces the recruitment of RelA[p65] to the gene promoter of the pro-
inflammatory cytokine IL-8 (Ziesche et al., 2013). In addition to HDAC3, HDAC1 & 
2 are also known to interact with RelA[p65] (Ashburner et al., 2001) and combined 
knockout of HDAC1 & 2 increases the acetylation of RelA[p65] (Chen et al., 2011). 
In the latter study, knocking out HDAC1 was accompanied with an upregulation of 
HDAC2 and vice versa, and when this happened the acetylation of RelA[p65] was 
not increased (Chen et al., 2011). This observation is consistent with the idea that the 
upregulated HDAC isoform compensates for a loss in the other, preserves the 
number of a specific functional HDAC complex, so there is no change in the 
acetylation state of RelA[p65]. Based on these data, it is possible that in BV2 
microglia following non-selective HDAC inhibition, selective inhibition of class I 
HDACs, or following HDAC2KD, or HDAC1KD when the upregulation of HDAC2 
is prevented, the acetylation and inhibition of RelA[p65]/NF- is involved in 
suppressing the inflammatory response. In support of this, studying the acetylome of 
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activated BV2 microglia treated to the anti-inflammatory non-selective HDAC 
inhibitor SAHA and the anti-inflammatory class I selective HDAC inhibitor apicidin 
for 6 hours, one observed an increase in the acetylation of a protein with an 
approximate molecular weight of 65 kDa. The identity of this protein and the 
acetylated lysine residues need to be confirmed but based on its molecular weight, 
this protein correlates well with acetylated RelA[p65]. The acetylation of this 65 kDa 
protein was not as abundant after 6 hours of MI192 treatment. This is consistent with 
the observed lack of an effect on the inflammatory response with this inhibitor 
during this time frame. Benzamide HDAC inhibitors like MI192 and MS-275 have 
slow binding kinetics so an increase in protein acetylation following HDAC 
inhibition takes longer to occur. If the acetylation of this 65 kDa protein is important 
in reducing the inflammatory response following class I HDAC inhibition, then one 
would predict the acetylation of this protein to be greater after 24 hours of MI192 
treatment, when after this length of time MI192 suppresses the expression of pro-
inflammatory mediators in activated BV2 microglia. Studying the acetylome 
following HDAC1KD, HDAC2KD and HDAC1KD with the upregulation of 
HDAC2 prevented, will also help determine if the acetylation of this 65 kDa protein 
is key to suppressing the inflammatory response. If the acetylation of this protein is 
important for an anti-inflammatory effect then I would predict that following 
HDAC2KD or HDAC1KD when the compensatory increase in HDAC2 is prevented, 
this protein would also become hyperacetylated like that induced by SAHA and 
apicidin. I would also predict that when knocking down HDAC1, the accompanying 
upregulation and increase in activity of HDAC2 would compensate for a loss of 
HDAC1 activity so there would be no change in the acetylation state of this 65 kDa 
protein compared to the control. 
 
Another signalling pathway that is activated upon inflammatory stimuli and induces 
the expression of pro-inflammatory mediators involves mitogen-activated protein 
kinases (MAPKs). When innate immune cells are stimulated with inflammatory 
stimuli, MAPKs are first phosphorylated by MAPK kinases and then enter the 
nucleus and activate transcription factors leading to the expression of pro-
inflammatory cytokines (reviewed by Dong et al. (2002)). MAPKs are inactivated 
when dephosphorylated by phosphatases located in the nucleus (reviewed by Jeffrey 
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et al. (2007)). One such phosphatase, MKP-1 (mitogen-activated protein kinase 
phosphatase 1), has been shown to be positively regulated by acetylation (Cao et al., 
2008). In macrophages stimulated with LPS, inhibiting HDACs 1, 2 & 3 with MS-
275, or silencing their expression leads to an increase in the acetylation of MKP-1, 
which dephosphorylates/inactivates p38 MAPK and ultimately reduces the LPS-
induced expression of pro-inflammatory mediators (Jeong et al., 2014). MKP-1 is a 
negative regulator of the inflammatory response not just in macrophages but also in 
microglia (Eljaschewitsch et al., 2006). However, an increase in the acetylation of a 
protein with the molecular weight of MKP-1 (39 kDa) was not detected in BV2 
microglia following class I HDAC inhibition. 
 
In addition to the acetylation of RelA[p65] and MKP-1, HDAC inhibition may be 
anti-inflammatory by increasing the acetylation state of other pre-existing proteins 
involved in the inflammatory cascade. As well as the 65 kDa acetylated protein, 
another protein with a molecular weight between 27 and 33 kDa was identified to be 
hyperacetylated by anti-inflammatory HDAC inhibitors in BV2 microglia (figure 
4.9). In an attempt to learn the identity of this protein a bioinformatics analysis was 
performed. All the proteins expressed in humans with a molecular weight between 
27 and 33 kDa (TagIdent tool, ExPASy, Swiss Institute of Bioinformatics, Artimo et 
al. (2012); Gasteiger et al. (2003); Gasteiger et al. (2005)) were compared with the 
proteins found to be hyperacetylated in the MV4-11 human monocyte/macrophage 
leukaemia cell-line when treated with SAHA or MS-275 (Choudhary et al., 2009). 
This analysis revealed seven proteins that matched these criteria (shown in table 4.2). 
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Table 4.2. Acetylated proteins with a molecular weight between 27 and 33 kDa in 
MV4-11 human monocytes/macrophages following treatment with HDAC inhibitors. 
UniProt ID Protein name 
~MW 
(kDa) 
Function 
Q16629 Serine/arginine-rich splicing factor 7 27 mRNA processing 
Q9UKM9 RNA-binding protein Raly 32 mRNA processing 
O75586 
Mediator of RNA polymerase II 
transcription subunit 6 
28 Transcription 
P18669 Phosphoglycerate mutase 1 29 Glycolysis 
Q8N954 G patch domain-containing protein 11 30 NA binding 
P00338-2 L-lactate dehydrogenase A chain 30 
Anaerobic 
respiration 
P00491 Purine nucleoside phosphorylase 32 Purine metabolism 
Abbreviations, MW: Molecular Weight, NA: Nucleic acid. Protein name, molecular weight 
and function were sourced from UniProt (2015).  
 
Because these proteins are involved in important cellular processes such as gene 
expression, DNA synthesis and respiration, it is likely that most will be ubiquitously 
expressed in all cell types including microglia. However, these proteins are unlikely 
to be involved in specifically activating or inhibiting the inflammatory response in 
innate immune cells. Next, a more comprehensive analysis was performed to look at 
the entire acetylome in both humans and mice (Liu et al., 2014) to determine if any 
acetylated proteins with a molecular weight between 27 and 33 kDa are involved in 
the inflammatory response of any of the innate immune cells in the whole organism, 
including microglia. Comparing all the proteins within this molecular weight range 
in each species with the respective organism’s acetylome (Liu et al., 2014), short-
listed 199 proteins in humans and 186 proteins in mice. Cross-referencing these 
acetylated proteins with those classified as being involved in the inflammatory 
response for each species (176 and 156 proteins for humans and mice respectively, 
UniProt (2015)) did not lead to the identification of any proteins of the desired 
molecular weight known to be involved in inflammation. If the protein with a 
molecular weight between 27 and 33 kDa observed to be acetylated following 
HDAC inhibition in BV2 microglia is indeed one of those identified by the 
bioinformatics analysis (table 4.2), then it is unlikely that this protein is responsible 
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for the anti-inflammatory effects seen with HDAC inhibitors. To confirm the identity 
of this acetylated protein, the protein could be isolated from the rest of the proteins in 
the acetylome and then analysed using mass spectrometry. 
 
Though not investigated in this thesis, another way HDAC inhibitors could suppress 
pro-inflammatory gene expression in microglia without requiring protein synthesis, 
is by increasing the acetylation of histone proteins or transcription factors, which 
leads to an increase in the expression of microRNAs (miRNAs). Mature miRNAs 
reduce protein expression by binding to target sites within mRNA encoding a 
particular protein. This interaction prevents mRNA translation or initiates mRNA 
degradation (reviewed by Bartel (2004)) and could account for an observed reduction 
in both mRNA expression and protein secretion of pro-inflammatory mediators in 
BV2 microglia and other innate immune cells. Grabiec et al. (2012) have observed a 
significant acceleration of IL-6 mRNA degradation in human fibroblast-like 
synoviocytes (inflammatory cells involved in the pathogenesis of arthritis) when 
stimulated with LPS in the presence of TSA, compared to LPS alone. This mRNA 
degradation could possibly be brought about by HDAC inhibition mediated 
expression of miRNAs. Indeed, in human fibroblast-like synoviocytes, SAHA 
treatment significantly increases the expression of miR-146a, which in turn 
suppresses IL-1 induced RelA[p65] phosphorylation/activation, inhibits the 
expression of proteins involved in the TNF- and IL-1 receptor-mediated signalling 
cascades and significantly reduces IL-6 protein secretion. The anti-inflammatory 
effects of SAHA in these cells could be prevented with a miR-146a inhibitor or by 
overexpressing either HDAC1, 4 or 6 (Wang et al., 2013a). Another miRNA, miR-
124, is also upregulated following SAHA or apicidin treatment (Wang et al., 2014) 
and has been shown to negatively regulate the inflammatory response. This miR-124 
is expressed in microglia of the brain and spinal cord in mice and is down-regulated 
in activated microglia in mice following experimental autoimmune 
encephalomyelitis and in isolated microglia stimulated with LPS & IFN 
(Ponomarev et al., 2011). Furthermore, when murine macrophages are transfected 
with mimics of miR-124, this leads to a reduction in the expression of the pro-
inflammatory mediators iNOS (Ponomarev et al., 2011), IL-6 (Sun et al., 2013) and 
TNF- (Ponomarev et al., 2011).  
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In addition to suppressing the expression of pro-inflammatory mediators like 
cytokines by the possible mechanisms discussed, HDAC inhibitors may also be 
neuroprotective in brain insults, injury and neurodegenerative disease where the 
inflammatory response is involved by suppressing the signalling pathways activated 
by them. Upon the expression of pro-inflammatory cytokines such as IL-1, IL-6, 
IFN and TNF-, these proteins are secreted by innate immune cells into the 
extracellular space and are free to bind to the their respective receptors in the cell 
membrane of other cells. In turn, this activates intracellular signalling cascades that 
lead to further cytokine expression and physiological responses such as the apoptosis 
of neurones. Components of these cytokine receptor mediated signalling cascades 
may also be regulated by acetylation. An example of this is STAT1 (signal 
transducer and activator of transcription 1) a protein activated by the IL-6 and IFN 
receptor-signalling pathways (Ihle, 2001), which is positively regulated by 
acetylation. Class I HDACs, HDAC1 & 3 but not HDAC2 or HDAC8 can 
deacetylate STAT1 (Kramer et al., 2006). The acetylation of this protein is increased 
in human derived cell-lines when HDACs are inhibited with VPA or TSA. Upon 
acetylation, STAT1 interacts with RelA[p65] reducing its affinity for DNA and 
triggering its export out of the nucleus (Kramer et al., 2006). 
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4.8. Conclusion 
 
BV2 microglia when stimulated with LPS is an appropriate model to study the 
inflammatory response of primary microglia and neuroinflammation in vivo. Using 
this model, it has been demonstrated that inhibiting class I HDACs, 1, 2 & 3 inhibits 
the inflammatory response of microglia as indicated by a suppression of the 
expression of pro-inflammatory mediators. Knocking down specific HDAC isoforms 
revealed that HDAC1 and HDAC2 are important for this response. Knockdown of 
HDAC2, or knockdown of HDAC1 when the accompanying upregulation and 
compensatory activity of HDAC2 was prevented, suppressed the expression of pro-
inflammatory cytokines. This suggests HDAC1 and HDAC2 are functionally 
redundant in regulating the inflammatory response of microglia. Mechanistically, 
HDAC1 & 2 may be interchangeable members of a specific multi-protein complex, 
which deacetylates specific proteins that regulate the inflammatory response. 
Reducing the activity of either or both of these isoforms and therefore a specific 
multi-protein complex, may lead to the acetylation of these proteins, which upon 
acetylation either no longer function to promote the inflammatory response or 
actively suppress it. Investigating some of the mechanisms of how HDAC inhibition 
could be anti-inflammatory suggests that HDAC inhibitors do not require novel 
protein synthesis to have their effect, rather they increase the acetylation of pre-
existing proteins which can regulate the inflammatory response directly. One 
promising candidate identified in this thesis is a protein with a molecular weight of 
~65 kDa. This protein correlates well with the RelA/p65 subunit of NF- a 
transcription factor that induces pro-inflammatory gene expression and has been 
shown by others to be negatively regulated when acetylated at specific lysine 
residues.
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5.1. Is selective inhibition of HDAC1 & 2 a therapeutically viable option to treat 
brain insults, injury and neurodegenerative disease? 
 
Over the last decade many studies have shown that HDAC inhibition has 
neuroprotective and neuro-restorative effects in in vitro, ex vivo and in vivo models 
relevant to brain insults such as cerebral ischaemia, injuries such as traumatic brain 
injury and neurodegenerative diseases such as Alzheimer’s, Parkinson’s, motor 
neurone disease and multiple sclerosis. Chronic neuroinflammation is thought to 
exacerbate neuronal injury and death in these conditions (reviewed by Block and 
Hong (2005); Block et al. (2007); Glass et al. (2010); Smith et al. (2012)) and one-
way HDAC inhibitors may be neuroprotective is by suppressing the inflammatory 
response of resident microglia and infiltrating peripheral innate immune cells. 
Despite substantial evidence suggesting HDAC inhibitors may be therapeutically 
useful in preventing neural cell death in brain conditions, these drugs have not been 
extensively tested in clinical trials for this purpose. Only two trials have studied the 
neuroprotective efficacy of HDAC inhibitors in patients (U.S. National Institutes of 
Health, 2015) one of which investigated the effects of sodium butyrate in individuals 
with motor neurone disease. However, inhibiting HDACs had no therapeutic effect 
as determined by measuring muscle function (Cudkowicz et al., 2009). Currently a 
clinical trial is in progress to investigate if the clinically available HDAC inhibitor 
VPA protects the brain and improves recovery of brain function in patients after 
traumatic brain injury (Zhou, 2013). HDAC inhibitors are also currently being tested 
in clinical trials for other conditions and at present there are 493 registered clinical 
trials worldwide that have tested or are currently testing HDAC inhibitors to treat 
injury and disease (U.S. National Institutes of Health, 2015). SAHA is used in the 
clinic to treat cutaneous T-cell lymphoma and the majority of the completed or 
ongoing clinical trials have or are investigating the use of HDAC inhibitors as a form 
of chemotherapy to treat a variety of other cancers. HDAC inhibitors have also been 
tested in the inflammatory condition of juvenile-onset arthritis. Here the non-
selective HDAC inhibitor Givonstat (ITF2357) significantly reduces the number of 
swollen/inflamed and arthritic joints and improves the range of motion of joints in 
patients with this condition (Vojinovic et al., 2011). 
 
Chapter 5    General Discussion 
141 
 
A problem identified when performing clinical trials and using non-selective HDAC 
inhibitors in the clinic is that these drugs can cause significant side effects. This is 
presumably from an inappropriate inhibition of particular HDACs when using non-
selective HDAC inhibitors and in the case of VPA, interacting with other molecular 
targets (see section 1.8).  Some of the adverse side effects associated with sodium 
butyrate, SAHA and VPA treatment include liver damage, dizziness, drowsiness & 
tiredness, headaches, mood changes, confusion, loss of motor coordination, nausea, 
vomiting, diarrhoea, loss of appetite, unusual weight gain or loss, peripheral oedema, 
anaemia, bleeding & bruising and respiratory difficulties (Cudkowicz et al., 2009; 
MedlinePlus, 2009; MedlinePlus, 2014). Furthermore, children exposed to HDAC 
inhibitors in the womb are at a high risk of serious developmental disorders 
(MedlinePlus, 2009; MedlinePlus, 2014). One-way these side effects could be 
minimised would be to use selective HDAC inhibitors that target only the HDAC 
isoforms important to produce a therapeutic response. In this thesis, progress has 
been made in identifying the specific HDACs to inhibit in order to reduce 
neuroinflammation in brain insults, injuries and neurodegenerative disease. Here, it 
has been shown that HDAC inhibitors, which are selective for isoforms HDAC1, 2 & 
3 or more specifically HDAC2 & 3, suppress the inflammatory response of 
microglia. In support of these findings, other studies have shown that the inhibition 
of these three HDAC isoforms reduces neuroinflammation and is neuroprotective in 
in vivo models of cerebral ischaemia (Lanzillotta et al., 2013; Murphy et al., 2014), 
experimental autoimmune neuritis (Zhang et al., 2010) and an amyloidosis model of 
Alzheimer’s disease (Zhang and Schluesener, 2013). HDAC inhibitors selective for 
these isoforms have also been shown to reduce the inflammatory response in rodent 
models of arthritis (Cantley et al., 2015; Lin et al., 2007). At present it remains to be 
determined if selectively inhibiting HDAC1, 2 & 3 is therapeutically beneficial in a 
clinical trial to treat brain insults, injuries and neurodegenerative disease, and if 
selectively inhibiting these HDAC isoforms has fewer side effects in patients 
compared to those caused by non-selective HDAC inhibitors. To understand these 
side effects, it is important to understand more about the substrates of HDACs and 
the function of these proteins in cells and physiological systems.  
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Histones are not the only proteins that are regulated by lysine acetylation. There are 
now 4817 proteins in humans that are known to be modified in this way (Liu et al., 
2014). Because of this, one has to consider that even with the currently available 
inhibitors selective for HDAC1, 2 & 3, it is likely that these too will effect the 
normal acetylation-deacetylation of a significant proportion of proteins in the 
acetylome and doing so may lead to unwanted changes in many physiological 
processes. Work by Choudhary et al. (2009) comparing the acetylome in MV4-11 
human monocyte/macrophage leukaemia cells following treatment with the non-
selective HDAC inhibitor SAHA and the HDAC1, 2 & 3 selective HDAC inhibitor 
MS-275 has provided some insight into this problem. Analysis of the available raw 
data reveals that of the 1058 acetylated sites examined in these cells, the acetylation 
of 8.22% of these is increased at least 1.5 fold by both SAHA and MS-275. SAHA 
also increases the acetylation of an additional 12.67% of the sites, which MS-275 
does not and MS-275 increases the acetylation of an additional 8.98% of the sites, 
which SAHA does not. Although there are differences in which sites become 
acetylated, the overall increase in acetylation following selective HDAC1, 2 & 3 
inhibition is similar to that induced by SAHA which inhibits HDACs 5, 6 & 8 in 
addition to HDACs 1, 2 & 3 (table 1.4). This analysis was performed on one cell-
type and so if this extrapolated to the effects of HDAC inhibition in the whole 
organism; it is likely that selective inhibition of HDAC1, 2 & 3 will still lead to 
changes in many cellular processes and physiological systems. With this in mind, it 
might be possible to minimise these side effects by inhibiting just one of these three 
HDAC isoforms. Identifying the most appropriate isoform to inhibit will require a 
clear understanding of the roles of each in physiological processes. 
 
In this thesis it has been demonstrated that specific knockdown of either HDAC1 or 
HDAC2 suppresses the inflammatory response of microglia. This suggests HDAC1 
and HDAC2 have functional redundancy in the inflammatory response of microglia 
and because of this; it may be possible to inhibit only one of these isoforms is to 
suppress neuroinflammation in brain insults, injuries and neurodegenerative disease. 
However, this would depend on HDAC inhibitors selective for HDAC1 over 
HDAC2 and vice versa to not cause an increase in the expression of the other 
isoform, which the HDAC inhibitor would not inhibit. If one could inhibit just one of 
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these isoforms without causing an up-regulatory increase in the other, is there any 
evidence to favour inhibiting one over the other? Some experimental evidence 
reported in the literature supports the idea that inhibiting HDAC1 is neuroprotective, 
yet another set of studies oppose this and show specific inhibition of HDAC1 in 
neurones causes neurotoxicity (see section 3.1.1). The reasons underlying these 
contradictions are not known, so inhibiting HDAC1 in the brain comes with the 
potential risk of causing damage not neuroprotection. If inhibiting HDAC1 is to be 
avoided, will selective inhibition of HDAC2 be sufficient to have neuroprotective 
and anti-inflammatory effect in brain insults, injuries and neurodegenerative disease? 
In support of this, silencing HDAC2 reduces the inflammatory response in microglia 
(figure 4.4), HDAC2KD prevents CGNs from undergoing apoptosis due to oxidative 
stress (Peng et al., 2015) and HDAC2 is found upregulated in the cortex of 
individuals with Alzheimer’s disease and in the cortex and hippocampus of the 
p25/Cdk5 mouse model of this condition (Graff et al., 2012). In this mouse model, 
mice display Alzheimer’s disease related pathologies such as neuronal loss (Cruz et 
al., 2003), -amyloid accumulation (Cruz et al., 2006), Tau hyperphosphorylation 
(Cruz et al., 2003), neurofibrilliary tangles (Cruz et al., 2003), reactive astrogliosis 
(Muyllaert et al., 2008), microgliosis (Muyllaert et al., 2008), neuroinflammation 
(Muyllaert et al., 2008) and reduced synaptic density (Fischer et al., 2005) in both the 
hippocampus and the cerebral cortex of mouse brains. The mechanism that causes 
HDAC2 upregulation in Alzheimer’s disease and in the p25/Cdk5 mouse model has 
not been explained. However the same laboratory has previously shown that p25 
inhibits HDAC1 in this mouse model (Kim et al., 2008). HDAC1 expression is 
unchanged in the post-mortem brain of patients with Alzheimer’s disease and 
p25/Cdk5 mice (Graff et al., 2012) but a loss of HDAC1 activity in this mouse model 
and inhibition of HDAC1 in isolated neurones causes neuronal death (Kim et al., 
2008). Although not examined in these studies, it is possible that a reduction in 
HDAC1 activity may cause a compensatory upregulation and increase in activity of 
HDAC2. This could explain why HDAC2 is found upregulated when HDAC1 
activity is reduced in the p25/Cdk5 mouse model of Alzheimer’s disease. Despite 
this upregulation of HDAC2, HDAC2 would not adopt the independent and specific 
functions of HDAC1. This is presented as neurotoxicity because HDAC1 is 
important for DNA repair processes in neurones (Kim et al., 2008; Wang et al., 
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2013b). Also, following the upregulation of HDAC2, the independent function of 
this isoform as a negative regulator of learning and memory would be enhanced 
(Graff et al., 2012; Guan et al., 2009) and in part cause the cognitive decline 
associated with Alzheimer’s disease (Graff et al., 2012). Is the upregulation of 
HDAC2 just a consequence of a loss of HDAC1 activity and it is this loss that causes 
neurotoxicity? Or does an increase in HDAC2 activity following upregulation also 
cause neurotoxicity? Knocking down HDAC2 in the hippocampus of p25/Cdk5 mice 
reduces the expression of HDAC2 back to normal levels and in doing so restores 
neuronal function and improves cognition but does not halt neurodegeneration in 
these mice. The lack of a neuroprotective effect would suggest HDAC2 upregulation 
does not cause neurotoxicity but contributes to cognitive decline by reducing 
functionality of neurones. However, knocking down HDAC2 below normal levels 
suppresses CGN apoptotic cell death (Peng et al., 2015) and the data presented in this 
thesis shows this knockdown also suppresses the inflammatory response of 
microglia. So why isn’t HDAC2KD neuroprotective in the in vivo model of 
Alzheimer’s disease by suppressing apoptosis or the neuroinflammatory component? 
By only knocking down HDAC2 in p25/Cdk5 mice to levels of expression found 
normally, HDAC2 will still be able to regulate the inflammatory response and/or 
other mechanisms which cause neurotoxicity and drive neurodegeneration. A 
reduction in HDAC2 expression below normal levels, like shown in BV2 microglia 
(figure 4.4) will be required to prevent the inflammatory response and associated 
neurotoxicity, because the expression level of HDAC2 is now reduced below that, 
which ordinarily would permit it. An alternative reason why neuroprotection is not 
seen in the hippocampus of p25/Cdk5 mice when the level of HDAC2 expression is 
returned to normal levels is due to the methodology used to reduce HDAC2 
expression. Graff et al. (2012) infected cells of the hippocampus with an AAV vector 
containing HDAC2 short hair-pin RNA (shRNA) and show HDAC2 levels are 
reduced in neurones. However, no mention is made of any changes in HDAC2 levels 
in microglia in the brains of the p25/Cdk5 mice compared to wild-type controls and 
following AAV-mediated HDAC2KD. Previous work by Dr Ian C Wood’s 
laboratory (School of Biomedical Sciences, University of Leeds, UK, unpublished 
data) has shown that the infection rate of AAV in BV2 microglia cultures is very 
low. Therefore, it is likely that in the hippocampus of p25/Cdk5 mice, only neurones 
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are infected with the virus and not microglia. This means that HDAC2 is not 
knocked down in microglia. Therefore, the inflammatory response initiated in the 
mouse model of Alzheimer’s disease is unaffected and continues to drive 
neurotoxicity and neurodegeneration in this model. A future area of study would be 
to determine if specific knockdown or selective inhibition of HDAC2 in microglia is 
neuroprotective in vivo by reducing neuroinflammation in models of brain insults, 
injuries and neurodegenerative disease. Nevertheless, experimental evidence 
reported in the literature shows reducing HDAC2 but not HDAC1 in mice improves 
cognitive functions such as learning and memory (Graff et al., 2012; Guan et al., 
2009) and this in itself may be of therapeutic benefit in conditions where a 
restoration in cognition is required. 
 
Although selective inhibition of HDAC1 and/or HDAC2 will avoid the side effects 
associated with inhibiting other HDACs, inhibiting these two isoforms together or 
individually will still produce side effects associated with inhibiting cellular 
processes they both regulate, or inhibiting their individual functions. For example, 
HDAC1 and HDAC2 are important in regulating intestinal function and the 
inhibition of this function could be the cause of the digestive problems reported by 
patients taking HDAC inhibitors.  In support of this, specific knock out of both these 
isoforms in intestinal cells in mice causes digestive system defects. These mice 
weigh less and produce looser stools (Turgeon et al., 2013). There is also an increase 
in the proliferation and migration of epithelial cells in the intestine, but a decrease in 
cell lineage commitment. Together this leads to cellular disorganisation, a thickening 
of the intestinal epithelium, an increase in the overall length of the intestine and 
disruption of normal intestinal function (Turgeon et al., 2013). Knockout of these 
two isoforms also increases the infiltration of immune cells into the intestine, which 
secrete inflammatory mediators (Turgeon et al., 2013). However, this pro-
inflammatory effect is not a consequence of the loss of HDAC1 & 2 in immune cells, 
because HDAC1 and 2 expression levels were only manipulated in intestinal cells. 
Therefore, immune cell infiltration and inflammation is an indirect effect, which may 
be stimulated by disrupted intestinal cells, digestion and behaviour of commensal 
bacterial in the intestine.  
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A loss of HDAC2 expression is however correlated with chronic inflammation in the 
lungs of patients with chronic obstructive pulmonary disorder (reviewed by Barnes 
(2009)). Therefore the inhibition of HDAC2 may be the cause of breathing 
difficulties reported by some patients taking HDAC inhibitors. Why and how class I 
HDAC inhibition is anti-inflammatory in in vivo brain conditions (Lanzillotta et al., 
2013; Murphy et al., 2014; Zhang and Schluesener, 2013; Zhang et al., 2010), in 
patients with and in in vivo models of inflammatory arthritis (Cantley et al., 2015; 
Lin et al., 2007; Vojinovic et al., 2011), in isolated microglia (figure 4.2A & E and 
4.4), monocytes (Gillespie et al., 2011), macrophages (Jeong et al., 2014; Zhang and 
Schluesener, 2013) and fibroblasts (Choo et al., 2010), but pro-inflammatory in the 
pulmonary system, is not understood.  
 
Taking side effects into consideration, is selective inhibition of HDAC1 and/or 2 a 
viable therapeutic strategy to treat brain insults, injuries and neurodegeneration? 
With every pharmacological intervention it is expected that there will be side effects. 
Currently available non-selective HDAC inhibitors used in the clinic have a 
numerous side effects, yet these drugs have still been approved and are in use 
because the gains of using them to treat cancer, epilepsy and bipolar disorder, which 
are severely debilitating conditions, outweigh the negative side effects these drugs 
may cause. Selectively inhibiting HDAC1 and/or 2 using the currently available 
selective HDAC inhibitors such as MS-275 or MI192, or newly developed 
compounds may not remove all the side effects associated with HDAC inhibition, 
but will prevent any side effects associated with inhibiting class II HDAC isoforms. 
The work presented in this thesis suggests there may be an alternative way of 
reducing the activity of HDAC1 and HDAC2, which generates fewer side effects 
compared to using selective HDAC inhibitors. Here it has been suggested that the 
anti-inflammatory effects seen when using HDAC inhibitors is brought about by the 
inhibition of a specific multi-protein complex which HDAC1 and HDAC2 are 
interchangeable members of. It may be possible to identify then target a specific non-
HDAC component, which is unique to this specific complex, such as a component 
important for targeting the complex to the appropriate protein substrate. Inhibiting 
such a component will reduce the side effects associated with inhibiting all of the 
functional complexes which HDAC1 and/or HDAC2 are members of. 
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5.2. Is activation of specific deacetylase enzymes also neuroprotective? 
 
Although this thesis and much of the literature has focussed on the use of HDAC 
inhibitors as neuroprotective agents, in some circumstances would it be beneficial to 
increase the activity of specific deacetylase enzymes to be neuroprotective and 
suppress neuroinflammation in brain insults, injuries and neurodegenerative disease? 
If inhibiting HDACs that cause neurotoxicity is neuroprotective, then it is plausible 
that increasing the activity of HDACs that promote neurone survival or are anti-
inflammatory will be neuroprotective also. Although, the role of HDAC1 in neuronal 
death and survival is debated (see section 3.1.1), one group is patenting the use of 
HDAC1 activators to treat Alzheimer’s disease, Parkinson’s disease, motor neurone 
disease, traumatic brain injury and cerebral ischaemia (Tsai et al., 2015). This 
application is based on their earlier observations that a loss of HDAC1 activity is 
toxic to isolated neurones by causing DNA damage (Kim et al., 2008; Wang et al., 
2013b) and HDAC1 activity is reduced in the brain of the p25/Cdk5 mouse model of 
Alzheimer’s disease (Kim et al., 2008). Furthermore, over-expressing HDAC1 
provides neuroprotection in this model as well as in forebrain ischaemia in rats (Kim 
et al., 2008). Apparent HDAC1 activators have been identified by this group 
following a screen of 1760 small molecules including synthetic compounds, natural 
products such as flavonoids and a subset of United States Food & Drug 
Administration (FDA) approved drugs (Tsai et al., 2015).  These compounds were 
tested for effects on the activity of recombinant HDACs 1, 2, 6, 8 & 10 in an in vitro 
substrate deacetylation assay. The most promising compound, ChemBridge 5104434, 
increased HDAC1 activity by 2.2 fold with little effect on the other HDAC isoforms 
(Tsai et al., 2015). How this compound activates HDAC1 and the effect of this on 
neurone survival in mouse models of the aforementioned brain conditions has yet to 
be examined. But, based on the work presented in this thesis, if inhibiting HDAC1 
suppresses neuroinflammation then it is possible that activating HDAC1 will 
augment it. Furthermore, other studies have shown an increase in the activity of 
HDAC1 causes toxicity to neurones (Bardai et al., 2012; Kim et al., 2010). Because 
of this, HDAC1 activators identified by Tsai et al. (2015), may actually promote the 
inflammatory response and exacerbate neurotoxicity in brain insults, injuries and 
neurodegenerative disease. 
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 Class III HDACs the sirtuins have not been discussed in this thesis however, 
experimental evidence reported in the literature suggests that increasing the activity 
of specific sirtuins may be neuroprotective and anti-inflammatory. All seven sirtuins 
(SIRT1-7) are expressed in the brain (Michishita et al., 2005) and SIRT1 and SIRT2 
are two isoforms that have been implicated in neuronal degeneration (reviewed by 
Harting and Knoll (2010); Raghavan and Shah (2012)). SIRT1 activity has mainly 
been attributed with neuroprotective effects; increasing SIRT1 activity through 
overexpression or by using apparent pharmacological activators like resveratrol 
protects neurones from OGD (Lanzillotta et al., 2013; Wang et al., 2009a). Inhibitors 
of SIRT1 & 2 such as sirtinol (Grozinger et al., 2001) prevent this neuroprotective 
effect. Increased activity of SIRT1 also protects neurones from DNA damage 
(Dobbin et al., 2013; Hasegawa and Yoshikawa, 2008), models of Alzheimer’s 
disease (Chen et al., 2005; Dobbin et al., 2013; Kim et al., 2007a), Parkinson’s 
disease (Okawara et al., 2007) and motor neurone disease (Kim et al., 2007a). 
Interestingly, increasing SIRT1 or SIRT2 activity with pharmacological agents 
including resveratrol also suppresses the inflammatory response of microglia (Chen 
et al., 2005; Pais et al., 2013; Yang et al., 2012; Ye et al., 2013). In neurone and 
microglia co-cultures, this anti-inflammatory effect prevents neuronal death triggered 
by the inflammatory response of activated microglia (Chen et al., 2005). 
Mechanistically it is thought that SIRT1 and SIRT2 suppress the inflammatory 
response of microglia by specifically deacetylating p65[RelA] at lysine 310 (Pais et 
al., 2013; Rothgiesser et al., 2010a; Yeung et al., 2004). Consistent with this, 
increasing SIRT1 activity with resveratrol leads to a decrease in the acetylation state 
of this lysine residue (Lanzillotta et al., 2013). Acetylation of this specific site has 
been shown to increase the transcriptional activity of NF- (Chen et al., 2002; 
Ziesche et al., 2013). Therefore promoting the deacetylation of this site by 
overexpressing SIRT1 & 2, or treating with a pharmacological activator, may reduce 
the transcriptional activity of this transcription factor. This could explain how 
increasing SIRT1 & 2 activity suppresses the expression of NF- dependent pro-
inflammatory mediators in microglia. Combining an increase in the deacetylation at 
K310 in p65[RelA] by using a SIRT1 or 2 activator, together with an increase in the 
acetylation of lysine residues 122, 123, 315 and 315 in p65[RelA] by using a class I 
selective HDAC inhibitor, may negatively regulate NF- function to a greater 
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extent compared to using these drugs on their own. In support of this idea, when MS-
275 and resveratrol are co-administered, there is less ischaemic brain damage in mice 
following MCAO compared to the protection provided when mice are treated to 
either compound alone (Lanzillotta et al., 2013). This study would suggest that 
combining these drugs would have a greater neuroprotective effect in clinical 
conditions compared to administering one drug or the other. However, it is important 
to consider that increasing SIRT1 activity and consequently decreasing the 
acetylation of SIRT1-regulated proteins in the acetylome (Chen et al., 2012b), may 
evoke additional side effects alongside those caused by inhibiting HDACs 1, 2 & 3. 
 
 
5.3. Further work 
 
5.3.1. Investigating the mechanisms underlying the functional redundancy of HDAC1 
& 2 in the inflammatory response 
 
The data presented in this thesis suggests HDAC1 and HDAC2 are functionally 
redundant in regulating the inflammatory response of microglia. Others have also 
shown these two isoforms are functionally redundant in the inflammatory response 
of other innate immune cells (Jeong et al., 2014). The functional redundancy of 
HDAC1 and HDAC2 means both these enzymes target and deacetylate the same 
protein substrates. When either enzyme is inhibited, the deacetylation of these 
specific proteins is reduced and this leads to an increase in the acetylation state and 
upon this, anti-inflammatory effects. The identity of these proteins has yet to be fully 
elucidated but a possible candidate protein with a molecular weight of 65 kDa has 
been identified in this thesis. This protein is suspected to be the p65/RelA subunit of 
NF- which is a key regulator of the inflammatory response. An obvious direction 
of further work would be to perform Western blots and mass spectrometry to confirm 
the identity of this protein, determine which lysine residues are acetylated and then 
perform functional assays to determine if and how this acetylation is responsible for 
the anti-inflammatory effects seen when using HDAC inhibitors or knocking down 
HDACs 1 or 2.  
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Further work is also required to understand the molecular mechanisms underlying 
the functional redundancy of HDAC1 and 2 in the inflammatory response. One of the 
potential mechanisms is that HDAC1 and HDAC2 are interchangeable members of a 
specific multi-protein complex, which is responsible for deacetylating a specific 
protein that can regulate the inflammatory response. Identifying which multi-protein 
complex is responsible i.e. the Sin3, NuRD or the CoREST complex and the proteins 
it is comprised of is one avenue for further study. Using a combination of co-
immunoprecipitation experiments and mass spectrometry one could examine the 
interacting partners of the protein substrate, which when acetylated is responsible for 
the suppressing the inflammatory response. Then having identified which multi-
protein complex interacts with the protein substrate, this can be compared to the 
complex that no longer interacts with the protein substrate following HDAC 
inhibition, HDAC2KD or HDAC1KD when the associated upregulation of HDAC2 
is prevented. One could also look at the composition of the complex that interacts 
with the substrate when HDAC1 is knocked down but HDAC2 is upregulated. 
 
5.3.2. Further investigations of the anti-inflammatory effects of inhibiting HDAC1 
and/or 2 in microglia 
 
In this thesis, the effects of various HDAC inhibitors as well as silencing of HDACs 
1 or 2 on neuroinflammation have been examined. This involved using a LPS-
stimulated BV2 murine microglia model system. Although using the BV2 murine 
microglia cell-line appropriately models the inflammatory response of microglia (see 
section 4.1), it is important to determine if selective HDAC1 and/or 2 inhibition has 
any clinical value in reducing neuroinflammation in humans. To do this, one could 
examine the effects of selective inhibition of HDAC1 and/or 2 in isolated human 
microglia using the protocols described by Suh et al. (2010).  
 
In this thesis, the inflammatory response of microglia was examined by measuring 
changes in IL-6, iNOS and TNF- expression. Even though these are good markers 
of neuroinflammation in the brain, it would also be good to look at a wider range of 
pro-inflammatory mediators in order to get a clearer idea of how effective selective 
inhibition of HDAC1 and/or 2 is in suppressing the inflammatory response of 
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microglia. To analyse the changes in expression of many neuroinflammatory markers 
at once, one experimental approach would be to use PCR arrays, which will allow 
the researcher to profile the expression of up to 384 genes simultaneously.  
 
The primary goal of suppressing the inflammatory response of microglia and 
reducing neuroinflammation by using HDAC inhibitors selective for HDAC1 and/or 
2, is to prevent the neurotoxic effects associated with the production and release of 
pro-inflammatory mediators. To investigate if HDAC inhibitor-mediated suppression 
of pro-inflammatory mediator expression is sufficient to significantly reduce the 
toxicity of the inflammatory response, one could either add the supernatants of 
stimulated microglia to isolated neurone cultures, or co-culture microglia with 
neurones (as used by Gresa-Arribas et al. (2012)). This would allow one to examine 
changes in neurone viability in response to microglia-mediated inflammation in the 
absence or presence of a HDAC1 and/or 2 selective inhibitor, or after specifically 
knocking down HDAC1 or HDAC2 in microglia. Another approach would be to 
stimulate the microglial inflammatory response in organotypic slice cultures of brain 
tissue such as cortex, hippocampus or cerebellum, or in the brains of rodents and 
then study the effects of this on neurone integrity, function and survival in the 
absence and presence of selective inhibitors of HDAC1 and 2, or knockdown of 
these isoforms in specific brain regions and cell types. 
 
Much has been discussed with respect to suppressing the expression of pro-
inflammatory mediators in microglia to have a neuroprotective effect in models 
relevant to brain insults, injuries and neurodegeneration. It is important to mention 
that not all consequences of microglial activation in these brain conditions are 
detrimental and some are important for tissue repair and recovery. One of these is the 
ability of microglia to phagocytose cell debris and cells damaged beyond repair. If 
such objects were not removed, then they would accumulate and possibly interfere 
with normal neurone connectivity and function, as well as act as stimulants for a 
chronic inflammatory response, which would continue to exacerbate neurone injury 
and cause neural cell death. Activated microglia are known to exist as two 
phenotypes termed M1 and M2. The M1-phenotype is associated with the release of 
toxic pro-inflammatory mediators such as cytokines and free radicals, on the other-
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hand M2 microglia suppress neuroinflammation, release neurotrophic factors and 
promote tissue repair and recovery. Microglia of the M2-phenotype also exhibit a 
stronger capacity to phagocytose cell debris, damaged cells and dead cells than M1 
microglia (reviewed by Cherry et al. (2014); Hu et al. (2015)). Recently, Wang et al. 
(2015) have shown that non-selective HDAC inhibitors suppress the expression of 
pro-inflammatory mediators by microglia in part by switching the phenotype from 
the pro-inflammatory and toxic M1-type to the protective M2-type (as discussed in 
section 1.10.5). Following on from this work, it would be interesting to examine if 
selective class I HDAC inhibition and in particular selective inhibition of HDAC1 
and/or HDAC2 also switches the phenotype of activated microglia to the M2-
phenotype. This switch may also improve the ability of microglia to phagocytose cell 
debris and cells that cannot be rescued following injury. Taken together, a reduction 
in pro-inflammatory mediator expression following HDAC inhibition, combined 
with improved phagocytosis of cell debris and dead cells, would limit the extent of 
brain damage and help improve recovery in brain insults, injuries and 
neurodegenerative disease. 
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5.4. Final conclusion 
 
Experimental evidence reported in the literature shows HDAC inhibitors are 
neuroprotective, neuro-restorative and improve neurological outcome in in vivo 
models of brain insults such as cerebral ischaemia, injuries such as traumatic brain 
injury and neurodegenerative diseases such as Alzheimer’s, multiple sclerosis, motor 
neurone disease and Parkinson’s disease. There is strong evidence to implicate 
neuroinflammation in the pathogenesis of these conditions and it has been shown that 
HDAC inhibitors can suppress the inflammatory response of microglia and other 
innate immune cells. However, which of the eleven zinc-dependent HDAC isoforms 
are important for this response and how inhibition of these leads to the anti-
inflammatory and neuroprotective effects is not clear. The data presented in this 
thesis shows for the first time that selective inhibition of HDAC1 and/or HDAC2 has 
an anti-inflammatory effect in microglia. The data presented here also suggests there 
is functional redundancy of these isoforms in regulating the inflammatory response. 
Based on this, selectively inhibiting either HDAC1 or HDAC2 and not the other 
HDAC isoforms may be a viable strategy to reduce neuroinflammation in brain 
conditions whilst minimising the side effects associated with inhibiting other 
HDACs. In support of this, MI192, which is selective for HDAC2 over HDAC1, 
suppressed the inflammatory response of BV2 microglia. Further work should now 
be carried out to understand the mechanisms underlying the functional redundancy of 
HDAC1 & 2 in the inflammatory response and to determine if selective inhibition of 
either of these isoforms suppresses neuroinflammation and is neuroprotective in 
more complex experimental models of brain insults, injuries and neurodegenerative 
disease. 
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